US20070122905A1 - PDX1-expressing dorsal and ventral foregut endoderm - Google Patents

PDX1-expressing dorsal and ventral foregut endoderm Download PDF

Info

Publication number
US20070122905A1
US20070122905A1 US11/588,693 US58869306A US2007122905A1 US 20070122905 A1 US20070122905 A1 US 20070122905A1 US 58869306 A US58869306 A US 58869306A US 2007122905 A1 US2007122905 A1 US 2007122905A1
Authority
US
United States
Prior art keywords
cells
pdx1
positive
cell
foregut endoderm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/588,693
Other languages
English (en)
Inventor
Kevin D'Amour
Alan Agulnick
Susan Eliazer
E. Baetge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cythera Inc
Original Assignee
Cythera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cythera Inc filed Critical Cythera Inc
Priority to US11/588,693 priority Critical patent/US20070122905A1/en
Assigned to CYTHERA, INC. reassignment CYTHERA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AGULNICK, ALAN D., BAETGE, E. EDWARD, D'AMOUR, KEVIN, ELIAZER, SUSAN
Publication of US20070122905A1 publication Critical patent/US20070122905A1/en
Priority to US12/729,084 priority patent/US20100233755A1/en
Priority to US13/962,978 priority patent/US9499795B2/en
Priority to US15/290,850 priority patent/US20170022474A1/en
Priority to US16/200,493 priority patent/US11427805B2/en
Priority to US17/814,791 priority patent/US20230040286A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • the present invention relates to the fields of medicine and cell biology.
  • the present invention relates to compositions comprising mammalian foregut endoderm cells and compositions comprising dorsal and/or ventral PDX1-positive foregut endoderm cells and methods of making, isolating and using such cells.
  • Human pluripotent stem cells such as embryonic stem (ES) cells and embryonic germ (EG) cells, were first isolated in culture without fibroblast feeders in 1994 (Bongso et al., 1994) and with fibroblast feeders (Hogan, 1997). Later, Thomson, Reubinoff and Shamblott established continuous cultures of human ES and EG cells using mitotically inactivated mouse feeder layers (Reubinoff et al., 2000; Shamblott et al., 1998; Thomson et al., 1998).
  • hESCs Human ES and EG cells
  • hESCs Human ES and EG cells
  • these diseases such as diabetes mellitus and Parkinson's disease.
  • the use of insulin-producing ⁇ -cells derived from hESCs would offer a vast improvement over current cell therapy procedures that utilize cells from donor pancreases for the treatment of diabetes.
  • current cell therapy treatments for diabetes mellitus, which utilize islet cells from donor pancreases are limited by the scarcity of high quality islet cells needed for transplant.
  • Cell therapy for a single Type I diabetic patient requires a transplant of approximately 8 x 108 pancreatic islet cells.
  • pluripotency is defined by the ability of hESCs to differentiate to derivatives of all 3 primary germ layers (endoderm, mesoderm, ectoderrn) which, in turn, form all somatic cell types of the mature organism in addition to extraembryonic tissues (e.g. placenta) and germ cells.
  • pluripotency imparts extraordinary utility upon hESCs, this property also poses unique challenges for the study and manipulation of these cells and their derivatives. Owing to the large variety of cell types that may arise in differentiating hESC cultures, the vast majority of cell types are produced at very low efficiencies. Additionally, success in evaluating production of any given cell type depends critically on defining appropriate markers. Achieving efficient, directed differentiation is of great importance for therapeutic application of hESCs.
  • hESCs In order to use hESCs as a starting material to generate cells that are useful in cell therapy applications, it would be advantageous to overcome the foregoing problems. For example, in order to achieve the level of cellular material required for islet cell transplantation therapy, it would be advantageous to efficiently direct hESCs toward the pancreatic islet/ ⁇ -cell lineage at the very earliest stages of differentiation.
  • Embodiments of the present invention relate to cell cultures of PDX1-negative foregut endoderm cells (foregut endoderm cells).
  • the foregut endoderm expresses the HNF1b and FOXA1 markers but does not substantially express PDX1.
  • Other embodiments of the present invention relate to cell cultures of PDX1-positive, dorsally-biased, foregut endoderm cells (dorsal PDX1-positive foregut endoderm cells).
  • the PDX1-positive, dorsally-biased, foregut endoderm cells express one or more markers selected from Table 3 and/or one or more markers selected from Table 4.
  • PDX1-positive, ventrally-biased, foregut endoderm cells relate to cell cultures of PDX1-positive, ventrally-biased, foregut endoderm cells (ventral PDX1-positive foregut endoderm cells).
  • the PDX1-positive, ventrally-biased, foregut endoderm cells express one or more markers selected from Table 3 but do not substantially express a marker selected from Table 4 as compared to the expression of the same marker in PDX1-positive, dorsally-biased, foregut endoderm cells.
  • Additional embodiments of the present invention relate to enriched, isolated and/or purified cell populations comprising PDX1-negative foregut endoderm cells.
  • Other embodiments relate to PDX1-positive, dorsally-biased, foregut endoderm cells.
  • Still other embodiments relate to enriched, isolated and/or purified cell populations comprising PDX1-positive, ventrally-biased, foregut endoderm cells.
  • aspects of the present invention also relate to methods or processes for the production of cell cultures of PDX1-negative foregut endoderm cells from definitive endoderm cells.
  • Such processes include reducing or eliminating TGF ⁇ superfamily growth factor signaling in a cell culture or cell population of definitive endoderm cells.
  • reducing or eliminating TGF ⁇ superfamily growth factor signaling is mediated by diluting or removing an exogenously added TGF ⁇ superfamily growth factor, such as activin A, from the cell culture or cell population of definitive endoderm.
  • differentiation of definitive endoderm cells to foregut endoderm cells is enhanced by providing the definitive endoderm cell culture or cell population with an FGF-family growth factor and/or a hedgehog pathway inhibitor.
  • the definitive endoderm cells are derived from stem cells.
  • the stem cells are embryonic stem cells.
  • the stem cells are human embryonic stem cells (hESCs).
  • the PDX1-negative foregut endoderm cells are differentiated to-PDX1-positive endoderm cells (pancreatic endoderm cells) by the addition of a retinoid, such as retinoic acid.
  • a retinoid such as retinoic acid.
  • Other aspects relate to methods or processes for the production of cell cultures of PDX1-positive, dorsally-biased, foregut endoderm cells. Such processes include providing definitive endoderm cells with retinoic acid.
  • the definitive endoderm cells are derived from stem cells.
  • the stem cells are embryonic stem cells. Even more preferably, the stem cells are human embryonic stem cells (hESCs). Further aspects of the present invention relate to methods or processes for the production of cell cultures of PDX1-positive, ventrally-biased, foregut endoderm cells. Such processes include providing. definitive endoderm cells with an FGF-family growth factor. In some embodiments, the definitive endoderm cells are derived from stem cells. Preferably, the stem cells are embryonic stem cells. Even more preferably, the stem cells are hESCs.
  • Additional embodiments of the present invention relate to methods of enriching, isolating and/or purifying PDX1-negative foregut endoderm cells.
  • PDX1-negative foregut endoderm cells are separated from other cells in the cell population by using an antibody, ligand or other molecule that binds to a molecule that is expressed on the cell surface of PDX1-negative foregut endoderm cells, such as a cell surface molecule.
  • Other embodiments of the present invention relate to methods of enriching, isolating and/or purifying PDX1-positive, dorsally-biased, foregut endoderm cells.
  • PDX1-positive, dorsally-biased, foregut endoderm cells are separated from other cells in the cell population by using an antibody, ligand or other molecule that binds to a molecule that is expressed on the cell surface of PDX1-positive, dorsally-biased, foregut endoderm cells, such as a cell surface molecule selected from Table 3 or a cell surface molecule selected from Table 4.
  • Still other embodiments of the present invention relate to methods of enriching, isolating and/or purifying PDX1-positive, ventrally-biased, foregut endoderm cells.
  • PDX1-positive, ventrally-biased, foregut endoderm cells are separated from other cells in the cell population by using an antibody, ligand or other molecule that binds to a molecule that is expressed on the cell surface of PDX1-positive, ventrally-biased, foregut endoderm cells, such as a cell surface molecule selected from Table 3.
  • Embodiments of the present invention relate to additional methods of enriching, isolating and/or purifying PDX1-negative foregut endoderm cells.
  • pluripotent or multipotent cells that are precursors to PDX1-negative foregut endoderm cells are engineered to contain a fluorescent reporter gene under control of a promoter that endogenously controls the expression of a marker gene such as HNF1b or FOXA1.
  • the fluorescently-tagged PDX1-negative foregut endoderm cells are then separated from other cells in the cell population by fluorescence activated cell sorting (FACS).
  • FACS fluorescence activated cell sorting
  • pluripotent or multipotent PDX1-negative cells that are precursors to PDX1-positive cells are engineered to contain a fluorescent reporter gene under control of a promoter that endogenously controls the expression of a marker gene selected from Table 3 or Table 4.
  • the fluorescently-tagged PDX1-positive, dorsally-biased, foregut endoderm cells are then separated from other cells in the cell population by fluorescence activated cell sorting (FACS).
  • pluripotent or multipotent PDX1-negative cells that are precursors to PDX1-positive cells are engineered to contain a fluorescent reporter gene under control of a promoter that endogenously controls the expression of a marker gene selected from Table 3.
  • the fluorescently-tagged PDX1-positive, ventrally-biased, foregut endoderm cells are then separated from other cells in the cell population by FACS.
  • Further embodiments of the present invention relate to methods of identifying a differentiation factor capable of promoting the differentiation of human PDX1-negative foregut endoderm cells in a cell population comprising human cells.
  • the method includes the steps of obtaining a cell population comprising human PDX1-negative foregut endoderm cells, providing a candidate differentiation factor to the cell population, determining expression of a marker, such as HNF1b, FOXA1 or PDX1, in the cell population at a first time point and determining expression of the same marker in the cell population at a second time point.
  • the second time point is subsequent to the first time point and the second time point is subsequent to providing the cell population with the candidate differentiation factor.
  • the candidate differentiation factor is capable of promoting the differentiation of the human PDX1-negative foregut endoderm cells.
  • Still further embodiments of the present invention relate to methods of identifying a differentiation factor capable of promoting the differentiation of human PDX1-positive, dorsally-biased, foregut endoderm cells in a cell population comprising human cells.
  • the method includes the steps of obtaining a cell population comprising human PDX1-positive, dorsally-biased, foregut endoderm cells, providing a candidate differentiation factor to the cell population, determining expression of a marker, such as a marker selected from Table 3 or a marker selected from Table 4, in the cell population at a first time point and determining expression of the same marker in the cell population at a second time point.
  • a marker such as a marker selected from Table 3 or a marker selected from Table 4
  • the second time point is subsequent to the first time point and the second time point is subsequent to providing the cell population with the candidate differentiation factor.
  • the candidate differentiation factor is capable of promoting the differentiation of the human PDX1-positive, dorsally-biased, foregut endoderm cells.
  • Yet further embodiments of the present invention relate to methods of identifying a differentiation factor capable of promoting the differentiation of human PDX1-positive, ventrally-biased, foregut endoderm cells in a cell population comprising human cells.
  • the method includes the steps of obtaining a cell population comprising human PDX1-positive, ventrally-biased, foregut endoderm cells, providing a candidate differentiation factor to the cell population, determining expression of a marker, such as a marker selected from Table 3, in the cell population at a first time point and determining expression of the same marker in the cell population at a second time point.
  • a marker such as a marker selected from Table 3
  • the second time point is subsequent to the first time point and the second time point is subsequent to providing the cell population with the candidate differentiation factor.
  • the candidate differentiation factor is capable of promoting the differentiation of the human PDX1-positive, ventrally-biased, foregut endoderm cells.
  • a cell culture comprising human cells wherein at least about 26% of said human cells are pancreatic-duodenal homoebox factor-1 (PDX1) positive, dorsally-biased, foregut endoderm cells that express at least one marker selected from Table 3, said PDX1-positive, dorsally-biased, foregut endoderm cells being multipotent cells that can differentiate into cells of the dorsal pancreatic bud.
  • PDX1 pancreatic-duodenal homoebox factor-1
  • a cell culture comprising human cells wherein at least about 2% of said human cells are pancreatic-duodenal homoebox factor-1 (PDX1) positive, ventrally-biased, foregut endoderm cells that express at least one marker selected from Table 3, said PDX1-positive, ventrally-biased, foregut endoderm cells being multipotent cells that can differentiate into cells of the ventral pancreatic bud.
  • PDX1 pancreatic-duodenal homoebox factor-1
  • a cell population comprising cells wherein at least about 90% of said cells are human PDX1-positive, dorsally-biased, foregut endoderm cells that express at least one marker selected from Table 3, said PDX1-positive, dorsally-biased, foregut endoderm cells being multipotent cells that can differentiate into cells of the dorsal pancreatic bud.
  • a cell population comprising cells wherein at least about 90% of said cells are human PDX1-positive, ventrally-biased, foregut endoderm cells that express at least one marker selected from Table 3, said PDX1-positive, ventrally-biased, foregut endoderm cells being multipotent cells that can differentiate into cells of the ventral pancreatic bud.
  • a method of producing PDX1-positive, dorsally-biased, foregut endoderm cells comprising the steps of obtaining a cell population comprising PDX1-negative definitive endoderm cells and providing said cell population with a retinoid in an amount sufficient to promote differentiation of at least 26% of said PDX1-negative definitive endoderm cell population to PDX1-positive, dorsally-biased, foregut endoderm cells that express at least one marker selected from Table 3, wherein said PDX1-positive, dorsally-biased, foregut endoderm cells are multipotent cells that can differentiate into cells of the dorsal pancreatic bud.
  • the method of paragraph 50 further comprising the step of allowing sufficient time for PDX1-positive, dorsally-biased, foregut endoderm cells to form, wherein said sufficient time for PDX1-positive, dorsally-biased, foregut endoderm cells to form has been determined by detecting the presence of a marker from Table 4 in dorsally-biased foregut endoderm cells in said cell population.
  • activin A is provided in a concentration ranging from about 10 ng/ml to about 200 ng/ml.
  • activin A is provided in a concentration ranging from about 20 ng/ml to about 100 ng/ml.
  • CMRL medium comprises RA at about 2 ⁇ M, activin A at about 25 ng/ml and B27 at about 0.5% of the total medium.
  • said step of obtaining a cell population comprising PDX1-negative definitive endoderm cells comprises obtaining a cell population comprising pluripotent human cells, providing said cell population with at least one growth factor of the TGF ⁇ superfamily in an amount sufficient to promote differentiation of said pluripotent cells to definitive endoderm cells and allowing sufficient time for definitive endoderm cells to form, wherein said sufficient time for definitive endoderm cells to form has been determined by detecting the presence of definitive endoderm cells in said cell population.
  • a PDX1-positive, dorsally-biased, foregut endoderm cell produced by the method of paragraph 49.
  • a method of producing PDX1-positive, ventrally-biased, foregut endoderm cells comprising the steps of obtaining a cell population comprising PDX1-negative definitive endoderm cells and providing said cell population with an FGF-family growth factor in an amount sufficient to promote differentiation of at least a portion of said PDX1-negative definitive endoderm cell population to PDX1-positive, ventrally-biased, foregut endoderm cells that express at least one marker selected from Table 3, wherein said PDX1-positive, ventrally-biased, foregut endoderm cells are multipotent cells that can differentiate into cells of the ventral pancreatic bud.
  • the method of paragraph 75 further comprising the step of allowing sufficient time for PDX1-positive, ventrally-biased, foregut endoderm cells to form, wherein said sufficient time for PDX1-positive, ventrally-biased, foregut endoderm cells to form has been determined by detecting the presence of a marker from Table 3 in ventrally-biased foregut endoderm cells in said cell population.
  • CMRL medium comprises FGF-10 at about 50 ng/ml, KAAD-cyclopamine at about 0.5 ⁇ M, and B27 at about 0.5% of the total medium.
  • step of obtaining a cell population comprising PDX1-negative definitive endoderm cells comprises obtaining a cell population comprising pluripotent human cells, providing said cell population with at least one growth factor of the TGF ⁇ superfamily in an amount sufficient to promote differentiation of said pluripotent cells to definitive endoderm cells and allowing sufficient time for definitive endoderm cells to form, wherein said sufficient time for definitive endoderm cells to form has been determined by detecting the presence of definitive endoderm cells in said cell population.
  • a method of producing a cell population enriched in PDX1-positive, dorsally-biased, foregut endoderm cells comprising the steps of differentiating cells in a population of PDX1-negative definitive endoderm cells so as to produce PDX1-positive, dorsally-biased, foregut endoderm cells, said PDX1-positive, dorsally-biased, foregut endoderm cells being multipotent cells that can differentiate into cells of the dorsal pancreatic bud, providing to said cell population a reagent which binds to a marker expressed in said PDX1-positive, dorsally-biased, foregut endoderm cells but which is not substantially expressed in other cell types present in said cell population and separating said PDX1-positive, dorsally-biased, foregut endoderm cells bound to said reagent from said other cell types present in said cell population, thereby producing a cell population enriched in PDX1-positive, do
  • said marker is selected from the group consisting of ADORA2A, CD47, EPB41L1, MAG, SFRP5, SLC16A10, SLC16A2, SLC1A3, SLC30A4, SLICK, SLITRK4 and XPR1.
  • the differentiating step further comprises obtaining a cell population comprising PDX1-negative definitive endoderm cells, providing said cell population with a retinoid in an amount sufficient to promote differentiation of said PDX1-negative definitive endoderm cells to PDX1-positive, dorsally-biased, foregut endoderm cells, said PDX1-positive, dorsally-biased, foregut endoderm cells being multipotent cells that can differentiate into cells of the dorsal pancreatic bud, and allowing sufficient time for PDX1-positive, dorsally-biased, foregut endoderm cells to form, wherein said sufficient time for PDX1-positive, dorsally-biased, foregut endoderm cells to form has been determined by detecting the presence of PDX1-positive, dorsally-biased, foregut endoderm cells in said cell population.
  • detecting comprises detecting the expression of at least one marker selected from Table 4.
  • a method of producing a cell population enriched in PDX1-positive, ventrally-biased, foregut endoderm cells comprising the steps of differentiating cells in a population of PDX1-negative definitive endoderm cells so as to produce PDX1-positive, ventrally-biased, foregut endoderm cells, said PDX1-positive, ventrally-biased, foregut endoderm cells being multipotent cells that can differentiate into cells of the ventral pancreatic bud, providing to said cell population a reagent which binds to a marker expressed in said PDX1-positive, ventrally-biased, foregut endoderm cells but which is not substantially expressed in other cell types present in said cell population and separating said PDX1-positive, ventrally-biased, foregut endoderm cells bound to said reagent from said other cell types present in said cell population, thereby producing a cell population enriched in PDX1-positive, ventrally-biased, foregut endoderm
  • the differentiating step further comprises obtaining a cell population comprising PDX1-negative definitive endoderm cells, providing said cell population with an FGF-family growth factor in an amount sufficient to promote differentiation of said PDX1-negative definitive endoderm cells to PDX1-positive, ventrally-biased, foregut endoderm cells, said PDX1-positive, ventrally-biased, foregut endoderm cells being multipotent cells that can differentiate into cells of the ventral pancreatic bud, and allowing sufficient time for PDX1-positive, ventrally-biased, foregut endoderm cells to form, wherein said sufficient time for PDX1-positive, ventrally-biased, foregut endoderm cells to form has been determined by detecting the presence of PDX1-positive, ventrally-biased, foregut endoderm cells in said cell population.
  • detecting comprises detecting the expression of at least one marker selected from Table 3.
  • a method of producing a cell population enriched in PDX1-positive, dorsally-biased, foregut endoderm cells comprising the steps of obtaining a population of pluripotent cells, wherein at least one cell of said pluripotent cell population comprises at least one copy of a nucleic acid under the control of the a promoter of any one of the marker genes selected from Table 4, said nucleic acid comprising a sequence encoding a fluorescent protein or a biologically active fragment thereof, differentiating said pluripotent cells so as to produce PDX1-positive, dorsally-biased foregut endoderm cells, said PDX1-positive, dorsally-biased, foregut endoderm cells being multipotent cells that can differentiate into cells of the dorsal pancreatic bud, and separating said PDX1-positive, dorsally-biased, foregut endoderm cells from other cell types present in the cell population.
  • said enriched cell population comprises at least about 95% PDX1-positive, dorsally-biased, foregut endoderm cells.
  • said enriched cell population comprises at least about 98% PDX1-positive, dorsally-biased, foregut endoderm cells.
  • the differentiating step further comprises, providing said pluripotent cell population with at least one growth factor of the TGF ⁇ superfamily in an amount sufficient to promote differentiation of said pluripotent cells to PDX1-negative definitive endoderm cells, and providing said PDX1-negative definitive endoderm cells with a retinoid in an amount sufficient to promote differentiation of said PDX1-negative definitive endoderm cells to PDX1-positive, dorsally-biased, foregut endoderm cells.
  • a method of producing a cell population enriched in PDX1-positive, ventrally-biased, foregut endoderm cells comprising the steps of obtaining a population of pluripotent cells, wherein at least one cell of said pluripotent cell population comprises at least one copy of a nucleic acid under the control of the a promoter of any one of the marker genes selected from Table 3, said nucleic acid comprising a sequence encoding a fluorescent protein or a biologically active fragment thereof, differentiating said pluripotent cells so as to produce PDX1-positive, ventrally-biased foregut endoderm cells, said PDX1-positive, ventrally-biased, foregut endoderm cells being multipotent cells that can differentiate into cells of the ventral pancreatic bud and separating said PDX1-positive, ventrally-biased, foregut endoderm cells from non-ventrally-biased foregut endoderm cells.
  • said enriched cell population comprises at least about 98% PDX1-positive, ventrally-biased, foregut endoderm cells.
  • the differentiating step further comprises, providing said pluripotent cell population with at least one growth factor of the TGF ⁇ superfamily in an amount sufficient to promote differentiation of said pluripotent cells to PDX1-negative definitive endoderm cells, and providing said PDX1-negative definitive endoderm cells with an FGF-family growth factor in an amount sufficient to promote differentiation of said PDX1-negative definitive endoderm cells to PDX1-positive, ventrally-biased, foregut endoderm cells.
  • a method of identifying a differentiation factor capable of promoting the differentiation of human PDX1-positive, dorsally-biased, foregut endoderm cells in a cell population comprising human cells comprising the steps of obtaining a cell population comprising human PDX1-positive, dorsally-biased, foregut endoderm cells, providing a candidate differentiation factor to said cell population, determining expression of a marker in said cell population at a first time point, determining expression of the same marker in said cell population at a second time point, wherein said second time point is subsequent to said first time point and wherein said second time point is subsequent to providing said cell population with said candidate differentiation factor and determining if expression of the marker in said cell population at said second time point is increased or decreased as compared to the expression of the marker in said cell population at said first time point, wherein an increase or decrease in expression of said marker in said cell population indicates that said candidate differentiation factor is capable of promoting the differentiation of said human PDX1-positive, dorsally-bia
  • a method of identifying a differentiation factor capable of promoting the differentiation of human PDX1-positive, ventrally-biased, foregut endoderm cells in a cell population comprising human cells comprising the steps of obtaining a cell population comprising human PDX1-positive, ventrally-biased, foregut endoderm cells, providing a candidate differentiation factor to said cell population, determining expression of a marker in said cell population at a first time point, determining expression of the same marker in said cell population at a second time point, wherein said second time point is subsequent to said first time point and wherein said second time point is subsequent to providing said cell population with said candidate differentiation factor and determining if expression of the marker in said cell population at said second time point is increased or decreased as compared to the expression of the marker in said cell population at said first time point, wherein an increase or decrease in expression of said marker in said cell population indicates that said candidate differentiation factor is capable of promoting the differentiation of said human PDX1-positive, ventrally-biased, for
  • FIG. 1 is a schematic of a proposed differentiation pathway for the production of beta-cells from hESCs.
  • the first step in the pathway commits the ES cell to the definitive endoderm lineage and also represents the first step prior to further differentiation events to pancreatic endoderm, endocrine endoderm, or islet/beta-cells.
  • the second step in the pathway shows the conversion of SOX17-positive/PDX1-negative definitive endoderm to PDX1-positive foregut endoderm. Some factors useful for mediating these transitions are italicized. Relevant markers for defining the target cells are underlined.
  • FIG. 2 is a diagram of the human SOX17 cDNA which displays the positions of conserved motifs and highlights the region used for the immunization procedure by GENOVAC.
  • FIG. 3 is a relational dendrogram illustrating that SOX17 is most closely related to SOX7 and somewhat less to SOX18.
  • the SOX17 proteins are more closely related among species homologs than to other members of the SOX group F subfamily within the same species.
  • FIG. 4 is a Western blot probed with the rat anti-SOX17 antibody. This blot demonstrates the specificity of this antibody for human SOX17 protein over-expressed in fibroblasts (lane 1) and a lack of immunoreactivity with EGFP (lane 2) or the most closely related SOX family member, SOX7 (lane 3).
  • FIGS. 5 A-B are micrographs showing a cluster of SOX17 + cells that display a significant number of AFP+co-labeled cells (A). This is in striking contrast to other SOX 17+clusters (B) where little or no AFP+cells are observed.
  • FIGS. 6 A-C are micrographs showing parietal endoderm and SOX17.
  • Panel A shows immunocytochemistry for human Thrombomodulin (TM) protein located on the cell surface of parietal endoderm cells in randomly differentiated cultures of hES cells.
  • Panel B is the identical field shown in A double-labeled for TM and SOX17.
  • Panel C is the phase contrast image of the same field with DAPI labeled nuclei. Note the complete correlation of DAPI labeled nuclei and SOX17 labeling.
  • FIGS. 7 A-B are bar charts showing SOX17 gene expression by quantitative PCR (Q-PCR) and anti-SOX17 positive cells by SOX17-specific antibody.
  • Panel A shows that activin A increases SOX 17 gene expression while retinoic acid (RA) strongly suppresses SOX 17 expression relative to the undifferentiated control media (SR20).
  • Panel B shows the identical pattern as well as a similar magnitude of these changes is reflected in SOX17 + cell number, indicating that Q-PCR measurement of SOX17 gene expression is very reflective of changes at the single cell level.
  • FIG. 8A is a bar chart which shows that a culture of differentiating hESCs in the presence of activin A maintains a low level of AFP gene expression while cells allowed to randomly differentiate in 10% fetal bovine serum (FBS) exhibit a strong upregulation of AFP. The difference in expression levels is approximately 7-fold.
  • FBS fetal bovine serum
  • FIGS. 8 B-C are images of two micrographs showing that the suppression of AFP expression by activin A is also evident at the single cell level as indicated by the very rare and small clusters of AFP + cells observed in activin A treatment conditions (bottom) relative to 10% FBS alone (top).
  • FIGS. 9 A-B are comparative images showing the quantitation of the AFP + cell number using flow cytometry. This figure demonstrates that the magnitude of change in AFP gene expression ( FIG. 8A ) in the presence (right panel) and absence (left panel) of activin A exactly corresponds to the number of AFP + cells, further supporting the utility of Q-PCR analyses to indicate changes occurring at the individual cell level.
  • FIGS. 10 A-F are micrographs which show that exposure of hESCs to nodal, activin A and activin B (NAA) yields a striking increase in the number of SOX17 + cells over the period of 5 days (A-C).
  • A-C activin A and activin B
  • FIG. 11 is a bar chart which demonstrates that activin A (0, 10, 30 or 100 ng/ml) dose-dependently increases SOX17 gene expression in differentiating hESCs. Increased expression is already robust after 3 days of treatment on adherent cultures and continues through subsequent 1, 3 and 5 days of suspension culture as well.
  • FIGS. 12 A-C are bar charts which demonstrate the effect of activin A on the expression of MIXLI (panel A), GATA4 (panel B) and HNF3b (panel C).
  • Activin A dose-dependent increases are also observed for three other markers of definitive endoderm; MIXLI, GATA4 and HNF3b.
  • the magnitudes of increased expression in response to activin dose are strikingly similar to those observed for SOX17, strongly indicating that activin A is specifying a population of cells that co-express all four genes (SOX17+, MIXLI+, GATA4+and HNF3b+).
  • FIGS. 13 A-C are bar charts which demonstrate the effect of activin A on the expression of AFP (panel A), SOX7 (panel B) and SPARC (panel C).
  • AFP panel A
  • SOX7 panel B
  • SPARC panel C
  • Markers of primitive endoderm (SOX7) and parietal endodenn (SPARC) remain either unchanged or exhibit suppression at some time points indicating that activin A does not act to specify these extra-embryonic endoderm cell types.
  • SOX17, MIXLI, GATA4, and HNF3b are due to an increase in the number of definitive endoderm cells in response to activin A.
  • FIGS. 14 A-B are bar charts showing the effect of activin A on ZIC1 (panel A) and Brachyury expression (panel B) Consistent expression of the neural marker ZIC1 demonstrates that there is not a dose-dependent effect of activin A on neural differentiation. There is a notable suppression of mesoderm differentiation mediated by 100 ng/ml of activin A treatment as indicated by the decreased expression of brachyury. This is likely the result of the increased specification of definitive endoderm from the mesendoderm precursors. Lower levels of activin A treatment (10 and 30 ng/ml) maintain the expression of brachyury at later time points of differentiation relative to untreated control cultures.
  • FIGS. 15 A-B are micrographs showing decreased parietal endoderm differentiation in response to treatment with activins. Regions of TMhi parietal endoderm are found through the culture (A) when differentiated in serum alone, while differentiation to TM+cells is scarce when activins are included (B) and overall intensity of TM immunoreactivity is lower.
  • FIGS. 16 A-D are micrographs which show marker expression in response to treatment with activin A and activin B. hESCs were treated for four consecutive days with activin A and activin B and triple labeled with SOX17, AFP and TM antibodies. Panel A—SOX17; Panel B—AFP; Panel C—TM; and Panel D—Phase/DAPI. Notice the numerous SOX 17 positive cells (A) associated with the complete absence of AFP (B) and TM (C) immunoreactivity.
  • FIG. 17 is a micrograph showing the appearance of definitive endoderm and visceral endoderm in vitro from hESCs.
  • the regions of visceral endoderm are identified by AFP hi /SOX17 lo/ while definitive endoderm displays the complete opposite profile, SOX17 hi /AFP lo/ .
  • This field was selectively chosen due to the proximity of these two regions to each other.
  • SOX17 hi /AFP lo/ regions are observed in absolute isolation from any regions of AFPhi cells, suggesting the separate origination of the definitive endoderm cells from visceral endoderm cells.
  • FIG. 18 is a diagram depicting the TGF ⁇ family of ligands and receptors. Factors activating AR Smads and BR Smads are useful in the production of definitive endoderm from human embryonic stem cells (see, J Cell Physiol.187:265-76).
  • FIG. 19 is a bar chart showing the induction of SOX17 expression over time as a result of treatment with individual and combinations of TGF ⁇ factors.
  • FIG. 20 is a bar chart showing the increase in SOX17+cell number with time as a result of treatment with combinations of TGF ⁇ factors.
  • FIG. 21 is a bar chart showing induction of SOX 17 expression over time as a result of treatment with combinations of TGF ⁇ factors.
  • FIG. 22 is a bar chart showing that activin A induces a dose-dependent increase in SOX17+cell number.
  • FIG. 23 is a bar chart showing that addition of Wnt3a to activin A and activin B treated cultures increases SOX17 expression above the levels induced by activin A and activin B alone.
  • FIGS. 24 A-C are bar charts showing differentiation to definitive endoderm is enhanced in low FBS conditions.
  • Treatment of hESCs with activins A and B in media containing 2% FBS (2AA) yields a 2-3 times greater level of SOX17 expression as compared to the same treatment in 10% FBS media (IOAA) (panel A).
  • Induction of the definitive endoderm marker MIXLI (panel B) is also affected in the same way and the suppression of AFP (visceral endoderm) (panel C) is greater in 2% FBS than in 10% FBS conditions.
  • FIGS. 25 A-D are micrographs which show SOX17 + cells are dividing in culture.
  • SOX17 immunoreactive cells are present at the differentiating edge of an hESC colony (C, D) and are labeled with proliferating cell nuclear antigen (PCNA) (panel B) yet are not co-labeled with OCT4 (panel C).
  • PCNA proliferating cell nuclear antigen
  • OCT4 panel C
  • clear mitotic figures can be seen by DAPI labeling of nuclei in both SOX17+cells (arrows) as well as OCT4+, undifferentiated hESCs (arrowheads) (D).
  • FIG. 26 is a bar chart showing the relative expression level of CXCR4 in differentiating hESCs under various media conditions.
  • FIGS. 27 A-D are bar charts that show how a panel of definitive endoderm markers share a very similar pattern of expression to CXCR4 across the same differentiation treatments displayed in FIG. 26 .
  • FIGS. 28 A-E are bar charts showing how markers for mesoderm (BRACHYURY, MOXI), ectoderm (SOX1, ZIC1) and visceral endoderm (SOX7) exhibit an inverse relationship to CXCR4 expression across the same treatments displayed in FIG. 26 .
  • FIGS. 29 A-F are micrographs that show the relative difference in SOX17 immunoreactive cells across three of the media conditions displayed in FIGS. 26-28 .
  • FIGS. 30 A-C are flow cytometry dot plots that demonstrate the increase in CXCR4+cell number with increasing concentration of activin A added to the differentiation media.
  • FIGS. 31 A-D are bar charts that show the CXCR4+cells isolated from the high dose activin A treatment (A100-CX+) are even further enriched for definitive endoderm markers than the parent population (A100).
  • FIG. 32 is a bar chart showing gene expression from CXCR4+and CXCR4-cells isolated using fluorescence-activated cell sorting (FACS) as well as gene expression in the parent populations. This demonstrates that the CXCR4+cells contain essentially all the CXCR4 gene expression present in each parent population and the CXCR4- populations contain very little or no CXCR4 gene expression.
  • FACS fluorescence-activated cell sorting
  • FIGS. 33 A-D are bar charts that demonstrate the depletion of mesoderm (BRACHYURY, MOXI), ectoderm (ZIC1) and visceral endoderm (SOX7) gene expression in the CXCR4+cells isolated from the high dose activin A treatment which is already suppressed in expression of these non-definitive endoderm markers.
  • FIGS. 34 A-M are bar charts showing the expression patterns of marker genes that can be used to identify definitive endoderm cells.
  • the expression analysis of definitive endoderm markers, FGF17, VWF, CALCR, FOXQI, CMKORI and CRIPI is shown in panels G-L, respectively.
  • the expression analysis of previously described lineage marking genes, SOX17, SOX7, SOX17/SOX7, TM, ZIC1, and MOXI is shown in panels A-F, respectively.
  • Panel M shows the expression analysis of CXCR4.
  • FIG. 35 is a chart which shows the relative expression of the PDX1 gene in a culture of hESCs after 4 days and 6 days with and without activin in the presence of retinoic acid (RA) and fibroblast growth factor (FGF-10) added on day 4.
  • RA retinoic acid
  • FGF-10 fibroblast growth factor
  • FIGS. 36 A-F are charts which show the relative expression of marker genes in a culture of hESCs after 4 days and 6 days with and without activin in the presence of retinoic acid (RA) and fibroblast growth factor (FGF-10) added on day 4.
  • the panels show the relative levels of expression of the following marker genes: (A) SOX I 7; (B) SOX7; (C) AFP; (D) SOX1; (E) ZIC1; and (F) NFM.
  • FIGS. 37 A-C are charts which show the relative expression of marker genes in a culture of hESCs after 4 days and 8 days with and without activin in the presence or absence of combinations of retinoic acid (RA), fibroblast growth factor (FGF-10) and fibroblast growth factor (FGF-4) added on day 4.
  • the panels show the relative levels of expression of the following marker genes: (A) PDX1; (B) SOX7; and (C) NFM.
  • FIGS. 38 A-G are charts which show the relative expression of marker genes in a culture of definitive endoderm cells contacted with 50 ng/ml FGF-10 in combination with either 1 ⁇ M, 0.2 ⁇ M or 0.04 ⁇ M retinoic acid (RA) added on day 4.
  • the panels show the relative levels of expression of the following marker genes: (A) PDX1; (B) HOXA3; (C) HOXC6; (D) HOXA13; (E) CDXI; (F) SOX1; and (G) NFM.
  • FIGS. 39 A-E are charts which show the relative expression of marker genes in a culture of hESCs after 4 days and 8 days with and without activin in the presence of combinations of retinoic acid (RA), fibroblast growth factor (FGF-10) and one of the following: serum replacement (SR), fetal bovine serum (FBS) or B27.
  • the panels show the relative levels of expression of the following marker genes: (A) PDX1; (B) SOX7; (C) AFP; (D) ZIC1; and (E) NFM.
  • FIGS. 40 A-B are charts which show the relative expression of marker genes for pancreas (PDX1, HNF6) and liver (HNF6) in a culture of hESCs after 6 days (just prior to addition of RA) and at 9 days (three days after exposure to RA).
  • Various conditions were included to compare the addition of activin B at doses of 10 ng/ml (alO), 25 ng/ml (a25) or 50 ng/ml (a5O) in the presence of either 25 ng/ml (A25) or 50 ng/ml (A50) activin A.
  • the condition without any activin A or activin B (NF) serves as the negative control for definitive endoderm and PDX1-positive endoderm production.
  • the panels show the relative levels of expression of the following marker genes: (A) PDX1 and (B) HNF6.
  • FIGS. 41 A-C are charts which show the relative expression of marker genes in a culture of hESCs with 100 ng/ml (A100), 50 ng/ml (A50) or without (NF) activin A at 5 days Oust prior to retinoic acid addition) and at 2, 4, and 6 days after RA exposure (day 7, 9, and I1, respectively).
  • the percentage label directly under each bar indicates the FBS dose during days 3-5 of differentiation.
  • cells treated with RA (R) were grown in RPMI medium comprising 0.5% FBS.
  • the RA concentration was 2 ⁇ M on day 7, 1 liM on day 9 and 0.2 ⁇ M on day I1.
  • the panels show the relative levels of expression of the following marker genes: (A) PDX1; (B) ZIC I; (C) SOX7.
  • FIGS. 42 A-B are charts which show the relative expression of marker genes in a culture of hESCs treated first with activin A in low FBS to induce definitive endoderm (day 5) and then with fresh (A25R) medium comprising 25 ng/ml activin A and RA or various conditioned media (MEFCM, CM#2, CM#3 and CM#4) and RA to induce PDX1-expressing endoderm. Marker expression was determined on days 5, 6, 7, 8 and 9. The panels show the relative levels of expression of the following marker genes: (A) PDX1; (B) CDXI.
  • FIG. 43 is a chart which shows the relative expression of PDX1 in a culture of hESCs treated first with activin A in low FBS to induce definitive endoderm and followed by fresh media comprising activin A and retinoic acid (A25R) or varying amounts of RA in conditioned media diluted into fresh media. Total volume of media is 5 ml in all cases.
  • FIG. 44 is a Western blot showing PDX1 immunoprecipitated from RA-treated definitive endoderm cells 3 days (d8) and 4 days (d9) after the addition of RA and 50 ng/ml activin A.
  • FIG. 45 is a summary chart displaying the results of a fluorescence-activated cell sort (FACs) of PDX1-positive foregut endoderm cells genetically tagged with a EGFP reporter under control of the PDX1 promoter.
  • FACs fluorescence-activated cell sort
  • FIG. 46 is a chart showing relative PDX1 expression levels normalized to housekeeping genes for sorted populations of live cells (Live), EGFP-negative cells (Neg) and EGFP-positive cells (GFP+).
  • FIG. 47 is a chart showing relative PDX1 expression levels normalized to housekeeping genes for sorted populations of live cells (Live), EGFP-negative cells (Neg), the half of the EGFP-positive cell population that has the lowest EGFP signal intensity (Lo) and the half of the EGFP-positive cell population that has the highest EGFP signal intensity (Hi).
  • FIGS. 48 A-E are a charts showing the relative expression levels normalized to housekeeping genes of five pancreatic endoderm markers in sorted populations of live cells (Live), EGFP-negative cells (Neg) and EGFP-positive cells (GFP+). Panels: A—NKX2.2; B—GLUT2; C—HNF3 ⁇ ; D—RT19 and E—HNF4 ⁇ .
  • FIG. 49 are a charts showing the relative expression levels normalized to housekeeping genes of two non-pancreatic endoderm markers in sorted populations of live cells (Live), EGFP-negative cells (Neg) and EGFP-positive cells (GFP+). Panels: A—ZIC1 and B—GFAP.
  • FIGS. 50 A-D are charts showing the relative expression of marker genes in a culture of hESCs at the start of differentiation prior to addition of any factor (O d), and either in the presence of 100 ng/ml activin A (A1OO) for 3 days (3 d) followed by 3 ng/ml BMP4 and 50 ng/ml FGF-10 (B3F50) on days 4-11 (7d, 9d and lid) or in the presence of 100 ng/ml activin A (A100) for 5 days (5d) followed by 25 ng/ml activin A and 2 ⁇ M RA (A25R) on day 6 and 7 (7 d).
  • the panels show the relative levels of expression of the following marker genes: (A) ALB; (B) PDX1; (C) HB9 and (D) HHEX.
  • FIGS. 51 A-D are charts showing the relative expression of marker genes in a culture of hESCs at the start of differentiation prior to addition of any factor (O d), and after four days of differentiation under one of the four following conditions: (a) 100 ng/ml BMP4 and 5 ⁇ M SU5402 (B/SU); (b) no factor (NF); (c) 15 ng/ml activin A (A15); or (d) 100 ng/ml activin A. This differentiation is followed by incubation in the presence of 3 ng/ml BMP4, 50 ng/ml FGF-10 and 0.5 ⁇ M KAAD-cyclopamine (B3F50KO.5) on days 5-12 (6d, 8d, lOd and 12d).
  • the panels show the relative levels of expression of the following marker genes: (A) CER; (B) SOX17; (C) PDX1 and (D) ALB.
  • FIGS. 52 A-B are charts showing the relative expression of marker genes in a culture of hESCs at the start of differentiation prior to addition of any factor (O d); in the presence of 100 ng/ml activin A (A1OO) for 3 days (3 d); in the presence of no factor (NF), 50 ng/ml FGF-10 and 0.5 ⁇ M KAAD-cyclopamine (FK) or 3 ng/ml BMP4, 50 ng/ml FGF-10 and 0.5 ⁇ M KAAD-cyclopamine (BFK) on days 4 and 5 (5d); and in the presence of no factor in RPMI medium (2R), no factor in RPMI medium supplemented with B27 (ORB), no factor in CMRL medium supplemented with B27 (OCB), 50 ng/ml FGF-10 and 0.5 ⁇ M KAAD-cyclopamine in CMRL medium supplemented with B27 (FK) or 3 ng/ml BMP4, 50 ng/ml FGF-10 and
  • FIGS. 53 A-E are charts showing the relative expression of marker genes in a culture of hESCs at the start of differentiation prior to addition of any factor (O d), and either in the presence of 100 ng/ml activin A (AIOO) for 3 days (3 d) followed by 3 ng/ml BMP4 and 50 ng/ml FGF-I0 (B3F50) on days 4-11 (7d, 9d and lid) or in the presence of 100 ng/ml activin A (A100) for 5 days (5d) followed by 25 ng/ml activin A and 2 ⁇ M RA (A25R) on day 6 and 7 (7 d).
  • the panels show the relative levels of expression of the following marker genes: (A) PDX1; (B) SERPINF2; (C) DUSP9; (D) CDH6 and (E) SOX9.
  • FIGS. 54 A-D are charts showing the relative expression of marker genes in a culture of hESCs at the start of differentiation prior to addition of any factor (0 d), and either in the presence of 100 ng/ml activin A (A100) for 3 days (3 d) followed by 3 ng/ml BMP4 and 50 ng/ml FGF-10 (B3F50) on days 4-11 (7d, 9d and lI d) or in the presence of 100 ng/ml activin A (AIOO) for 5 days (5d) followed by 25 ng/ml activin A and 2 ⁇ M RA (A25R) on day 6 and 7 (7 d).
  • the panels show the relative levels of expression of the following marker genes: (A) HOXAI; (B) PDEI IA; (C) FAM49A and (D) WNT5A.
  • Gastrulation is extremely significant because it is at this time that the three primary germ layers are first specified and organized (Lu et al., 2001; Schoenwolf and Smith, 2000).
  • the ectoderm is responsible for the eventual formation of the outer coverings of the body and the entire nervous system whereas the heart, blood, bone, skeletal muscle and other connective tissues are derived from the mesoderm.
  • Definitive endoderm is defined as the germ layer that is responsible for formation of the entire gut tube which includes the esophagus, stomach and small and large intestines, and the organs which derive from the gut tube such as the lungs, liver, thymus, parathyroid and thyroid glands, gall bladder and pancreas (Grapin-Botton and Melton, 2000; Kimelman and Griffin, 2000; Tremblay et al., 2000; Wells and Melton, 1999; Wells and Melton, 2000).
  • the primitive endoderm is primarily responsible for formation of extra-embryonic tissues, mainly the parietal and visceral endoderm portions of the placental yolk sac and the extracellular matrix material of Reichert's membrane.
  • definitive endoderm formation begins with a cellular migration event in which mesendoderm cells (cells competent to form mesoderm or endoderm) migrate through a structure called the primitive streak.
  • mesendoderm cells cells competent to form mesoderm or endoderm
  • Definitive endoderm is derived from cells, which migrate through the anterior portion of the streak and through the node (a specialized structure at the anterior-most region of the streak).
  • definitive endoderm populates first the most anterior gut tube and culminates with the formation of the posterior end of the gut tube.
  • PDX1 (also called STF-1, IDX-1, IPF-1, IUF-I and GSF) is a transcription factor that is necessary for development of the pancreas and rostral duodenum. PDX1 is first expressed in the pancreatic endoderm, which arises from posterior foregut endoderm and will produce both the exocrine and endocrine cells, starting at E8.5 in the mouse. Later, PDX1 becomes restricted to beta-cells and some delta-cells. This expression pattem is maintained in the adult.
  • PDX1 is also expressed in duodenal endoderm early in development, which is adjacent to the forming pancreas, then in the duodenal enterocytes and enteroendocrine cells, antral stomach and in the common bile, cystic and biliary ducts. This region of expression also becomes limited, at the time that pancreatic expression becomes restricted, to predominantly the rostral duodenum.
  • PDX1 pancreatic agenesis
  • PDX1 is also required during terminal differentiation of the insulin and somatostatin pancreatic endocrine cells and functional disruption of a single allele in humans is associated with severe pancreatic dysfunction of MODY type 4 (maturity onset diabetes of the young) and late onset type 1I diabetes (Stoffers D. A., et al. Nature Genetics 138-139, 1997).
  • pancreas During embryogenesis of the pancreas a budding of the prospective pancreatic tissue occurs on both the dorsal and ventral side of the primitive gut endoderm. These protrusions occur in a regionally defined manner at the most posterior end of the foregut endoderm. In mice this occurs at approximately 8.5-9.5 days post conception (dpc) and in humans at 30 dpc. By 35 dpc in the human, the ventral and dorsal buds have grown, developed a branched ductal system and fused to form the definitive organ. PDX1 protein is required for the early pancreatic buds to expand and differentiate into the principal cells comprising the pancreas which include duct, acinar and endocrine cells.
  • aspects of the present invention relate to the discovery that definitive endoderm cells can be differentiated into at least two distinguishable types of PDX1-expressing (PDX1-positive) foregut endoderm cells.
  • definitive endoderm cells can be differentiated into a PDX1-negative foregut endoderm cell.
  • a retinoid compound such as retinoic acid, induces the expression of PDX1.
  • definitive endoderm cells are differentiated to form dorsal PDX1-positive foregut endoderm cells.
  • PDX1-positive foregut endoderm “dorsal” or “dorsally-biased” means that the PDX1-positive foregut endoderm cells are those that can give rise to tissues derived from the dorsal side of the posterior portion of the foregut, such as the dorsal pancreatic bud. Once a PDX1-positive foregut endoderm cell becomes “dorsally-biased” it does not typically develop into tissues derived from the ventral side of the posterior portion of the foregut. In another aspect, definitive endoderm cells are differentiated to form ventral PDX1-positive foregut endoderm cells.
  • PDX1-positive foregut endoderm As used herein, with respect to PDX1-positive foregut endoderm, “ventral” or “ventrally-biased” means that the PDX1-positive foregut endoderm cells are those that can give rise to tissues derived from the ventral side of the posterior portion of the foregut, such as the liver and the ventral pancreatic bud. Once a PDX1-positive foregut endoderm cell becomes “ventrally-biased” it does not typically develop into tissues derived from the dorsal side of the posterior portion of the foregut.
  • embodiments of the present invention relate to compositions of PDX1-negative foregut endoerm cells, dorsally-biased PDX1-positive foregut endoderm cells, ventrally-biased PDX1-positive foregut endoderm cells and/or compositions comprising mixtures of dorsally-biased and ventrally-biased PDX1-positive foregut endoderm cells as well as methods for the production of such compositions.
  • Other embodiments of the present invention relate to screening of PDX1-negative foregut endoderm cells for factors that promote the differentiation of such cells.
  • Still other embodiments relate to screening dorsal, ventral or mixed populations of PDX1-positive foregut endoderm cells for factors that promote the differentiation of such cells.
  • mixed populations is meant a cell population comprising significant amounts of both dorsal PDX1-positive foregut endoderm cells and ventral PDX1-positive foregut endoderm cells.
  • FGF-family growth factor includes, but is not limited to, FGF-family growth factor selected from the group consisting of FGFI, FGF2, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGF10, FGFII, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF 18, FGF 19, FGF20, FGF21, FGF22 and/or FGF23.
  • hedgehog inhibitor includes, but is not limited to, KKAD-cyclopamine, KKAD-cyclopamine analogs, jervine, jervine analogs, hedgehog pathway blocking antibodies and any other inhibitors of hedgehog pathway function known to those of ordinary skill in the art.
  • Embodiments of the present invention relate to novel, defined processes for the production of PDX1-negative endoderm cells, wherein the PDX1-negative endoderm cells are multipotent cells that can differentiate into cells, tissues or organs derived from the foregut/midgut region of the gut tube (PDX1-negative foregut/midgut endoderm).
  • multipotent or “multipotent cell” refers to a cell type that can give rise to a limited number of other particular cell types but which cannot give rise to all three primary embryonic cells lineages (endoderm, ectoderm and mesoderm).
  • foregut/midgut refers to cells of the anterior portion of the gut tube as well as cells of the middle portion of the gut tube, including cells of the foregut/midgut junction.
  • Some preferred embodiments of the present invention relate to processes for the production of PDX1-negative foregut endoderm cells.
  • these PDX1-negative foregut endoderm cells are multipotent cells that can differentiate into cells, tissues or organs derived from the anterior portion of the gut tube (PDX1-negative foregut endoderm).
  • Embodiments of the present invention relate to novel, defined processes for the production of PDX1-negative endoderm cells, wherein the PDX1-positive endoderm cells are multipotent cells that can differentiate into cells, tissues or organs derived from the foregut/midgut region of the gut tube (PDX1-positive foregut/midgut endoderm).
  • Other embodiments of the present invention relate to novel, defined processes for the production of PDX1-positive endoderm cells, wherein the PDX1-positive endoderm cells are multipotent cells that can differentiate into cells, tissues or organs derived from the foregut/midgut region of the gut tube (PDX1-positive foregut/midgut endoderm).
  • multipotent or “multipotent cell” refers to a cell type that can give rise to a limited number of other particular cell types but which cannot give rise to all three primary embryonic cells lineages (endoderm, ectoderm and mesoderm).
  • foregut/midgut refers to cells of the anterior portion of the gut tube as well as cells of the middle portion of the gut tube, including cells of the foregut/midgut junction.
  • the PDX1 positive endoderm cells are dorsal foregut endoderm cells. In other embodiments, the PDX1 positive endoderm cells are ventral foregut endoderm cells.
  • Some preferred embodiments of the present invention relate to processes for the production of PDX1-positive foregut endoderm cells.
  • these PDX1-positive foregut endoderm cells are multipotent cells that can differentiate into cells, tissues or organs derived from the anterior portion of the gut tube (PDX1-positive foregut endoderm).
  • the PDX1 positive endoderm cells are dorsal foregut endoderm cells.
  • the PDX1 positive endoderm cells are ventral foregut endoderm cells.
  • PDX1-positive endoderm cells of the posterior portion of the foregut.
  • these PDX1-positive endoderm cells are multipotent cells that can differentiate into cells, tissues or organs derived from the posterior portion of the foregut region of the gut tube.
  • the PDX1 positive endoderm cells are dorsal endoderm cells that can differentiate into cells, tissues or organs derived from the posterior portion of the foregut, such as cells of the dorsal pancreatic bud.
  • the PDX1 positive endoderm cells are ventral foregut endoderm cells that can differentiate into cells, tissues or organs derived from the posterior portion of the foregut, such as cells of the ventral pancreatic bud.
  • the dorsal and/or ventral PDX1-positive foregut endoderm cells can be used to produce fully differentiated insulin-producing ⁇ -cells.
  • positive dorsal and/or ventral PDX1- foregut endoderm cells are produced by differentiating definitive endoderm cells that do not substantially express PDX1 (PDX1-negative definitive endoderm cells; also referred to herein as definitive endoderm) so as to form positive dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • PDX1-negative definitive endoderm cells can be prepared by differentiating pluripotent cells, such as embryonic stem cells, as described herein or by any other known methods.
  • pluripotent cells such as embryonic stem cells
  • a convenient and highly efficient method for producing PDX1-negative definitive endoderm from pluripotent cells is described in U.S. Pat. No. 11/021,618, entitled DEFINITIVE ENDODERM, filed Dec. 23, 2004, the disclosure of which is incorporated herein by reference in its entirety.
  • Processes of producing PDX1-positive foregut endoderm cells provide a basis for efficient production of pancreatic tissues such as acinar cells, ductal cells and islet cells from pluripotent cells.
  • human dorsal and/or ventral PDX1-positive foregut endoderm cells are derived from human PDX1-negative definitive endoderm cells, which in turn, are derived from hESCs. These human dorsal and/or ventral PDX1-positive foregut endoderm cells can then be used to produce functional insulin-producing ⁇ -cells.
  • some aspects of the present invention relate to in vitro methodology that results in approximately 2-25% conversion of PDX1-negative definitive endoderm cells to PDX1-positive foregut endoderm cells. Some aspects of the present invention relate to in vitro methodology that results in approximately 26% to at least approximately 75% conversion of PDX1-negative definitive endoderm cells to dorsal PDX1-positive foregut endoderm cells.
  • aspects of the present invention relate to in vitro methodology that results in approximately 26% to at least approximately 75% conversion of PDX1-negative definitive endoderm cells to ventral PDX1-positive foregut endoderm cells.
  • the above-described methods encompass the application of culture and growth factor conditions in a defined and temporally specified fashion. Further enrichment of the cell population for PDX1-positive foregut endoderm cells, including dorsal and/or ventral PDX1-positive foregut endoderm cells, can be achieved by isolation and/or purification of the PDX1-positive foregut endoderm cells from other cells in the population by using a reagent that specifically binds to the PDX1-positive foregut endoderm cells.
  • PDX1-positive foregut endoderm cells can be labeled with a reporter gene, such as green fluorescent protein (GFP), so as to enable the detection of PDX1 expression.
  • a reporter gene such as green fluorescent protein (GFP)
  • GFP green fluorescent protein
  • Such fluorescently labeled cells can then be purified by fluorescent activated cell sorting (FACS).
  • FACS fluorescent activated cell sorting
  • Additional aspects of the present invention relate to cell cultures and enriched cell populations comprising dorsal PDX1-positive foregut endoderm cells as well as methods for identifying factors useful in the differentiation to and from dorsal PDX1-positive foregut endoderm. Still other aspects of the present invention relate to cell cultures and enriched cell populations comprising ventral PDX1-positive foregut endoderm cells as well as methods for identifying factors useful in the differentiation to and from ventral PDX1-positive foregut endoderm.
  • certain embodiments of the present invention relate to cell markers whose presence, absence and/or relative expression levels are indicative of PDX1-positive foregut endoderm cells, including dorsal and/or ventral PDX1-positive foregut endoderm cells, as well as methods for detecting and determining the expression of such markers.
  • expression refers to the production of a material or substance as well as the level or amount of production of a material or substance.
  • determining the expression of a specific marker refers to detecting either the relative or absolute amount of the marker that is expressed or simply detecting the presence or absence of the marker.
  • “marker” refers to any molecule that can be observed or detected.
  • a marker can include, but is not limited to, a nucleic acid, such as a transcript of a specific gene, a polypeptide product of a gene, a non-gene product polypeptide, a glycoprotein, a carbohydrate, a glycolipd, a lipid, a lipoprotein or a small molecule (for example, molecules having a molecular weight of less than 10,000 amu).
  • the presence, absence and/or level of expression of a marker is determined by quantitative PCR (Q-PCR).
  • Q-PCR quantitative PCR
  • the amount of transcript produced by certain genetic markers such as PDX1, SOX 17, SOX7, SOX1, ZIC1, NFM, alpha-fetoprotein (AFP), homeobox A13 (HOXA13), homeobox C6 (HOXC6), and/or other markers described herein is determined by Q-PCR.
  • immunohistochemistry is used to detect the proteins expressed by the above-mentioned genes.
  • Q-PCR and immunohistochemical techniques are both used to identify and determine the amount or relative proportions of such markers.
  • markers that are common to both dorsal and ventral PDX1-positive foregut endoderm cells are detected by Q-PCR and/or immunohistochemistry.
  • markers that are preferentially, specifically or uniquely expressed in dorsal PDX1-positive foregut endoderm cells are detected by Q-PCR and/or immunohistochemistry.
  • the differentiation and detection methods described herein it is possible to identify PDX1-positive foregut endoderm cells, including dorsal and/or ventral PDX1-positive foregut endoderm cells, as well as determine the proportion of dorsal and/or ventral PDX1-positive foregut endoderm cells in a cell culture or cell population.
  • the dorsal and/or ventral PDX1-positive foregut endoderm cells or cell populations that are produced express the PDX1 gene at a level of at least about 2 orders of magnitude greater than PDX1-negative cells or cell populations.
  • the dorsal and/or ventral PDX1-positive foregut endoderm cells and cell populations that are produced express the PDX1 gene at a level of more than 2 orders of magnitude greater than PDX1-negative cells or cell populations.
  • the dorsal and/or ventral PDX1-positive foregut endoderm cells or cell populations that are produced express one or more of the markers selected from the group consisting of PDX1, SOX17, HOXA13 and HOXC6 at a level of about 2 or more than 2 orders of magnitude greater than PDX1-negative definitive endoderm cells or cell populations.
  • the dorsal and/or ventral PDX1-positive foregut endoderm cells or cell populations that are produced express one or more of the markers selected from Table 3 at a level of about 2 or more than 2 orders of magnitude greater than PDX1-negative definitive endoderm cells or cell populations.
  • the dorsal PDX1-positive foregut endoderm cells or cell populations that are produced express one or more of the markers selected from Table 4 at a level of about 2 or more than 2 orders of magnitude greater than PDX1-negative definitive endoderm cells or cell populations.
  • compositions and methods described herein have several useful features.
  • the cell cultures and cell populations comprising PDX1-positive endoderm, including dorsal and/or ventral PDX1-positive foregut endoderm, as well as the methods for producing such cell cultures and cell populations are useful for modeling the early stages of human development.
  • the compositions and methods described herein can also serve for therapeutic intervention in disease states, such as diabetes mellitus.
  • PDX1 -positive foregut endoderm serves as the source for only a limited number of tissues, it can be used in the development of pure tissue or cell types.
  • Cell cultures and/or cell populations comprising PDX1-positive foregut endoderm cells are produced from pluripotent cells by first producing PDX1-negative definitive endoderm (also referred to as “definitive endoderm”). Processes for differentiating pluripotent cells to produce cell cultures and enriched cell populations comprising definitive endoderm is described briefly below and in detail in U.S. Pat. No. 11/021,618, entitled DEFINITIVE ENDODERM, filed Dec. 23, 2004, the disclosure of which is incorporated herein by reference in its entirety. In some of these processes, the pluripotent cells used as starting material are stem cells. In certain processes, definitive endoderm cell cultures and enriched cell populations comprising definitive endoderm cells are produced from embryonic stem cells.
  • embryonic refers to a range of developmental stages of an organism beginning with a single zygote and ending with a multicellular structure that no longer comprises pluripotent or totipotent cells other than developed gametic cells.
  • embryos derived by gamete fusion the term “embryonic” refers to embryos derived by somatic cell nuclear transfer.
  • a preferred method for deriving definitive endoderm cells utilizes human embryonic stem cells as the starting material for definitive endoderm production.
  • pluripotent cells can be cells that originate from the morula, embryonic inner cell mass or those obtained from embryonic gonadal ridges.
  • Human embryonic stem cells can be maintained in culture in a pluripotent state without substantial differentiation using methods that are known in the art.
  • hESCs are maintained on a feeder layer.
  • any feeder layer which allows hESCs to be maintained in a pluripotent state can be used.
  • One commonly used feeder. layer for the cultivation of human embryonic stem cells is a layer of mouse fibroblasts. More recently, human fibroblast feeder layers have been developed for use in the cultivation of hESCs (see U.S. Pat. Application No. 2002/0072117, the disclosure of which is incorporated herein by reference in its entirety).
  • Alternative processes for producing definitive endoderm permit the maintenance of pluripotent hESC without the use of a feeder layer. Methods of maintaining pluripotent hESCs under feeder-free conditions have been described in US Patent Application No. 2003/0175956, the disclosure of which is incorporated herein by reference in its entirety.
  • the human embryonic stem cells used herein can be maintained in culture either with or without serum. In some embryonic stem cell maintenance procedures, serum replacement is used. In others, serum free culture techniques, such as those described in US Patent Application No. 2003/0190748, the disclosure of which is incorporated herein by reference in its entirety, are used.
  • Stem cells are maintained in culture in a pluripotent state by routine passage until it is desired that they be differentiated into definitive endoderm.
  • differentiation to definitive endoderm is achieved by providing to the stem cell culture a growth factor of the TGF ⁇ superfamily in an amount sufficient to promote differentiation to definitive endoderm.
  • Growth factors of the TGF ⁇ superfamily which are useful for the production of definitive endoderm are selected from the Nodal/Activin or BMP subgroups.
  • the growth factor is selected from the group consisting of Nodal, activin A, activin B and BMP4.
  • the growth factor Wnt3a and other Wnt family members are useful for the production of definitive endoderm cells.
  • combinations of any of the above-mentioned growth factors can be used.
  • the above-mentioned growth factors are provided to the cells so that the growth factors are present in the cultures at concentrations sufficient to promote differentiation of at least a portion of the stem cells to definitive endoderm cells.
  • the above-mentioned growth factors are present in the cell culture at a concentration of at least about 5 ng/ml, at least about 10 ng/ml, at least about 25 ng/ml, at least about 50 ng/ml, at least about 75 ng/ml, at least about 100 ng/ml, at least about 200 ng/ml, at least about 300 ng/ml, at least about 400 ng/ml, at least about 500 ng/ml, at least about 1000 ng/ml, at least about 2000 ng/ml, at least about 3000 ng/ml, at least about 4000 ng/ml, at least about 5000 ng/ml or more than about 5000 ng/ml.
  • the above-mentioned growth factors are removed from the cell culture subsequent to their addition.
  • the growth factors can be removed within about one day, about two days, about three days, about four days, about five days, about six days, about seven days, about eight days, about nine days or about ten days after their addition.
  • the growth factors are removed about four days after their addition.
  • serum concentrations can range from about 0.05% v/v to about 20% v/v.
  • the serum concentration of the medium can be less than about 0.05% (v/v), less than about 0.1% (v/v), less than about 0.2% (v/v), less than about 0.3% (v/v), less than about 0.4% (v/v), less than about 0.5% (v/v), less than about 0.6% (v/v), less than about 0.7% (v/v), less than about 0.8% (v/v), less than about 0.9% (v/v), less than about 1% (v/v), less than about 2% (v/v), less than about 3% (v/v), less than about 4% (v/v), less than about 5% (v/v), less than about 6% (v/v), less than about 7% (v/v), less than about 8% (v/v), less than about 9% (v/v), less than about 1% (v/v), less than about 2% (v/v), less than about 3% (v/v), less
  • definitive endoderm cells are grown without serum or with serum replacement. In still other processes, definitive endoderm cells are grown in the presence of B27. In such processes, the concentration of B27 supplement can range from about 0.1% v/v to about 20% v/v.
  • the progression of the hESC culture to definitive endoderm can be monitored by determining the expression of markers characteristic of definitive endoderm.
  • the expression of certain markers is determined by detecting the presence or absence of the marker.
  • the expression of certain markers can be determined by measuring the level at which the marker is present in the cells of the cell culture or cell population.
  • the measurement of marker expression can be qualitative or quantitative.
  • One method of quantitating the expression of markers that are produced by marker genes is through the use of quantitative PCR (Q-PCR). Methods of performing Q-PCR are well known in the art. Other methods which are known in the art can also be used to quantitate marker gene expression.
  • the expression of a marker gene product can be detected by using antibodies specific for the marker gene product of interest.
  • the expression of marker genes characteristic of definitive endoderm as well as the lack of significant expression of marker genes characteristic of hESCs and other cell types is determined.
  • a reliable marker of definitive endoderm is the SOX17 gene.
  • the definitive endoderm cells produced by the processes described herein express the SOX17 marker gene, thereby producing the SOX17 gene product.
  • Other markers of definitive endoderm are MIXLI, GATA4, HNF3b, GSC, FGF17, VWF, CALCR, FOXQI, CMKORI and CRIPI. Since definitive endoderm cells express the SOX17 marker gene at a level higher than that of the SOX7 marker gene, which is characteristic of primitive and visceral endoderm (see Table 1), in some processes, the expression of both SOX17 and SOX7 is monitored.
  • CXCR4 gene Another marker of definitive endoderm is the CXCR4 gene.
  • the CXCR4 gene encodes a cell surface chemokine receptor whose ligand is the chemoattractant SDF-1.
  • SDF-1 chemoattractant
  • the principal roles of the CXCR4 receptor-bearing cells in the adult are believed to be the migration of hematopoetic cells to the bone marrow, lymphocyte trafficking and the differentiation of various B cell and macrophage blood cell lineages [Kim, C., and Broxmeyer, H. J. Leukocyte Biol. 65, 6-15 (1999)].
  • the CXCR4 receptor also functions as a coreceptor for the entry of HIV-1 into T-cells [Feng, Y., et al. Science, 272, 872-877 (1996)].
  • CXCR4 is the most abundant chemokine receptor messenger RNA detected during early gastrulating embryos (E7.5) using a combination of RNase protection and in situ hybridization methodologies.
  • CXCR4/SDF-I signaling appears to be mainly involved in inducing migration of primitive-streak germlayer cells and is expressed on definitive endoderm, mesoderm and extraembryonic mesoderm present at this time.
  • E7.2-7.8 mouse embryos CXCR4 and alpha-fetoprotein are mutually exclusive indicating a lack of expression in visceral endoderm [McGrath, K.E. et al. Dev. Biology 213, 442-456 (1999)].
  • definitive endoderm cells produced by differentiating pluripotent cells express the CXCR4 marker gene
  • expression of CXCR4 can be monitored in order to track the production of definitive endoderm cells.
  • definitive endoderm cells produced by the methods described herein express other markers of definitive endoderm including, but not limited to, SOX17, MIXLI, GATA4, HNF3b, GSC, FGF17, VWF, CALCR, FOXQI, CMKORI and CRIPI.
  • definitive endoderm cells express the CXCR4 marker gene at a level higher than that of the SOX7 marker gene, the expression of both CXCR4 and SOX7 can be monitored. In other processes, expression of the both the CXCR4 marker gene and the OCT4 marker gene, is monitored.
  • definitive endoderm cells express the CXCR4 marker gene at a level higher than that of the AFP, SPARC or Thrombomodulin (TM) marker genes, the expression of these genes can also be monitored. 102761 It will be appreciated that expression of CXCR4 in endodermal cells does not preclude the expression of SOX17. As such, definitive endoderm cells produced by the processes described herein will substantially express SOX17 and CXCR4 but will not substantially express AFP, TM, SPARC or PDX1.
  • Definitive endoderm cells produced by any of the above-described processes can be enriched, isolated and/or purified by using an affinity tag that is specific for such cells.
  • affinity tags specific for definitive endoderm cells are antibodies, ligands or other binding agents that are specific to a marker molecule, such as a polypeptide, that is present on the cell surface of definitive endoderm cells but which is not substantially present on other cell types that would be found in a cell culture produced by the methods described herein.
  • an antibody which binds to CXCR4 is used as an affinity tag for the enrichment, isolation or purification of definitive endoderm cells.
  • the chemokine SDF-I or other molecules based on SDF-I can also be used as affinity tags. Such molecules include, but not limited to, SDF-I fragments, SDF-I fusions or SDF-I mimetics.
  • an antibody which binds to CXCR4 is attached to a magnetic bead and then allowed to bind to definitive endoderm cells in a cell culture which has been enzymatically treated to reduce intercellular and substrate adhesion.
  • the cell/antibody/bead complexes are then exposed to a movable magnetic field which is used to separate bead-bound definitive endoderm cells from unbound cells. Once the definitive endoderm cells are physically separated from other cells in culture, the antibody binding is disrupted and the cells are replated in appropriate tissue culture medium.
  • the CXCR4 antibody is incubated with a definitive endoderm-containing cell culture that has been treated to reduce intercellular and substrate adhesion.
  • the cells are then washed, centrifuged and resuspended.
  • the cell suspension is then incubated with a secondary antibody, such as an FITC-conjugated antibody that is capable of binding to the primary antibody.
  • the cells are then washed, centrifuged and resuspended in buffer.
  • the cell suspension is then analyzed and sorted using a fluorescence activated cell sorter (FACS).
  • FACS fluorescence activated cell sorter
  • CXCR4-positive cells are collected separately from CXCR4-negative cells, thereby resulting in the isolation of such cell types.
  • the isolated cell compositions can be further purified by using an alternate affinity-based method or by additional rounds of sorting using the same or different markers that are specific for definitive endoderm.
  • definitive endoderm cells are enriched, isolated and/or purified using a ligand or other molecule that binds to CXCR4.
  • the molecule is SDF-I or a fragment, fusion or mimetic thereof.
  • definitive endoderm cells are enriched, isolated and/or purified from other non-definitive endoderm cells after the stem cell cultures are induced to differentiate towards the definitive endoderm lineage. It will be appreciated that the above-described enrichment, isolation and purification procedures can be used with such cultures at any stage of differentiation.
  • definitive endoderm cells may also be isolated by other techniques for cell isolation. Additionally, definitive endoderm cells may also be enriched or isolated by methods of serial subculture in growth conditions which promote the selective survival or selective expansion of the definitive endoderm cells.
  • enriched, isolated and/or purified populations of definitive endoderm cells and or tissues can be produced in vitro from pluripotent cell cultures or cell populations, such as stem cell cultures or populations, which have undergone at least some differentiation. In some methods, the cells undergo random differentiation. In a preferred method, however, the cells are directed to differentiate primarily into definitive endoderm. Some preferred enrichment, isolation and/or purification methods relate to the in vitro production of definitive endoderm from human embryonic stem cells. Using the methods described herein, cell populations or cell cultures can be enriched in definitive endoderm content by at least about 2- to about 1000-fold as compared to untreated cell populations or cell cultures.
  • compositions Comprising PDX1-Negative Definitive Endoderm (Definitive Endoderm)
  • Cell compositions produced by the above-described methods include cell cultures comprising definitive endoderm and cell populations enriched in definitive endoderm.
  • cell cultures which comprise definitive endoderm cells, wherein at least about 50-80% of the cells in culture are definitive endoderm cells, can be produced.
  • the differentiation procedures described herein can result in about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or greater than about 95% conversion of pluripotent cells to definitive endoderm.
  • isolation of definitive endoderm cells is employed, for example, by using an affinity reagent that binds to the CXCR4 receptor, a substantially pure definitive endoderm cell population can be recovered.
  • Definitive endoderm cells can be specified toward pancreatic differentiation by further differentiation of these cells to produce PDX1-negative foregut endoderm cells.
  • cell cultures as well as enriched or purified cell populations comprising definitive endoderm cells can be used for further differentiation to cell cultures and/or enriched cell populations comprising PDX1-negative foregut endoderm cells.
  • definitive endoderm cells are differentiated to PDX1-negative foregut endoderm cells by reducing or eliminating TGF ⁇ superfamily growth factor signaling in a cell culture or cell population of SOX17-positive definitive endoderm cells.
  • reducing or eliminating TGFP superfamily growth factor signaling is mediated by diluting or removing an exogenously added TGF ⁇ superfamily growth factor, such as activin A, from the cell culture or cell population of definitive endoderm.
  • TGF ⁇ superfamily growth factor signaling is reduced or eliminated by providing the definitive endoderm cells with a compound that blocks TGF ⁇ superfamily growth factor signaling, such as follistatin and/or noggin.
  • TGF ⁇ superfamily growth factor signaling can be reduced or eliminated for about one day, about two days, about three days, about four days, about five days, about six days, about seven days, about eight days, about nine days, about ten days or greater than about ten days subsequent to the differentiation of the human pluripotent cells to definitive endoderm cells.
  • differentiation of definitive endoderm cells to foregut endoderm cells is enhanced by providing the definitive endoderm cell culture or cell population with an FGF-family growth factor and/or a hedgehog pathway inhibitor.
  • the FGF-family growth factor and/or hedgehog pathway inhibitor is provided at about one day, about two days, about three days, about four days, about five days, about six days, about seven days, about eight days, about nine days, about ten days or greater than about ten days subsequent to reducing or eliminating TGF ⁇ superfamily growth factor signaling in the definitive endoderm cell culture.
  • the FGF-family growth factor and/or hedgehog pathway inhibitor is provided at about the same time as reducing or eliminating TGFP superfamily growth factor signaling in the definitive endoderm cell culture.
  • the FGF-family growth factor provided to the definitive endoderm cell culture or cell population is FGFIO and/or FGF7.
  • FGFIO and/or FGF7 FGFIO and/or FGF7.
  • FGF-family growth factor selected from the group consisting of FGF1, FGF2, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGFIO, FGFII, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGFI9, FGF20, FGF21, FGF22 and/or FGF23 may be provided.
  • the FGF-family growth factor and/or the FGF-family growth factor analog or mimetic is provided to the cells of a cell culture such that it is present at a concentration of at least about 10 ng/ml, at least about 25 ng/ml, at least about 50 ng/ml, at least about 75 ng/ml, at least about 100 ng/ml, at least about 200 ng/ml, at least about 300 ng/ml, at least about 400 ng/ml, at least about 500 ng/ml, or at least about 1000 ng/ml.
  • the hedgehog inhibitor is KAAD-cyclopamine.
  • hedgehog inhibitors include, but are not limited to, KKAD-cyclopamine analogs, jervine, jervine analogs, hedgehog pathway blocking antibodies and any other inhibitors of hedgehog pathway function known to those of ordinary skill in the art.
  • the hedgehog inhibitor can be provided at a concentration of at least about 0.01 ⁇ M, at least about 0.02 ⁇ M, at least about 0.04 ⁇ M, at least about 0.08 ⁇ M, at least about 0.1 ⁇ M, at least about 0.2 ⁇ M, at least about 0.3 ⁇ M, at least about 0.4 ⁇ M, at least about 0.5 ⁇ M, at least about 0.6 ⁇ M, at least about 0.7 ⁇ M, at least about 0.8 ⁇ M, at least about 0.9 ⁇ M, at least about 1 ⁇ M, at least about 1.1 ⁇ M, at least about 1.2 ⁇ M, at least about 1.3 ⁇ M, at least about 1.4 ⁇ M, at least about 1.5 ⁇ M, at least about 1.6 ⁇ M, at least about 1.7 ⁇ M, at least about 1.8 ⁇ M, at least about 1.9 ⁇ M, at least about 2 ⁇ M, at least about 2.1 ⁇ M, at least about 2.2 ⁇
  • TGF ⁇ superfamily growth factor signaling is reduced or eliminated for about two day subsequent to the differentiation of a substantial portion of human pluripotent cells to definitive endoderm (for example, after a three day, four or five day differentiation protocol as described in the examples below).
  • the cell culture or cell population of definitive endoderm cells is provided with 50 ng/ml of FGF-10 and 0.2 ⁇ M KAAD-cyclopamine.
  • Cultures of PDX1-negative foregut endoderm cells can be differentiated and further grown in a medium containing reduced or no serum. Serum concentrations can range from about 0.05% (v/v) to about 20% (v/v). In some processes, PDX1-negative foregut endoderm cells are grown with serum replacement.
  • the serum concentration of the medium can be less than about 0.05% (v/v), less than about 0.1% (v/v), less than about 0.2% (v/v), less than about 0.3% (v/v), less than about 0.4% (v/v), less than about 0.5% (v/v), less than about 0.6% (v/v), less than about 0.7% (v/v), less than about 0.8% (v/v), less than about 0.9% (v/v), less than about 1% (v/v), less than about 2% (v/v), less than about 3% (v/v), less than about 4% (v/v), less than about 5% (v/v), less than about 6% (v/v), less than about 7% (v/v), less than about 8% (v/v), less than about 9% (v/v), less than about 10% (v/v), less than about 15% (v/v) or less than about 20% (v/v).
  • the differentiation medium does not include serum, serum replacement or any supplement comprising serum, serum replacement or any supplement comprising serum
  • B27 can be provided to the culture medium in concentrations ranging from about 0.1% (v/v) to about 20% (v/v) or in concentrations greater than about 20% (v/v).
  • the concentration of B27 in the medium is about 0.1% (v/v), about 0.2% (v/v), about 0.3% (v/v), about 0.4% (v/v), about 0.5% (v/v), about 0.6% (v/v), about 0.7% (v/v), about 0.8% (v/v), about 0.9% (v/v), about 1% (v/v), about 2% (v/v), about 3% (v/v), about 4% (v/v), about 5% (v/v), about 6% (v/v), about 7% (v/v), about 8% (v/v), about 9% (v/v), about 10% (v/v), about 15% (v/v) or about 20% (v/v).
  • the concentration of the added B27 supplement can be measured in terms of multiples of the strength of a commercially available B27 stock solution.
  • B27 is available from Invitrogen (Carlsbad, CA) as a 5OX stock solution. Addition of a sufficient amount of this stock solution to a sufficient volume of growth medium produces a medium supplemented with the desired amount of B27. For example, the addition of 10 ml of 5OX B27 stock solution to 90 ml of growth medium would produce a growth medium supplemented with 5X B27.
  • the concentration of B27 supplement in the medium can be about O.IX, about 0.2X, about 0.3X, about 0.4X, about 0.5X, about 0.6X, about 0.7X, about 0.8X, about 0.9X, about 1 X, about 1.1 X, about 1.2X, about 1.3X, about 1.4X, about 1.5X, about 1.6X, about 1.7X, about 1.8X, about 1.9X, about 2X, about 2.5X, about 3X, about 3.5X, about 4X, about 4.5X, about 5X, about 6X, about 7X, about 8X, about 9X, about IOX, about I IX, about 12X, about 13X, about 14X, about 15X, about 16X, about 17X, about 18X, about 19X, about 20X and greater than about 20X.
  • the PDX1-negative foregut endoderm cells can be further differentiated to PDX1-positive foregut endoderm cells by contacting the cells with a medium comprising, or otherwise providing to the cells, a retinoid, such as retinoic acid (RA).
  • a retinoid such as retinoic acid (RA).
  • the retinoid is provided to the cells of a cell culture such that it is present at a concentration of at least about 1 nM, at least about 0.01 ⁇ M, at least about 0.02 ⁇ M, at least about 0.04 PM, at least about 0.08 ⁇ M, at least about 0.1 PM, at least about 0.2 ⁇ M, at least about 0.3 ⁇ M, at least about 0.4 PM, at least about 0.5 ⁇ M, at least about 0.6 PM, at least about 0.7 PM, at least about 0.8 ⁇ M, at least about 0.9 PM, at least about 1 ⁇ M, at least about 1.1 ⁇ M, at least about 1.2 PM, at least about 1.3 ⁇ M, at least about 1.4 ⁇ M, at least about 1.5 ⁇ M, at least about 1.6 ⁇ M, at least about 1.7 ⁇ M, at least about 1.8 ⁇ M, at least about 1.9 ⁇ M, at least about 2 ⁇ M, at least about 2.1 ⁇ M, at least about 2.2 ⁇ M,
  • the retinoid is provided to the cells at about one day, about two days, about three days, about four days, about five days, about six days, about seven days, about eight days, about nine days, about ten days or greater than about ten days subsequent to reducing or eliminating TGF ⁇ superfamily growth factor signaling in the definitive endoderm cell culture.
  • from about 0.05 ⁇ M RA to about 2 ⁇ M RA is provided to the PDX-1 negative foregut endoderm cell culture about 2 to 3 days subsequent to reducing or eliminating TGFP superfamily growth factor signaling.
  • the above-mentioned differentiation factors are removed from the cell culture subsequent to their addition.
  • the above-mentioned differentiation factors can be removed within about one day, about two days, about three days, about four days, about five days, about six days, about seven days, about eight days, about nine days or about ten days after their addition.
  • HNF1b and/or FOXA1 and the lack of expression of PDX1 can be detected and/or quantitated using the above-described methods, such as Q-PCR and/or immunocytochemistry, to monitor the differentiation of PDX1-negative definitive endoderm to PDX1-negative foregut endoderm.
  • the expression of SOX17 is also determined.
  • PDX1-negative foregut endoderm cell cultures produced by the methods described herein are substantially free of cells expressing the SOX7, AFP, SOX1, ZIC1 or NFM marker genes.
  • the PDX1-negative foregut endoderm cell cultures produced by the processes described herein are substantially free of visceral endoderm, parietal endoderm and/or neural cells.
  • compositions comprising PDX1-Negative Foregut Endoderm
  • Some embodiments of the present invention relate to cell compositions, such as cell cultures or cell populations, comprising PDX1-negative foregut endoderm cells, wherein the PDX1-negtive foregut endoderm cells are multipotent cells that can differentiate into cells, tissues or organs derived from the anterior portion of the gut tube.
  • the PDX1-negative foregut endoderm cells are mammalian cells, and in a preferred embodiment, such cells are human cells.
  • compositions such as cell cultures or cell populations, comprising cells of one or more cell types selected from the group consisting of hESCs, PDX1-negative definitive endoderm cells, PDX1-negative foregut endoderm cells and mesoderm cells.
  • hESCs comprise less than about 5%, less than about 4%, less than about 3%, less than about 2% or less than about 1% of the total cells in the culture.
  • PDX1-negative definitive endoderm cells comprise less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 12%, less than about 10%, less than about 8%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2% or less than about 1% of the total cells in the culture.
  • mesoderm cells comprise less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 12%, less than about 10%, less than about 8%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2% or less than about 1% of the total cells in the culture.
  • compositions such as cell cultures or cell populations, produced by the processes described herein comprise PDX1-negative foregut endoderm as the majority cell type.
  • the processes described herein produce cell cultures and/or cell populations comprising at least about 99%, at least about 98%, at least about 97%, at least about 96%, at least about 95%, at least about 94%, at least about 93%, at least about 92%, at least about 91%, at least about 90%, at least about 89%, at least about 88%, at least about 87%, at least about 86%, at least about 85%, at least about 84%, at least about 83%, at least about 82%, at least about 81%, at least about 80%, at least about 79%, at least about 78%, at least about 77%, at least about 76%, at least about 75%, at least about 74%, at least about 73%, at least about 72%, at least about 71%, at least about 70%, at least about 69%, at least about 68%
  • the cells of the cell cultures or cell populations comprise human cells.
  • the processes described herein produce cell cultures or cell populations comprising at least about 50%, at least about 45%, at least about 40%, at least about 35 %, at least about 30%, at least about 25%, at least about 24%, at least about 23%, at least about 22%, at least about 21%, at least about 20%, at least about 19%, at least about 18%, at least about 17%, at least about 16%, at least about 15%, at least about 14%, at least about 13%, at least about 12%, at least about 11%, at least about 10%, at least about 9%, at least about 8%, at least about 7%, at least about.
  • the cells of the cell cultures or cell populations comprise human cells.
  • the percentage of PDX1-negative foregut endoderm cells in the cell cultures or populations is calculated Without regard to the feeder cells remaining in the culture.
  • compositions such as cell cultures or cell populations, comprising PDX1-negative foregut endoderm cells and PDX1-negative definitive endoderm cells.
  • cell cultures or cell populations comprising at least about 5 PDX1-negative foregut endoderm cells for about every 95 PDX1-negative definitive endoderm cells can be produced.
  • cell cultures or cell populations comprising at least about 95 PDX1-negative foregut endoderm cells for about every 5 PDX1-negative definitive endoderm cells can be produced.
  • cell cultures or cell populations comprising other ratios of PDX1-negative foregut endoderm cells to PDX1-negative definitive endoderm cells are contemplated.
  • compositions comprising at least about I PDX1-negative foregut endoderm cell for about every 1,000,000 PDX1-negative definitive endoderm cells, at least about I PDX1-negative foregut endoderm cell for about every 100,000 PDX1-negative definitive endoderm cells, at least about I PDX1-negative foregut endoderm cell for about every 10,000 PDX1-negative definitive endoderm cells, at least about I PDX1-negative foregut endoderm cell for about every 1000 PDX1-negative definitive endoderm cells, at least about I PDX1-negative foregut endoderm cell for about every 500 PDX1-negative definitive endoderm cells, at least about I PDX1-negative foregut endoderm cell for about every 100 PDX1-negative definitive endoderm cells, at least about I PDX1-negative foregut endoderm cell for about every 10 PDX1-negative definitive endoderm cells, at least about I PDX1-negative foregut endoderm
  • the PDX1-negative definitive endoderm cells from which PDX1-negative foregut endoderm cells are produced are derived from human pluripotent cells, such as human pluripotent stem cells.
  • the human pluripotent cells are derived from a morula, the inner cell mass of an embryo or the gonadal ridges of an embryo.
  • the human pluripotent cells are derived from the gonadal or germ tissues of a multicellular structure that has developed past the embryonic stage.
  • compositions such as cell cultures or cell populations, comprising human cells, including human PDX1-negative foregut endoderm cells, wherein the expression of the SOX 17, HNF I b and/or FOXA I marker is greater than the expression of the AFP, SOX7, SOX , ZIC I and/or NFM marker in at least about 2% of the human cells.
  • the expression of the SOX17, HNF1b and/or FOXA1 marker is greater than the expression of the AFP, SOX7, SOX1, ZIC1 and/or NFM marker in at least about 5% of the human cells, in at least about 10% of the human cells, in at least about 15% of the human cells, in at least about 20% of the human cells, in at least about 25% of the human cells, in at least about 30% of the human cells, in at least about 35% of the human cells, in at least about 40% of the human cells, in at least about 45% of the human cells, in at least about 50% of the human cells, in at least about 55% of the human cells, in at least about 60% of the human cells, in at least about 65% of the human cells, in at least about 70% of the human cells, in at least about 75% of the human cells, in at least about 80% of the human cells, in at least about 85% of the human cells, in at least about 90% of the human cells, in at least about 95% of the human cells or in at least about 9
  • the percentage of human cells in the cell cultures or populations, wherein the expression of SOX17, HNFIb and/or FOXA1 is greater than the expression of the AFP, SOX7, SOX 1, ZIC I and/or NFM marker, is calculated without regard to feeder cells.
  • compositions such as cell cultures or cell populations, comprising human PDX1-negative foregut endoderm cells, wherein the expression of one or more markers selected from the group consisting of SOX17, HNF1b and/or FOXA1 is greater than the expression of the PDX1 marker in from at least about 2% to greater than at least about 98% of the human cells.
  • the expression of one or more markers selected from the group consisting of SOX17, HNF1b and/or FOXA1 is greater than the expression of the PDX1 marker in at least about 5% of the human cells, in at least about 10% of the human cells, in at least about 15% of the human cells, in at least about 20% of the human cells, in at least about 25% of the human cells, in at least about 30% of the human cells, in at least about 35% of the human cells, in at least about 40% of the human cells, in at least about 45% of the human cells, in at least about 50% of the human cells, in at least about 55% of the human cells, in at least about 60% of the human cells, in at least about 65% of the human cells, in at least about 70% of the human cells, in at least about 75% of the human cells, in at least about 80% of the human cells, in at least about 85% of the human cells, in at least about 90% of the human cells, in at least about 95% of the human cells or in at least about 98% of the human cells
  • the percentage of human cells in the cell cultures or populations, wherein the expression of one or more markers selected from the group consisting of SOX17, HNFIb and/or FOXA1 is greater than the expression of the PDX1 marker, is calculated without regard to feeder cells.
  • compositions comprising PDX1-negative foregut endoderm cells substantially free of other cell types can be produced.
  • substantially free of means that the specified cell type of which the cell culture or cell population is free, is present in an amount of less than about 5% of the total number of cells present in the cell culture or cell population.
  • the PDX1-negative foregut endoderm cell populations or cell cultures produced by the methods described herein are substantially free of cells that significantly express the AFP, SOX7, SOX1, ZIC1 and/or NFM marker genes.
  • a description of a PDX1-negative foregut endoderm cell based on the expression of marker genes is, SOX17 high, HNF1b high, FOXA1 high, PDX1 low, AFP low, SOX7 low, SOX1 low, ZIC1 low and NFM low.
  • the PDX1-positive foregut endoderm cell cultures and populations comprising PDX1-positive foregut endoderm cells that are described herein are produced from PDX1-negative definitive endoderm, which is generated from pluripotent cells as described above.
  • a preferred method utilizes human embryonic stem cells as the starting material.
  • hESCs are first converted to PDX1-negative definitive endoderm cells, which are then converted to PDX1-positive foregut endoderm cells. It will be appreciated, however, that the starting materials for the production of PDX1-positive foregut endoderm is not limited to definitive endoderm cells produced using pluripotent cell differentiation methods. Rather, any PDX1-negative definitive endoderm cells can be used in the methods described herein regardless of their origin.
  • cell cultures or cell populations comprising PDX1-negative definitive endoderm cells can be used for further differentiation to cell cultures and/or enriched cell populations comprising PDX1-positive foregut endoderm cells.
  • a cell culture or cell population comprising human PDX1-negative, SOX17-positive definitive endoderm cells can be used.
  • the cell culture or cell population may also comprise differentiation factors, such as activins, nodals and/or BMPs, remaining from the previous differentiation step (that is, the step of differentiating pluripotent cells to definitive endoderm cells).
  • factors utilized in the previous differentiation step are removed from the cell culture or cell population prior to the addition of factors used for the differentiation of the PDX1-negative, SOX I 7-positive definitive endoderm cells to PDX1-positive foregut endoderm cells.
  • cell populations enriched for PDX1-negative, SOX17-positive definitive endoderm cells are used as a source for the production of PDX1-positive foregut endoderm cells.
  • PDX1-negative definitive endoderm cells in culture are differentiated to PDX1-positive endoderm cells by providing to a cell culture comprising PDX1-negative, SOX17-positive definitive endoderm cells- ⁇ differentiation factor that promotes differentiation of the cells to PDX1-positive foregut endoderm cells (foregut differentiation factor).
  • the foregut differentiation factor is retinoid, such as retinoic acid (RA).
  • the retinoid is used in conjunction with a fibroblast growth factor, such as FGF-4 or FGF-10.
  • the retinoid is used in conjunction with a member of the TGF ⁇ superfamily of growth factors and/or a conditioned medium.
  • conditioned medium is meant, a medium that is altered as compared to a base medium.
  • the conditioning of a medium may cause molecules, such as nutrients and/or growth factors, to be added to or depleted from the original levels found in the base medium.
  • a medium is conditioned by allowing cells of certain types to be grown or maintained in the medium under certain conditions for a certain period of time.
  • a medium can be conditioned by allowing hESCs to be expanded, differentiated or maintained in a medium of defined composition at a defined temperature for a defined number of hours.
  • numerous combinations of cells, media types, durations and environmental conditions can be used to produce nearly an infinite array of conditioned media.
  • a medium is conditioned by allowing differentiated pluripotent cells to be grown or maintained in a medium comprising about 1% to about 20% serum concentration. In other embodiments, a medium is conditioned by allowing differentiated pluripotent cells to be grown or maintained in a medium comprising about I ng/ml to about 1000 ng/ml activin A. In still other embodiments, a medium is conditioned allowing differentiated pluripotent cells to be grown or maintained in a medium comprising about I ng/ml to about 1000 ng/ml BMP4. In a preferred embodiment, a conditioned medium is prepared by allowing differentiated hESCs to be grown or maintained for 24 hours in a medium, such as RPMI, comprising about 25 ng/ml activin A and about 2 ⁇ M RA.
  • a medium such as RPMI, comprising about 25 ng/ml activin A and about 2 ⁇ M RA.
  • the cells used to condition the medium are cells that are differentiated from pluripotent cells, such as hESCs, over about a 5 day time period in a medium such as RPMI comprising about 0% to about 20% serum and/or one or more growth/differentiation factors of the TGF ⁇ superfamily.
  • a medium such as RPMI comprising about 0% to about 20% serum and/or one or more growth/differentiation factors of the TGF ⁇ superfamily.
  • Differentiation factors such as activin A and BMP4 are supplied at concentrations ranging from about I ng/ml to about 1000 ng/ml.
  • the cells used to condition the medium are differentiated from hESCs over about a 5 day period in low serum RPMI.
  • low serum RPMI refers to a low serum containing medium, wherein the serum concentration is gradually increased over a defined time period.
  • low serum RPMI comprises a concentration of about 0.2% fetal bovine serum (FBS) on the first day of cell growth, about 0.5% FBS on the second day of cell growth and about 2% FBS on the third through fifth day of cell growth.
  • low serum RPMI comprises a concentration of about 0% on day one, about 0.2% on day two and about 2% on days 3-6.
  • low serum RPMI is supplemented with one or more differentiation factors, such as activin A and BMP4.
  • low serum RPMI can be used as a medium for the differentiation of PDX1-positive foregut endoderm cells from PDX1-negative definitive endoderm cells.
  • conditioned media can be prepared from media other than RPMI provided that such media do not interfere with the growth or maintenance of PDX1-positive foregut endoderm cells.
  • the cells used to condition the medium can be of various types. In embodiments where freshly differentiated cells are used to condition a medium, such cells can be differentiated in a medium other than RPMI provided that the medium does not inhibit the growth or maintenance of such cells.
  • a skilled artisan will appreciate that neither the duration of conditioning nor the duration of preparation of cells used for conditioning is required to be 24 hours or 5 days, respectively, as other time periods will be sufficient to achieve the effects reported herein.
  • a retinoid in combination with a fibroblast growth factor, a member of the TGF ⁇ superfamily of growth factors, a conditioned medium or a combination of any of these foregut differentiation factors causes greater differentiation of PDX1-negative definitive endoderm to PDX1-positive foregut endoderm than the use of a retinoid alone.
  • RA and FGF- ⁇ 0 are both provided to the PDX1-negative definitive endoderm cell culture.
  • PDX1-negative definitive endoderm cells are differentiated in a culture comprising a conditioned medium, activin A, activin B and RA.
  • the above-mentioned foregut differentiation factors are provided to the cells so that these factors are present in the cell culture or cell population at concentrations sufficient to promote differentiation of at least a portion of the PDX1-negative definitive endoderm cell culture or cell population to PDX1-positive foregut endoderm cells.
  • portion means any non-zero amount of the cell culture or cell population, which ranges from a single cell to the entirety of the cell culture or cells population.
  • a retinoid is provided to the cells of a cell culture such that it is present at a concentration of at least about 0.01 ⁇ M, at least about 0.02 ⁇ M, at least about 0.04 ⁇ M, at least about 0.08 ⁇ M, at least about 0.1 ⁇ M, at least about 0.2 ⁇ M, at least about 0.3 ⁇ M, at least about 0.4 ⁇ M, at least about 0.5 ⁇ M, at least about 0.6 ⁇ M, at least about 0.7 ⁇ M, at least about 0.8 ⁇ M, at least about 0.9 ⁇ M, at least about I PM, at least about 1.1 ⁇ M, at least about 1.2 ⁇ M, at least about 1.3 ⁇ M, at least about 1.4 ⁇ M, at least about 1.5 ⁇ M, at least about 1.6 ⁇ M, at least about 1.7 ⁇ M, at least about 1.8 PM, at least about 1.9 ⁇ M, at least about 2 ⁇ M, at least about 2.1 ⁇ M, at least
  • one or more differentiation factors of the fibroblast growth factor family are present in the cell culture.
  • FGF-4 can be present in the cell culture at a concentration of at least about 10 ng/ml, at least about 25 ng/ml, at least about 50 ng/ml, at least about 75 ng/ml, at least about 100 ng/ml, at least about 200 ng/ml, at least about 300 ng/ml, at least about 400 ng/ml, at least about 500 ng/ml, or at least about 1000 ng/ml.
  • FGF-10 is present in the cell culture at a concentration of at least about 10 ng/ml, at least about 25 ng/ml, at least about 50 ng/ml, at least about 75 ng/ml, at least about 100 ng/ml, at least about 200 ng/ml, at least about 300 ng/ml, at least about 400 ng/ml, at least about 500 ng/ml, or at least about 1000 ng/ml.
  • either FGF-4 or FGF-10, but not both is provided to the cell culture along with RA.
  • RA is present in the cell culture at 1 ⁇ M and FGF-10 is present at a concentration of 50 ng/ml.
  • growth factors of the TGF ⁇ superfamily and/or a conditioned medium are present in the cell culture. These differentiation factors can be used in combination with RA and/or other mid-foregut differentiation factors including, but not limited to, FGF-4 and FGF-10.
  • activin A and/or activin B can be present in the cell culture at a concentration of at least about 5 ng/ml, at least about 10 ng/ml, at least about 25 ng/ml, at least about 50 ng/ml, at least about 75 ng/ml, at least about 100 ng/ml, at least about 200 ng/ml, at least about 300 ng/ml, at least about 400 ng/ml, at least about 500 ng/ml, or at least about 1000 ng/ml.
  • a conditioned medium is present in the cell culture at a concentration of at least about 1%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% of the total medium.
  • activin A, activin B and a conditioned medium are provided to the cell culture along with RA.
  • PDX1-negative definitive endoderm cells are differentiated to PDX1-positive foregut endoderm cells in cultures comprising about 1 ⁇ M RA, about 25 ng/ml activin A and low serum RPMI medium that has been conditioned for about 24 hours by differentiated hESCs, wherein the differentiated hESCs have been differentiated for about 5 days in low serum RPMI comprising about 100 ng/ml activin A.
  • activin B and/or FGF-10 are also present in the culture at 25 ng/ml and 50 ng/ml, respectively.
  • the above-mentioned foregut differentiation factors are removed from the cell culture subsequent to their addition.
  • the foregut differentiation factors can be removed within about one day, about two days, about three days, about four days, about five days, about six days, about seven days, about eight days, about nine days or about ten days after their addition.
  • Cultures of PDX1-positive foregut endoderm cells can be grown in a medium containing reduced serum. Serum concentrations can range from about 0.05% (v/v) to about 20% (v/v). In some embodiments, PDX1-positive foregut endoderm cells are grown with serum replacement.
  • the serum concentration of the medium can be less than about 0.05% (v/v), less than about 0.1% (v/v), less than about 0.2% (v/v), less than about 0.3% (v/v), less than about 0.4% (v/v), less than about 0.5% (v/v), less than about 0.6% (v/v), less than about 0.7% (v/v), less than about 0.8% (v/v), less than about 0.9% (v/v), less than about 1% (v/v), less than about 2% (v/v), less than about.
  • PDX1-positive foregut endoderm cells are grown without serum. In other embodiments, PDX1-positive foregut endoderm cells are grown with serum replacement.
  • PDX1-positive foregut endoderm cells are grown in the presence of B27.
  • B27 can be provided to the culture medium in concentrations ranging from about 0.1% (v/v) to about 20% (v/v) or in concentrations greater than about 20% (v/v).
  • the concentration of B27 in the medium is about 0.1% (v/v), about 0.2% (v/v), about 0.3% (v/v), about 0.4% (v/v), about 0.5% (v/v), about 0.6% (v/v), about 0.7% (v/v), about 0.8% (v/v), about 0.9% (v/v), about 1% (v/v), about 2% (v/v), about 3% (v/v), about 4% (v/v), about 5% (v/v), about 6% (v/v), about 7% (v/v), about 8% (v/v), about 9% (v/v), about 10% (v/v), about 15% (v/v) or about 20% (v/v).
  • the concentration of the added B27 supplement can be measured in terms of multiples of the strength of a commercially available B27 stock solution.
  • B27 is available from Invitrogen (Carlsbad, CA) as a 5OX stock solution. Addition of a sufficient amount of this stock solution to a sufficient volume of growth medium produces a medium supplemented with the desired amount of B27. For example, the addition of 10 ml of 5OX B27 stock solution to 90 ml of growth medium would produce a growth medium supplemented with 5X B27.
  • the concentration of B27 supplement in the medium can be about O.IX, about 0.2X, about 0.3X, about 0.4X, about 0.5X, about 0.6X, about 0.7X, about 0.8X, about 0.9X, about IX, about 1.1X, about 1.2X, about 1.3X, about 1.4X, about 1.5X, about 1.6X, about 1.7X, about 1.8X, about 1.9X, about 2X, about 2.5X, about 3X, about 3.5X, about 4X, about 4.5X, about 5X, about 6X, about 7X, about 8X, about 9X, about 10X, about I IX, about 12X, about 13X, about 14X, about 1 5X, about 1 6X, about 1 7X, about 1 8X, about 1 9X, about 20X and greater than about 2OX.
  • the dorsal PDX1-positive foregut endoderm cell cultures and populations comprising dorsal PDX1-positive foregut endoderm cells that are described herein are produced from PDX1-negative definitive endoderm, which is generated from pluripotent cells as described above. Furthermore, as described above, a preferred method utilizes human embryonic stem cells as the starting material. In one embodiment, hESCs are first converted to PDX1-negative definitive endoderm cells, which are then converted to dorsal PDX1-positive foregut endoderm cells. It will be appreciated, however, that the starting materials for the production of dorsal PDX1-positive foregut endoderm is not limited to definitive endoderm cells produced using pluripotent cell differentiation methods. Rather, any PDX1-negative definitive endoderm cells can be used in the methods described herein regardless of their origin.
  • cell cultures or cell populations comprising PDX1-negative definitive endoderm cells can be used for further differentiation to cell cultures and/or enriched cell populations comprising dorsal PDX1-positive foregut endoderm cells.
  • a cell culture or cell population comprising human PDX1-negative, SOX17-positive definitive endoderm cells can be used.
  • the cell culture or cell population may also comprise differentiation factors, such as activins, nodals and/or BMPs, remaining from the previous differentiation step (that is, the step of differentiating pluripotent cells to definitive endoderm cells).
  • factors utilized in the previous differentiation step are removed from the cell culture or cell population prior to the addition of factors used for the differentiation of the PDX1-negative, SOX17-positive definitive endoderm cells to dorsal PDX1-positive foregut endoderm cells.
  • cell populations enriched for PDX1-negative, SOX17-positive definitive endoderm cells are used as a source for the production of dorsal PDX1-positive foregut endoderm cells.
  • PDX1-negative definitive endoderm cells in culture are differentiated to dorsal PDX1-positive endoderm cells by providing to a cell culture comprising PDX1-negative, SOX17-positive definitive endoderm cells a retinoid, such as retinoic acid (RA).
  • a retinoid such as retinoic acid (RA).
  • the retinoid is used in conjunction with a member of the TGFD superfamily of growth factors and/or Connaught Medical Research Labs niedium (CRML medium) (Invitrogen, Carlsbad, Calif.).
  • the RA or a combination of the above-mentioned differentiation factors are provided to the cells so that these factors are present in the cell culture or cell population at concentrations sufficient to promote differentiation of at least a portion of the PDX1-negative definitive endoderm cell culture or cell population to dorsal PDX1-positive foregut endoderm cells.
  • portion means any non-zero amount of the cell culture or cell population, which ranges from a single cell to the entirety of the cell culture or cell population.
  • portion means at least 5 %, at least 6 %, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23 %, at least 24%, at least 25%, at least 26 %, at least 27 %, at least 28%, at least 29%, at least 30%, at least 3 1%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%,
  • a retinoid is provided to the cells of a cell culture such that it is present at a concentration of at least about 0.01 ⁇ M, at least about 0.02 PM, at least about 0.04 ⁇ M, at least about 0.08 ⁇ M, at least about 0.1 ⁇ M, at least about 0.2 ⁇ M, at least about 0.3 ⁇ M, at least about 0.4 ⁇ M, at least about 0.5 ⁇ M, at least about 0.6 ⁇ M, at least about 0.7 ⁇ M, at least about 0.8 ⁇ M, at least about 0.9 ⁇ M, at least about I PM, at least about 1.1 ⁇ M, at least about 1.2 ⁇ M, at least about 1.3 PM, at least about 1.4 ⁇ M, at least about 1.5 ⁇ M, at least about 1.6 ⁇ M, at least about 1.7 ⁇ M, at least about 1.8 ⁇ M, at least about 1.9 PM, at least about 2 ⁇ M, at least about 2.1 ⁇ M, at least about 2.2
  • a population of dorsally-biased PDX1-positive foregut endoderm cells is produced by providing retinoic acid in the absence of exogenous FGF-10 or other FGF family growth factor.
  • RA is provided at a concentration of about 2 ⁇ M.
  • RA is provided at a concentration of about 2 ⁇ M in CMRL medium.
  • activin A and/or activin B are provided to the cell culture along with RA.
  • RA is provided to the cell culture at a concentration of about 2 ⁇ M and activin A and/or activin B is provided to the cell culture at a concentration of at least about 5 ng/ml, at least about 10 ng/ml, at least about 25 ng/ml, at least about 50 ng/ml, at least about 75 ng/ml, at least about 100 ng/ml, at least about 200 ng/ml, at least about 300 ng/ml, at least about 400 ng/ml, at least about 500 ng/ml, or at least about 1000 ng/ml.
  • the differentiation factors and/or CRML medium is provided to the PDX1-negative definitive endoderm cells at about three days, at about four days, at about five days, at about six days, at about seven days, at about eight days, at about nine days, at about ten days or at about greater than ten days subsequent to the initiation of differentiation from hESCs.
  • differentiation factors and/or CRML medium is provided to the PDX1-negative definitive endoderm cells at about five days subsequent to the initiation of differentiation from hESCs.
  • the above-mentioned differentiation factors are removed from the cell culture subsequent to their addition.
  • the above-mentioned differentiation factors can be removed within about one day, about two days, about three days, about four days, about five days, about six days, about seven days, about eight days, about nine days or about ten days after their addition.
  • Cultures of dorsal PDX1-positive foregut endoderm cells can be grown in a medium containing reduced serum. Serum concentrations can range from about 0.05% (v/v) to about 20% (v/v). In some embodiments, dorsal PDX1-positive foregut endoderm cells are grown with serum replacement.
  • the serum concentration of the medium can be less than about 0.05% (v/v), less than about 0.1% (v/v), less than about 0.2% (v/v), less than about 0.3% (v/v), less than about 0.4% (v/v), less than about 0.5% (v/v), less than about 0.6% (v/v), less than about 0.7% (v/v), less than about 0.8% (v/v), less than about 0.9% (v/v), less than about 1% (v/v), less than about 2% (v/v), less than about 3% (v/v), less than about 4% (v/v), less than about 5% (v/v), less than about 6% (v/v), less than about 7% (v/v), less than about 8% (v/v), less than about 9% (v/v), less than about 10% (v/v), less than about 15% (v/v) or less than about 20% (v/v).
  • dorsal PDX1-positive foregut endoderm cells are grown in the presence of B27.
  • B27 can be provided to the culture medium in concentrations ranging from about 0.1% (v/v) to about 20% (v/v) or in concentrations greater than about 20% (v/v).
  • the concentration of B27 in the medium is about 0.1% (v/v), about 0.2% (v/v), about 0.3% (v/v), about 0.4% (v/v), about 0.5% (v/v), about 0.6% (v/v), about 0.7% (v/v), about 0.8% (v/v), about 0.9% (v/v), about 1% (v/v), about 2% (v/v), about 3% (v/v), about 4% (v/v), about 5% (v/v), about 6% (v/v), about 7% (v/v), about 8% (v/v), about 9% (v/v), about 10% (v/v), about 15% (v/v) or about 20% (v/v).
  • the concentration of the added B27 supplement can be measured in terms of multiples of the strength of a commercially available B27 stock solution.
  • B27 is available from Invitrogen (Carlsbad, CA) as a 5OX stock solution. Addition of a sufficient amount of this stock solution to a sufficient volume of growth medium produces a medium supplemented with the desired amount of B27. For example, the addition of 10 ml of 5OX B27 stock solution to 90 ml of growth medium would produce a growth medium supplemented with 5X B27.
  • the concentration of B27 supplement in the medium can be about 0.1X, about 0.2X, about 0.3X, about 0.4X, about 0.5X, about 0.6X, about 0.7X, about 0.8X, about 0.9X, about 1X, about 1X, about 1.2X, about 1.3X, about 1.4X, about 1.5X, about 1.6X, about 1.7X, about 1.8X, about 1.9X, about 2X, about 2.5X, about 3X, about 3.5X, about 4X, about 4.5X, about 5X, about 6X, about 7X, about 8X, about 9X, about 10X, about I IX, about 12X, about 13X, about 14X, about 15X, about 16X, about 17X, about 18X, about 19X, about 20X and greater than about 20X.
  • ventral PDX1-positive foregut endoderm cell cultures and populations comprising ventral PDX1-positive foregut endoderm cells that are described herein are produced from PDX1-negative definitive endoderm, which is generated from pluripotent cells as described above. Furthermore, as described above, a preferred method utilizes human embryonic stem cells as the starting material. In one embodiment, hESCs are first converted to PDX1-negative definitive endoderm cells, which are then converted to ventral PDX1-positive foregut endoderm cells. It will be appreciated, however, that the starting materials for the production of ventral PDX1-positive foregut endoderm is not limited to definitive endoderm cells produced using pluripotent cell differentiation methods. Rather, any PDX1-negative definitive endoderm cells can be used in the methods described herein regardless of their origin.
  • cell cultures or cell populations comprising PDX1-negative definitive endoderm cells can be used for further differentiation to cell cultures and/or enriched cell populations comprising ventral PDX1-positive foregut endoderm cells.
  • a cell culture or cell population comprising human PDX1-negative, SOX17-positive definitive endoderm cells can be used.
  • the cell culture or cell population may also comprise differentiation factors, such as activins, nodals and/or BMPs, remaining from the previous differentiation step (that is, the step of differentiating pluripotent cells to definitive endoderm cells).
  • factors utilized in the previous differentiation step are removed from the cell culture or cell population prior to the addition of factors used for the differentiation of the PDX1-negative, SOX17-positive definitive endoderm cells to ventral PDX1-positive foregut endoderm cells.
  • cell populations enriched for PDX1-negative, SOX17-positive definitive endoderm cells are used as a source for the production of ventral PDX1-positive foregut endoderm cells.
  • PDX1-negative definitive endoderm cells in culture are differentiated to ventral PDX1-positive endoderm cells by providing to a cell culture comprising PDX1-negative, SOX 17-positive definitive endoderm cells an FGF-family growth factor or FGF-family growth factor analog or mimetic.
  • the FGF-family growth factor or FGF-family growth factor analog or mimetic is used in conjunction with a hedgehog inhibitor and/or Connaught Medical Research Labs medium (CRML medium) (Invitrogen, Carlsbad, CA).
  • FGF-10 and/or KAAD-cyclopamine is provided to a cell culture comprising PDX1-negative definitive endoderm cells in the absence of RA or other retinoid.
  • BMP4 may be included in FGF-10 and/or KAAD-cyclopamine in the absence of RA or other retinoid.
  • a retinoid such as RA
  • a retinoid containing supplement such as B27
  • B27 is provided at about the same time as providing the FGF-family growth factor analog or mimetic and/or hedgehog inhibitor.
  • a retinoid and a combination of the above-mentioned differentiation factors are provided to the cells so that these factors are present in the cell culture or cell population at concentrations sufficient to promote differentiation of at least a portion of the PDX1-negative definitive endoderm cell culture or cell population to ventral PDX1-positive foregut endoderm cells.
  • portion means any non-zero amount of the cell culture or cell population, which ranges from a single cell to the entirety of the cell culture or cell population.
  • portion means at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least I 1%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40 %, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 5
  • the FGF-family growth factor or FGF-family growth factor analog or mimetic is provided to the cells of a cell culture such that it is present at a concentration of at least about 10 ng/ml, at least about 25 ng/ml, at least about 50 ng/ml, at least about 75 ng/ml, at least about 100 ng/ml, at least about 200 ng/ml, at least about 300 ng/ml, at least about 400 ng/ml, at least about 500 ng/ml, or at least about 1000 ng/ml.
  • KAAD-cyclopamine when used alone or in conjunction with FGF-10, can be provided at a concentration of at least about 0.01 ⁇ M, at least about 0.02 ⁇ M, at least about 0.04 ⁇ M, at least about 0.08 ⁇ M, at least about 0.1 ⁇ M, at least about 0.2 ⁇ M, at least about 0.3 ⁇ M, at least about 0.4 ⁇ M, at least about 0.5 ⁇ M, at least about 0.6 ⁇ M, at least about 0.7 ⁇ M, at least about 0.8 ⁇ M, at least about 0.9 ⁇ M, at least about 1 ⁇ M, at least about 1.1 ⁇ M, at least about 1.2 ⁇ M, at least about 1.3 ⁇ M, at least about 1.4 ⁇ M, at least about 1.5 ⁇ M, at least about 1.6 ⁇ M, at least about 1.7 ⁇ M, at least about 1.8 ⁇ M, at least about 1.9 ⁇ M, at least about 2 ⁇ M, at least about 2.1 ⁇ M, at
  • a population of ventrally-biased PDX1-positive foregut endoderm cells is produced by providing a population of PDX1-negative definitive endoderm with 50 ng/ml of FGF-10 and 0.5 ⁇ M KAAD-cyclopamine in CMRL medium in the absence of RA. About two days subsequent to the addition of FGF-10 and KAAD-cyclopamine 2 ⁇ M RA is added to complete the differentiation of the cells to PDX1-positive cells.
  • the differentiation factors and/or CRML medium is provided to the PDX1-negative definitive endoderm cells at about three days, at about four days, at about five days, at about six days, at about seven days, at about eight days, at about nine days, at about ten days or at about greater than ten days subsequent to the initiation of differentiation from hESCs.
  • differentiation factors and/or CRML medium is provided to the PDX1-negative definitive endoderm cells at about three days subsequent to the initiation of differentiation from hESCs.
  • the above-mentioned differentiation factors are removed from the cell culture subsequent to their addition.
  • the above-mentioned differentiation factors can be removed within about one day, about two days, about three days, about four days, about five days, about six days, about seven days, about eight days, about nine days or about ten days after their addition.
  • ventral PDX1-positive foregut endoderm cells can be grown in a medium containing reduced serum. Serum concentrations can range from about 0.05% (v/v) to about 20% (v/v). In some embodiments, ventral PDX1-positive foregut endoderm cells are grown with serum replacement.
  • the serum concentration of the medium can be less than about 0.05% (v/v), less than about 0.1% (v/v), less than about 0.2% (v/v), less than about 0.3% (v/v), less than about 0.4% (v/v), less than about 0.5% (v/v), less than about 0.6% (v/v), less than about 0.7% (v/v), less than about 0.8% (v/v), less than about 0.9% (v/v), less than about 1% (v/v), less than about 2% (v/v), less than about 3% (v/v), less than about 4% (v/v), less than about 5% (v/v), less than about 6% (v/v), less than about 7% (v/v), less than about 8% (v/v), less than about 9% (v/v), less than about 10% (v/v), less than about 15% (v/v) or less than about 20% (v/v).
  • ventral PDX1-positive foregut endoderm cells are grown in the presence of B27.
  • B27 can be provided to the culture medium in concentrations ranging from about 0.1% (v/v) to about 20% (v/v) or in concentrations greater than about 20% (v/v).
  • the concentration of B27 in the medium is about 0.1% (v/v), about 0.2% (v/v), about 0.3% (v/v), about 0.4% (v/v), about 0.5% (v/v), about 0.6% (v/v), about 0.7% (v/v), about 0.8% (v/v), about 0.9% (v/v), about 1% (v/v), about 2% (v/v), about 3% (v/v), about 4% (v/v), about 5% (v/v), about 6% (v/v), about 7% (v/v), about 8% (v/v), about 9% (v/v), about 10% (v/v), about 15% (v/v) or about 20% (v/v).
  • the concentration of the added B27 supplement can be measured in terms of multiples of the strength of a commercially available B27 stock solution.
  • B27 is available from Invitrogen (Carlsbad, CA) as a 5OX stock solution. Addition of a sufficient amount of this stock solution to a sufficient volume of growth medium produces a medium supplemented with the desired amount of B27. For example, the addition of 10 ml of 5OX B27 stock solution to 90 ml of growth medium would produce a growth medium supplemented with 5X B27.
  • the concentration of B27 supplement in the medium can be about 0.1X, about 0.2X, about 0.3X, about 0.4X, about 0.5X, about 0.6X, about 0.7X, about 0.8X, about 0.9X, about IX, about 1.1 X, about 1.2X, about 1.3X, about 1.4X, about 1.5X, about 1.6X, about 1.7X, about 1.8X, about 1.9X, about 2X, about 2.5X, about 3X, about 3.5X, about 4X, about 4.5X, about 5X, about 6X, about 7X, about 8X, about 9X, about 10X, about 11X, about 12X, about 13X, about 14X, about 15X, about 16X, about 17X, about 18X, about 19X, about 20X and greater than about 20X.
  • a retinoid is not provided to complete the differentiation of the PDX1-negative cells to ventral PDX1-positive foregut endoderm.
  • the progression of differentiation from PDX1-negative, SOX 17-positive definitive endoderm to PDX1-positive foregut endoderm can be monitored by determining the expression of markers characteristic of these cell types.
  • Such monitoring permits one to determine the amount of time that is sufficient for the production of a desired amount of PDX1-positive foregut endoderm under various conditions, for example, one or more differentiation factor concentrations and environmental conditions.
  • the amount of time that is sufficient for the production of a desired amount of PDX1-positive foregut endoderm is determined by detecting the expression of PDX1.
  • the expression of certain markers is determined by detecting the presence or absence of the marker.
  • the expression of certain markers can be determined by measuring the level at which the marker is present in the cells of the cell culture or cell population.
  • the measurement of marker expression can be qualitative or quantitative.
  • a preferred method of quantitating the expression markers that are produced by marker genes is through the use of Q-PCR.
  • Q-PCR is used to monitor the progression of cells of the PDX1-negative, SOX17-positive definitive endoderm culture to PDX1-positive foregut endoderm cells by quantitating expression of marker genes characteristic of PDX1-positive foregut endoderm and the lack of expression of marker genes characteristic of other cell types.
  • Other methods which are known in the art can also be used to quantitate marker gene expression.
  • the expression of a marker gene product can be detected by using antibodies specific for the marker gene product of interest.
  • the expression of marker genes characteristic of PDX1-positive foregut endoderm as well as the lack of significant expression of marker genes characteristic of PDX1-negative definitive endoderm, hESCs and other cell types is determined.
  • PDX1 is a marker gene that is associated with PDX1-positive foregut endoderm.
  • the expression of PDX1 is determined.
  • the expression of other markers, which are expressed in PDX1-positive foregut endoderm including, but not limited to, SOX17, HOXA13 and/or HOXC6 is also determined.
  • PDX1 can also be expressed by certain other cell types (that is, visceral endoderm and certain neural ectoderm)
  • some embodiments of the present invention relate to demonstrating the absence or substantial absence of marker gene expression that is associated with visceral endoderm and/or neural ectoderm.
  • the expression of markers, which are expressed in visceral endoderm and/or neural cells including, but not limited to, SOX7, AFP, SOX1, ZIC1 and/or NFM is determined.
  • PDX1-positive foregut endoderm cell cultures produced by the methods described herein are substantially free of cells expressing the SOX7, AFP, SOX1, ZIC1 or NFM marker genes. In certain embodiments, the PDX1-positive foregut endoderm cell cultures produced by the processes described herein are substantially free of visceral endoderm, parietal endoderm and/or neural cells.
  • markers described in Table 3 and/or Table 4 can be detected and/or quantitated using the above-described methods, such as Q-PCR and/or immunocytochemistry, to monitor the differentiation of PDX1-negative definitive endoderm to dorsal PDX1-positive endoderm.
  • Markers associated with both dorsally-biased and ventrally-biased PDX1-positive foregut endoderm cells are described in Table 3.
  • the markers selected from the group consisting of CDH6, GABRA2, GRIA3, IL6R, KCNJ2, LGALS3, LGALS3/GALIG, SERPINF2 and SLC27A2 are cell surface markers.
  • Some preferred markers listed in Table 3 for monitoring the production of dorsal PDX1-positive foregut endoderm are selected from the group consisting of SERPINF2, DUSP9, CDH6 and SOX9. Markers associated with dorsally-biased foregut endoderm are described in Table 4. Each of the Table 4 markers is expressed preferentially, specifically or uniquely in dorsal PDX1-positive foregut endoderm cells as compared to other PDX1-positive cells.
  • markers selected from the group consisting of ADORA2A, CD47, EPB41L1, MAG, SFRP5, SLC16A10, SLC16A2, SLCIA3, SLC3OA4, SLICK, SLITRK4 and XPRI are cell surface markers.
  • Some preferred markers listed in Table 4 for monitoring the production of dorsal PDX1-positive foregut endoderm are selected from the group consisting of HOXAI, PDEI IA, FAM49A and WNT5A.
  • the expression of other markers, which are expressed in PDX1-positive foregut endoderm is also determined. Since PDX1 can also be expressed by certain other cell types (that is, visceral endoderm and certain neural ectoderm), some embodiments of the present invention relate to demonstrating the absence or substantial absence of marker gene expression that is associated with visceral endoderm and/or neural ectoderm. For example, in some embodiments, the expression of markers, which are expressed in visceral endoderm and/or neural cells, including, but not limited to, SOX7, AFP, PDX1 ZIC1 and/or NFM is determined.
  • dorsal PDX1-positive foregut -endoderm cell cultures produced by the methods described herein are substantially free of cells expressing the SOX7, AFP, SOX1, ZIC1 or NFM marker genes.
  • the dorsal PDX1-positive foregut endoderm cell cultures produced by the processes described herein are substantially free of visceral endoderm, parietal endoderm and/or neural cells.
  • markers associated with both dorsally-biased and ventrally-biased PDX1-positive foregut endoderm cells are described in Table 3.
  • expression of one or more of the markers described in Table 3 can be detected and/or quantitated using the above-described methods, such as Q-PCR and/or immunocytochemistry, to monitor the differentiation of PDX1-negative definitive endoderm to ventral PDX1-positive endoderm.
  • the markers selected from the group consisting of CDH6, GABRA2, GRIA3, IL6R, KCNJ2, LGALS3, LGALS3/GALIG, SERPINF2 and SLC27A2 are cell surface markers.
  • Some preferred markers listed in Table 3 for monitoring the production of ventral PDX1-positive foregut endoderm are selected from the group consisting of SERPINF2, DUSP9, CDH6 and SOX9. Furthermore, because the markers described in Table 4 are preferentially, specifically or uniquely expressed in dorsally-biased foregut endoderm, detecting the lack of expression, or reduced expression relative to the expression in dorsal PDX1-positive foregut endoderm, of one or more of these markers is also useful for monitoring the differentiation of PDX1-negative definitive endoderm to ventral PDX1-positive foregut endoderm.
  • the markers selected from the group consisting of ADORA2A, CD47, EPB41LI, MAG, SFRP5, SLC16AI0, SLC16A2, SLCIA3, SLC3OA4, SLICK, SLITRK4 and XPRI are cell surface markers.
  • Some preferred markers listed in Table 4 for monitoring the production of dorsal PDX1-positive foregut endoderm are selected from the group consisting of HOXAI, PDEIIA, FAM49A and WNT5A. As such, the absence, or insubstantial expression, of these markers in PDX1-positive cells expressing one or more markers selected from Table 3, is indicative of ventral PDX1-positive
  • the expression of other markers, which are expressed in PDX1-positive foregut endoderm is also determined. Since PDX1 can also be expressed by certain other cell types (that is, visceral endoderm and certain neural ectoderm), some embodiments of the present invention relate to demonstrating the absence or substantial absence of marker gene expression that is associated with visceral endoderm and/or neural ectoderm.
  • the expression of markers, which are expressed in visceral endoderm and/or neural cells including, but not limited to, SOX7, AFP, SOX1, ZIC1 and/or NFM is determined.
  • ventral PDX1-positive foregut endoderm cell cultures produced by the methods described herein are substantially free of cells expressing the SOX7, AFP, SOX1, ZIC1 or NFM marker genes.
  • the ventral PDX1-positive foregut endoderm cell cultures produced by the processes described herein are substantially free of visceral endoderm, parietal endoderm and/or neural cells.
  • PDX1-positive foregut endoderm cells including dorsal and/or ventral PDX1-positive foregut endoderm cells, produced by any of the above-described processes can be enriched, isolated and/or purified by using an affinity tag that is specific for such cells.
  • affinity tags specific for dorsal and/or ventral PDX1-positive foregut endoderm cells are antibodies, ligands or other binding agents that are specific to a marker molecule, such as a polypeptide, that is present on the cell surface of dorsal and/or ventral PDX1-positive foregut endoderm cells but which is not substantially present on other cell types that would be found in a cell culture produced by the methods described herein.
  • an antibody which binds to a cell surface marker selected from the group consisting of CDH6, GABRA2, GRIA3, IL6R, KCNJ2, LGALS3, LGALS3/GALIG, SERPINF2, SLC27A2, ADORA2A, CD47, EPB41L1, MAG, SFRP5, SLC16AI0, SLC16A2, SLCIA3, SLC3OA4, SLICK, SLITRK4 and XPRI is used as an affinity tag for the enrichment, isolation or purification of dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • an antibody which binds to a marker selected from CDH6, GABRA2, GRIA3, IL6R, KCNJ2, LGALS3, LGALS3/GALIG, SERPINF2, SLC27A2, ADORA2A, CD47, EPB41LI, MAG, SFRP5, SLC16A10, SLC16A2, SLCIA3, SLC3OA4, SLICK, SLITRK4 and XPRI is attached to a magnetic bead and then allowed to bind to dorsal and/or ventral PDX1-positive foregut endoderm cells in a cell culture which has been enzymatically treated to reduce intercellular and substrate adhesion.
  • the cell/antibody/bead complexes are then exposed to a movable magnetic field which is used to separate bead-bound definitive endoderm cells from unbound cells.
  • a movable magnetic field which is used to separate bead-bound definitive endoderm cells from unbound cells.
  • an antibody that binds to a marker selected from the group consisting of CDH6, GABRA2, GRIA3, IL6R, KCNJ2, LGALS3, LGALS3/GALIG, SERPINF2, SLC27A2, ADORA2A, CD47, EPB41LI, MAG, SFRP5, SLC16AI0, SLC16A2, SLCIA3, SLC3OA4, SLICK, SLITRK4 and XPRI is incubated with a dorsal and/or ventral PDX1-positive foregut endoderm-containing cell culture that has been treated to reduce intercellular and substrate adhesion.
  • the cells are then washed, centrifuged and resuspended.
  • the cell suspension is then incubated with a secondary antibody, such as an FITC-conjugated antibody that is capable of binding to the primary antibody.
  • the cells are then washed, centrifuged and resuspended in buffer.
  • the cell suspension is then analyzed and sorted using a fluorescence activated cell sorter (FACS).
  • FACS fluorescence activated cell sorter
  • the marker-positive cells are collected separately from marker-negative cells, thereby resulting in the isolation of such cell types.
  • the isolated cell compositions can be further purified by using an alternate affinity-based method or by additional rounds of sorting using the same or different markers that are specific for dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • dorsal and/or ventral PDX1-positive foregut endoderm cells are enriched, isolated and/or purified using a ligand or other molecule that binds to a marker selected from the group consisting of CDH6, GABRA2, GRIA3, IL6R, KCNJ2, LGALS3, LGALS3/GALIG, SERPINF2, SLC27A2, ADORA2A, CD47, EPB41LI, MAG, SFRP5, SLC16A10, SLC16A2, SLCIA3, SLC30A4, SLICK, SLITRK4 and XPRI.
  • a marker selected from the group consisting of CDH6, GABRA2, GRIA3, IL6R, KCNJ2, LGALS3, LGALS3/GALIG, SERPINF2, SLC27A2, ADORA2A, CD47, EPB41LI, MAG, SFRP5, SLC16A10, SLC16A2, SLCIA3, SLC30A4, SLICK, SLITRK4 and XPRI
  • dorsal and/or ventral PDX1-positive foregut endoderm cells are enriched, isolated and/or purified from other cells after the PDX1-negative definitive endoderm cell cultures are induced to differentiate towards the dorsal and/or ventral PDX1-positive foregut endoderm lineage. It will be appreciated that the above-described enrichment, isolation and purification procedures can be used with such cultures at any stage of differentiation.
  • dorsal and/or ventral PDX1-positive foregut endoderm cells may also be isolated by other techniques for cell isolation. Additionally, dorsal and/or ventral PDX1-positive foregut endoderm cells may also be enriched or isolated by methods of serial subculture in growth conditions which promote the selective survival or selective expansion of the dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • enriched, isolated and/or purified populations of dorsal and/or ventral PDX1-positive foregut endoderm cells and or tissues can be produced in vitro from PDX1-negative definitive endoderm cell cultures or cell populations, which have undergone at least some differentiation.
  • the cells undergo random differentiation.
  • the cells are directed to differentiate primarily into dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • Some preferred enrichment, isolation and/or purification methods relate to the in vitro production of dorsal and/or ventral PDX1-positive foregut endoderm cells from human PDX1-negative definitive endoderm cells.
  • cell populations or cell cultures can be enriched in dorsal and/or ventral PDX1-positive foregut endoderm content by at least about 2- to about 1000-fold as compared to untreated cell populations or cell cultures.
  • dorsal and/or ventral PDX1-positive foregut endoderm cells can be enriched by at least about 5- to about 500-fold as compared to untreated cell populations or cell cultures.
  • dorsal and/or ventral PDX1-positive foregut endoderm cells can be enriched from at least about 10- to about 200-fold as compared to untreated cell populations or cell cultures.
  • dorsal and/or ventral PDX1-positive foregut endoderm cells can be enriched from at least about 20- to about 100-fold as compared to untreated cell populations or cell cultures. In yet other embodiments, dorsal and/or ventral PDX1-positive foregut endoderm cells can be enriched from at least about 40- to about 80-fold as compared to untreated cell populations or cell cultures. In certain embodiments, dorsal and/or ventral PDX1-positive foregut endoderm cells can be enriched from at least about 2- to about 20-fold as compared to untreated cell populations or cell cultures.
  • dorsal and/or ventral PDX1-positive foregut endoderm cells can be enriched, isolated and/or purified.
  • cell populations enriched for dorsal and/or ventral PDX1-positive foregut endoderm cells are produced by isolating such cells from cell cultures.
  • dorsal and/or ventral PDX1-positive foregut endoderm cells are fluorescently labeled then isolated from non-labeled cells by using a fluorescence activated cell sorter (FACS).
  • FACS fluorescence activated cell sorter
  • a nucleic acid encoding fluorescent protein (GFP) or another nucleic acid encoding an expressible fluorescent marker gene, such as the gene encoding luciferase is used to label PDX1-positive cells.
  • GFP fluorescent protein
  • an expressible fluorescent marker gene such as the gene encoding luciferase
  • at least one copy of a nucleic acid encoding GFP or a biologically active fragment thereof is introduced into a pluripotent cell, preferably a human embryonic stem cell,.
  • the entire coding region of the nucleic acid, which encodes the marker selected from Table 3 or Table 4 is replaced by a nucleic acid encoding GFP or a biologically active fragment thereof.
  • the nucleic acid encoding GFP or a biologically active fragment thereof is fused in frame with at least a portion of the nucleic acid encoding the marker selected from Table 3 or Table 4, thereby generating a fusion protein.
  • the fusion protein retains a fluorescent activity similar to GFP.
  • Fluorescently marked cells such as the above-described pluripotent cells, are differentiated to definitive endoderm and then to dorsal and/or ventral PDX1-positive foregut endoderm cells as described previously above. Because dorsal and/or ventral PDX1-positive foregut endoderm cells express the fluorescent marker gene, whereas PDX1-negative cells do not, these two cell types can be separated.
  • cell suspensions comprising a mixture of fluorescently-labeled dorsal and/or ventral PDX1-positive foregut endoderm cells and unlabeled PDX1-negative cells are sorted using a FACS.
  • Dorsal and/or ventral PDX1-positive foregut endoderm cells are collected separately from PDX1-negative cells, thereby resulting in the isolation of such cell types. If desired, the isolated cell compositions can be further purified by additional rounds of sorting using the same or different markers that are specific for dorsal and/or ventral PDX1-positive foregut endoderm.
  • enriched, isolated and/or purified populations of dorsal and/or ventral PDX1-positive foregut endoderm cells and/or tissues can be produced in vitro from PDX1-negative, SOX17-positive definitive endoderm cell cultures or cell populations which have undergone at least some differentiation.
  • the cells undergo random differentiation.
  • the cells are directed to differentiate primarily into dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • Some preferred enrichment, isolation and/or purification methods relate to the in vitro production of dorsal and/or ventral PDX1-positive foregut endoderm cells from human embryonic stem cells.
  • cell populations or cell cultures can be enriched in dorsal and/or ventral PDX1-positive foregut endoderm cell content by at least about 2- to about 1000-fold as compared to untreated cell populations or cell cultures.
  • dorsal and/or ventral PDX1-positive foregut endoderm cells can be enriched by at least about 5- to about 500-fold as compared to untreated cell populations or cell cultures.
  • dorsal and/or ventral PDX1-positive foregut endoderm cells can be enriched from at least about 10- to about 200-fold as compared to untreated cell populations or cell cultures.
  • dorsal and/or ventral PDX1-positive foregut endoderm cells can be enriched from at least about 20- to about 100-fold as compared to untreated cell populations or cell cultures. In yet other embodiments, dorsal and/or ventral PDX1-positive foregut endoderm cells can be enriched from at least about 40- to about 80-fold as compared to untreated cell populations or cell cultures. In certain embodiments, dorsal and/or ventral PDX1-positive foregut endoderm cells can be enriched from at least about 2- to about 20-fold as compared to untreated cell populations or cell cultures.
  • Some embodiments of the present invention relate to cell compositions, such as cell cultures or cell populations, comprising dorsal and/or ventral PDX1-positive foregut endoderm cells, wherein the dorsal and/or ventral PDX1-positive foregut endoderm cells are multipotent cells that can differentiate into cells, tissues or organs derived from the anterior portion of the gut tube, such as the dorsal pancreatic bud and/or the ventral pancreatic bud.
  • the dorsal and/or ventral PDX1-positive foregut endoderm cells are mammalian cells, and in a preferred embodiment, such cells are human cells.
  • compositions such as cell cultures or cell populations, comprising cells of one or more cell types selected from the group consisting of hESCs, PDX1-negative definitive endoderm cells, dorsal and/or ventral PDX1-positive foregut endoderm cells and mesoderm cells.
  • hESCs comprise less than about 5%, less than about 4%, less than about 3%, less than about 2% or less than about 1% of the total cells in the culture.
  • PDX1-negative definitive endoderm cells comprise less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 12%, less than about 10%, less than about 8%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2% or less than about 1% of the total cells in the culture.
  • mesoderm cells comprise less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 12%, less than about 10%, less than about 8%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2% or less than about 1% of the total cells in the culture.
  • compositions such as cell cultures or cell populations, produced by the processes described herein comprise dorsal and/or ventral PDX1-positive foregut endoderm as the majority cell type.
  • the processes described herein produce cell cultures and/or cell populations comprising at least about 99%, at least about 98%, at least about 97%, at least about 96%, at least about 95%, at least about 94%, at least about 93%, at least about 92%, at least about 91%, at least about 90%, at least about 89%, at least about 88%, at least about 87%, at least about 86%, at least about 85%, at least about 84%, at least about 83%, at least about 82%, at least about 81%, at least about 80%, at least about 79%, at least about 78%, at least about 77%, at least about 76%, at least about 75%, at least about 74%, at least about 73%, at least about 72%, at least about 71%.
  • the cells of the cell cultures or cell populations comprise human cells.
  • the processes described herein produce cell cultures or cell populations comprising at least about 50%, at least about 45%, at least about 40%, at least about 35%, at least about 30%, at least about 25%, at least about 24%, at least about 23%, at least about 22%, at least about 21%, at least about 20%, at least about 19%, at least about 18%, at least about 17%, at least about 16%, at least about 15%, at least about 14%, at least about 13%, at least about 12%, at least about 11%, at least about 10%, at least about 9%, at least about 8%, at least about 7%, at least about 6%, at least about 5%, at least about 4%, at least about 3%, at least about 2% or at least about 1% dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • the cells of the cell cultures or cell populations comprise human cells.
  • the percentage of dorsal and/or ventral PDX1-positive foregut endoderm cells in the cell cultures or populations is calculated without regard to the feeder cells remaining in the culture.
  • compositions such as cell cultures or cell populations, comprising mixtures of dorsal and/or ventral PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells.
  • cell cultures or cell populations comprising at least about 5 dorsal and/or ventral PDX1-positive foregut endoderm cells for about every 95 PDX1-negative definitive endoderm cells can be produced.
  • cell cultures or cell populations comprising at least about 95 dorsal and/or ventral PDX1-positive foregut endoderm cells for about every 5 PDX1-negative definitive endoderm cells can be produced.
  • compositions comprising at least about 1 dorsal or ventral PDX1-positive foregut endoderm cell for about every 1,000,000 PDX1-negative definitive endoderm cells, at least about I dorsal or ventral PDX1-positive foregut endoderm cell for about every 100,000 PDX1-negative definitive endoderm cells, at least about I dorsal or ventral PDX1-positive foregut endoderm cell for about every 10,000 PDX1-negative definitive endoderm cells, at least about I dorsal or ventral PDX1-positive foregut endoderm cell for about every 1000 PDX1-negative definitive endoderm cells, at least about I dorsal or ventral PDX1-positive foregut endoderm cell for about every 500 PDX1-negative definitive definitive
  • the PDX1-negative definitive endoderm cells from which dorsal and/or ventral PDX1-positive foregut endoderm cells are produced are derived from human pluripotent cells, such as human pluripotent stem cells.
  • human pluripotent cells are derived from a morula, the inner cell mass of an embryo or the gonadal ridges of an embryo.
  • the human pluripotent cells are derived from the gonadal or germ tissues of a multicellular structure that has developed past the embryonic stage.
  • compositions such as cell cultures or cell populations, comprising human cells, including human dorsal and/or ventral PDX1-positive foregut endoderm cells, wherein the expression of the PDX1 marker is greater than the expression of the AFP, SOX7, SOX I, ZIC I and/or NFM marker in at least about 2% of the human cells.
  • the expression of the PDX1 marker is greater than the expression of the AFP, SOX7, SOX1, ZIC1 and/or NFM marker in at least about 5% of the human cells, in at least about 10% of the human cells, in at least about 15% of the human cells, in at least about 20% of the human cells, in at least about 25% of the human cells, in at least about 30% of the human cells, in at least about 35% of the human cells, in at least about 40% of the human cells, in at least about 45% of the human cells, in at least about 50% of the human cells, in at least about 55% of the human cells, in at least about 60% of the human cells, in at least about 65% of the human cells, in at least about 70% of the human cells, in at least about 75% of the human cells, in at least about 80% of the human cells, in at least about 85% of the human cells, in at least about 90% of the human cells, in at least about 95% of the human cells or in at least about 98% of the human cells.
  • compositions such as cell cultures or cell populations, comprising human dorsal and/or ventral PDX1-positive foregut endoderm cells, wherein the expression of one or more markers selected from the group consisting of SOX 17, HOXA 13 and HOXC6 is greater than the expression of the AFP, SOX7, SOX1, ZIC1 and/or NFM marker in from at least about 2% to greater than at least about 98% of the human cells.
  • the expression of one or more markers selected from the group consisting of SOX17, HOXA13 and HOXC6 is greater than the expression of the AFP, SOX7, SOX1, ZIC1 and/or NFM marker in at least about 5% of the human cells, in at least about 10% of the human cells, in at least about 15% of the human cells, in at least about 20% of the human cells, in at least about 25% of the human cells, in at least about 30% of the human cells, in at least about 35% of the human cells, in at least about 40% of the human cells, in at least about 45% of the human cells, in at least about 50% of the human cells, in at least about 55% of the human cells, in at least about 60% of the human cells, in at least about 65% of the human cells, in at least about 70% of the human cells, in at least about 75% of the human cells, in at least about 80% of the human cells, in at least about 85% of the human cells, in at least about 90% of the human cells, in at least about 95% of
  • the percentage of human cells in the cell cultures or populations, wherein the expression of one or more markers selected from the group consisting of SOX7, HOXA 13 and HOXC6 is greater than the expression of the AFP, SOX7, SOX 1, ZIC I and/or NFM marker, is calculated without regard to feeder cells.
  • compositions such as cell cultures or cell populations, comprising human cells, including human dorsal and/or ventral PDX1-positive foregut endoderm cells, wherein the expression of one or more markers selected from Table 3 is greater than the expression of the AFP, SOX7, SOX I, ZIC I and/or NFM marker in at least about 2% of the human cells.
  • the expression of the one or more markers selected from Table 3 is greater than the expression of the AFP, SOX7, SOX1, ZIC1 and/or NFM marker in at least about 5% of the human cells, in at least about 10% of the human cells, in at least about 15% of the human cells, in at least about 20% of the human cells, in at least about 25% of the human cells, in at least about 30% of the human cells, in at least about 35% of the human cells, in at least about 40% of the human cells, in at least about 45% of the human cells, in at least about 50% of the human cells, in at least about 55% of the human cells, in at least about 60% of the human cells, in at least about 65% of the human cells, in at least about 70% of the human cells, in at least about 75% of the human cell in at least about 80% of the human cells, in at least about 85% of the human cells, in at least about 90% of the human cells, in at least about 95% of the human cells or in at least about 98% of the human cells.
  • the percentage of human cells in the cell cultures or populations, wherein the expression of one or more markers selected from Table 3 is greater than the expression of the AFP, SOX7, SOX1, ZIC1 and/or NFM marker, is calculated without regard to feeder cells.
  • compositions such as cell cultures or cell populations, comprising human cells, including human dorsal PDX1-positive foregut endoderm cells, wherein the expression of one or more markers selected from Table 4 is greater than the expression of the AFP, SOX7, SOX I, ZIC I and/or NFM marker in at least about 2% of the human cells.
  • the expression of the one or more markers selected from Table 4 is greater than the expression of the AFP, SOX7, SOX1, ZIC1 and/or NFM marker in at least about 5% of the human cells, in at least about 10% of the human cells, in at least about 15% of the human cells, in at least about 20% of the human cells, in at least about 25% of the human cells, in at least about 30% of the human cells, in at least about 35% of the human cells, in at least about 40% of the human cells, in at least about 45% of the human cells, in at least about 50% of the human cells, in at least about 55% of the human cells, in at least about 60% of the human cells, in at least about 65% of the human cells, in at least about 70% of the human cells, in at least about 75% of the human cells, in at least about 80% of the human cells, in at least about 85% of the human cells, in at least about 90% of the human cells, in at least about 95% of the human cells or in at least about 98% of the human cells.
  • the percentage of human cells in the cell cultures or populations, wherein the expression of one or more markers selected from Table 4 is greater than the expression of the AFP, SOX7, SOX I, ZIC I and/or NFM marker, is calculated without regard to feeder cells.
  • compositions such as cell cultures or cell populations, comprising human cells, including human ventral PDX1-positive foregut endoderm cells, wherein the expression of a marker selected from Table 3 is greater than the expression of the AFP, SOX7, SOX1, ZIC I and/or NFM marker in at least about 2% of the human cells, and wherein a marker selected from Table 4 is not substantially expressed as compared to the expression of the same marker in dorsal PDX1-positive foregut endoderm cells.
  • the expression of the marker selected from Table 3 is greater than the expression of the AFP, SOX7, SOX 1, ZIC I and/or NFM marker in at least about 5% of the human cells, in at least about 10% of the human cells, in at least about 15% of the human cells, in at least about 20% of the human cells, in at least about 25% of the human cells, in at least about 30 % of the human cells, in at least about 35 % of the human cells, in at least about 40% of the human cells, in at least about 45% of the human cells, in at least about 50% of the human cells, in at least about 55% of the human cells, in at least about 60% of the human cells, in at least about 65% of the human cells, in at least about 70% of the human cells, in at least about 75% of the human cells, in at least about 80% of the human cells, in at least about 85% of the human cells, in at least about 90% of the human cells, in at least about 95% of the human cells or in at least about 98% of the human cells.
  • a marker selected from Table 4 is not substantially expressed as compared to the expression of the same marker in dorsal PDX1-positive foregut endoderm cells.
  • compositions such as cell cultures or cell populations, comprising mammalian endodermal cells, such as human endoderm cells, wherein the expression of the PDX1 marker and the expression of one or more markers selected from Table 3 or Table 4 is greater than the expression of the AFP, SOX7, SOX1, ZIC1 and/or NFM marker in at least about 2% of the endodermal cells.
  • the expression of the PDX1 marker and the expression of one or more markers selected from Table 3 or Table 4 is greater than the expression of the AFP, SOX7, SOX1, ZIC1 and/or NFM marker in at least about 5% of the endodermal cells, in at least about 10% of the endodermal cells, in at least about 15% of the endodermal cells, in at least about 20% of the endodermal cells, in at least about 25% of the endodermal cells, in at least about 30% of the endodermal cells, in at least about 35% of the endodermal cells, in at least about 40% of the endodermal cells, in at least about 45% of the endodermal cells, in at least about 50% of the endodermal cells, in at least about 55% of the endodermal cells, in at least about 60% of the endodermal cells, in at least about 65% of the endodermal cells, in at least about 70% of the endodermal cells, in at least about 75% of the endodermal cells, in at least about 80% of the endodermal cells, in
  • compositions such as cell cultures or cell populations, comprising mammalian endodermal cells, such as human endodermal cells, wherein the expression of one or more markers selected from the group consisting of SOX 17, HOXA 13 and HOXC6 and the expression of one or more markers selected from Table 3 or Table 4 is greater than the expression of the AFP, SOX7, SOX1, ZIC1 and/or NFM marker in at least about 2% of the endodermal cells.
  • the expression of one or more markers selected from the group consisting of SOX17, HOXA13 and HOXC6 and the expression of one or more markers selected from Table 3 or Table 4 is greater than the expression of the AFP, SOX7, SOX1, ZIC1 and/or NFM marker in at least about 5% of the endodermal cells, in at least about 10% of the endodermal cells, in at least about 15% of the endodermal cells, in at least about 20% of the endodermal cells, in at least about 25% of the endodermal cells, in at least about 30% of the endodermal cells, in at least about 35% of the endodermal cells, in at least about 40% of the endodermal cells, in at least about 45% of the endodermal cells, in at least about 50% of the endodermal cells, in at least about 55% of the endodermal cells, in at least about 60% of the endodermal cells, in at least about 65% of the endodermal cells, in at least about 70% of the endodermal cells, in at least about 75% of
  • compositions comprising dorsal and/or ventral PDX1-positive foregut endoderm cells substantially free of other cell types can be produced.
  • substantially free of means that the specified cell type of which the cell culture or cell population is free, is present in an amount of less than about 5% of the total number of cells present in the cell culture or cell population.
  • the dorsal and/or ventral PDX1-positive foregut endoderm cell populations or cell cultures produced by the methods described herein are substantially free of cells that significantly express the AFP, SOX7, SOX I, ZIC I and/or NFM marker genes.
  • a description of a dorsal PDX1-positive foregut endoderm cell based on the expression of marker genes is, PDX1 high, a marker selected from Table 3 high, a marker selected from Table 4 high, AFP low, SOX7 low, SOX I low, ZIC1 low and NFM low.
  • a description of a ventral PDX1-positive foregut endoderm cell based on the expression of marker genes is, PDX1 high, a marker selected from Table 3 high, a marker selected from Table 4 low as compared to the expression of the same marker in dorsal PDX1-positive foregut endoderm, AFP low, SOX7 low, SOX1 low, ZIC1 low and NFM low.
  • Some aspects of the present invention are related to methods of increasing the expression of the PDX1 gene product in cell cultures or cell populations comprising SOX17-positive definitive endoderm cells.
  • the SOX17-positive definitive endoderm cells are contacted with a differentiation factor in an amount that is sufficient to increase the expression of the PDX1 gene product.
  • the SOX17-positive definitive endoderm cells that are contacted with the differentiation factor can be either PDX1-negative or PDX1-positive.
  • the differentiation factor can be a retinoid.
  • SOX17-positive definitive endoderm cells are contacted with a retinoid at a concentration ranging from about 0.01 ⁇ M to about 50 ⁇ M. In a preferred embodiment, the retinoid is RA.
  • the expression of the PDX1 gene product in cell cultures or cell populations comprising SOX I 7-positive definitive endoderm cells is increased by contacting the SOX17-positive cells with a differentiation factor of the fibroblast growth factor family.
  • a differentiation factor of the fibroblast growth factor family can either be used alone or in conjunction with RA.
  • the SOX17-positive definitive endoderm cells are contacted with a fibroblast growth factor at a concentration ranging from about 10 ng/ml to about 1000 ng/ml.
  • the FGF growth factor is FGF-10.
  • the expression of the PDX1 gene product in cell cultures or cell populations comprising SOX17-positive definitive endoderm cells is increased by contacting the SOX17-positive cells with B27.
  • This differentiation factor can either be used alone or in conjunction with one or both of retinoid and FGF family differentiation factors.
  • the SOX17-positive definitive endoderm cells are contacted with B27 at a concentration ranging from about 0.1% (v/v) to about 20% (v/v).
  • the SOX17-positive definitive endoderm cells are contacted with RA, FGF-10 and B27.
  • Methods for increasing the expression of the PDX1 gene product in cell cultures or cell populations comprising SOX17-positive definitive endoderm cells can be carried out in growth medium containing reduced or no serum.
  • serum concentrations range from about 0.05% (v/v) to about 20% (v/v).
  • the SOX17-positive cells are grown with serum replacement.
  • Additional aspects of the present invention relate to methods of identifying one or more differentiation factors capable of promoting the differentiation of PDX1-negative definitive endoderm cells to PDXl-positive foregut endoderm cells.
  • a cell culture or cell population comprising PDX1-negative definitive endoderm cells is obtained and the expression of PDX1 in the cell culture or cell population is determined.
  • the cells of the cell culture or cell population are contacted with a candidate differentiation factor.
  • the expression of PDX1 is determined at the time of contacting or shortly after contacting the cells with a candidate differentiation factor.
  • PDX1 expression is then determined at one or more times after contacting the cells with the candidate differentiation factor.
  • the candidate differentiation factor is identified as capable of promoting the differentiation of PDX1-negative definitive endoderm cells to PDX1-positive foregut endoderm cells.
  • the above-described methods of identifying factors capable of promoting the differentiation of PDX1-negative definitive endoderm cells to PDX1-positive foregut endoderm cells also include determining the expression of the HOXAI3 gene and/or the HOXC6 gene in the cell culture or cell population. In such embodiments, the expression of HOXA13 and/or HOXC6 is determined both before and after the cells are contacted with the candidate differentiation factor.
  • the candidate differentiation factor is identified as capable of promoting the differentiation of PDX1-negative definitive endoderm cells to PDX1-positive foregut endoderm cells.
  • the candidate differentiation factor is identified as capable of promoting the differentiation of PDX1-negative definitive endoderm cells to PDX1-positive foregut endoderm cells.
  • a candidate differentiation factor is identified as being capable of promoting the differentiation of PDX1-negative definitive endoderm cells to PDX1-positive foregut endoderm cells by determining the expression of PDX1, HOXA13 and HOXC6 both before and after contacting the cells of the cell culture or cell population with the candidate differentiation factor.
  • the expression of PDX1, HOXA13 and/or HOC16 is determined Q-PCR.
  • the expression of one or more of PDX1, HOXA13 and HOXC6 can be determined at the time of contacting or shortly after contacting the cells of the cell cultures or cell populations with a candidate differentiation factor rather than prior to contacting the cells with a candidate differentiation factor.
  • the expression of one or more of PDX1, HOXA13 and HOXC6 at the time of contacting or shortly after contacting the cells with a candidate differentiation factor is compared to the expression of one or more of PDX1, HOXA13 and HOXC6 at one or more times after contacting the cells with a candidate differentiation factor.
  • the one or more times at which PDX1 expression is determined after contacting the cells with the candidate differentiation factor can range from about 1 hour to about 10 days.
  • PDX1 expression can be determined about I hour after contacting the cells with the candidate differentiation factor, about 2 hours after contacting the cells with the candidate differentiation factor, about 4 hours after contacting the cells with the candidate differentiation factor, about 6 hours after contacting the cells with the candidate differentiation factor, about 8 hours after contacting the cells with the candidate differentiation factor, about 10 hours after contacting the cells with the candidate differentiation factor, about 12 hours after contacting the cells with the candidate differentiation factor, about 16 hours after contacting the cells with the candidate differentiation factor, about 24 hours after contacting the cells with the candidate differentiation factor, about 2 days after contacting the cells with the candidate differentiation factor, about 3 days after contacting the cells with the candidate differentiation factor, about 4 days after contacting the cells with the candidate differentiation factor, about 5 days after contacting the cells with the candidate differentiation factor, about 6 days after contacting the cells with the candidate differentiation factor, about
  • candidate differentiation factors for use in the methods described herein can be selected from compounds, such as polypeptides and small molecules.
  • candidate polypeptides can include, but are not limited to, growth factors, cytokines, chemokines, extracellular matrix proteins, and synthetic peptides.
  • the growth factor is from the FGF family, for example FGF-10.
  • candidate small molecules include, but are not limited to, compounds generated from combinatorial chemical synthesis and natural products, such as steroids, isoprenoids, terpenoids, phenylpropanoids, alkaloids and flavinoids.
  • small molecules will have a molecular weight less than 10,000 amu.
  • the small molecule is a retinoid, for example RA.
  • the above-described methods can be used to identify factors capable of promoting the differentiation of PDX1-negative definitive endoderm cells to dorsal PDX1-positive foregut endoderm cells by monitoring the expression of one or more markers expression from Table 4.
  • the expression of one or more markers selected from Table 3 and one or more markers selected from Table 4 is monitored.
  • the above-described methods can be used to identify factors capable of promoting the differentiation of PDX1-negative definitive endoderm cells to ventral PDX1-positive foregut endoderm cells by monitoring the expression of one or more markers expression from Table 3.
  • the expression of one or more markers selected from Table 3 and one or more markers selected from Table 4 is monitored.
  • Certain screening methods described herein relate to methods for identifying at least one differentiation factor that is capable of promoting the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • cell populations comprising dorsal and/or ventral PDX1-positive foregut endoderm cells, such as human dorsal and/or ventral PDX1-positive foregut endoderm cells, are obtained.
  • the cell population is then provided with a candidate differentiation factor.
  • expression of a marker is determined.
  • expression of the marker can be determined after providing the candidate differentiation factor.
  • expression of the same marker is again determined. Whether the candidate differentiation factor is capable of promoting the differentiation of the dorsal and/or ventral PDX1-positive foregut endoderm cells is determined by comparing expression of the marker at the first time point with the expression of the marker at the second time point. If expression of the marker at the second time point is increased or decreased as compared to expression of the marker at the first time point, then the candidate differentiation factor is capable of promoting the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells. In preferred embodiments, expression of the marker is determined by Q-PCR.
  • Some embodiments of the screening methods described herein utilize cell populations or cell cultures which comprise human dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • the cell population can be a substantially purified population of human dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • the cell population can be an enriched population of human dorsal and/or ventral PDX1-positive foregut endoderm cells, wherein at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97% or greater than at least about 97% of the human cells in the cell population are human dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • the cell population comprises human cells wherein at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85% or greater than at least about 85% of the human cells are human dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • the cell population includes non-human cells such as non-human feeder cells. In other embodiments, the cell population includes human feeder cells.
  • the cell population is contacted or otherwise provided with a candidate (test) differentiation factor.
  • the candidate differentiation factor can comprise any molecule that may have the potential to promote the differentiation of human dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • the candidate differentiation factor comprises a molecule that is known to be a differentiation factor for one or more types of cells.
  • the candidate differentiation factor comprises a molecule that in not known to promote cell differentiation.
  • the candidate differentiation factor comprises molecule that is not known to promote the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • the candidate differentiation factor comprises a small molecule.
  • a small molecule is a molecule having a molecular mass of about 10,000 amu or less.
  • the small molecule comprises a retinoid.
  • the small molecule comprises retinoic acid.
  • the candidate differentiation factor comprises a polypeptide.
  • the polypeptide can be any polypeptide including, but not limited to, a glycoprotein, a lipoprotein, an extracellular matrix protein, a cytokine, a chemokine, a peptide hormone, an interleukin or a growth factor.
  • Preferred polypeptides include growth factors.
  • the candidate differentiation factors comprise one or more growth factors selected from the group consisting of Amphiregulin, B-lymphocyte stimulator, IL-16, Thymopoietin, TRAIL/Apo-2, Pre B cell colony enhancing factor, Endothelial differentiation-related factor I (EDFI), Endothelial monocyte activating polypeptide 11, Macrophage migration inhibitory factor (MIF), Natural killer cell enhancing factor (NKEFA), Bone mophogenetic protein 2, Bone mophogenetic protein 8 (osteogeneic protein 2), Bone morphogenic protein 6, Bone morphogenic protein 7, Connective tissue growth factor (CTGF), CGI-149 protein (neuroendocrine differentiation factor), Cytokine A3 (macrophage inflammatory protein ⁇ -alpha), Gliablastoma cell differentiation-related protein (GBDRI), Hepatoma-derived growth factor, Neuromedin U-25 precursor, Vascular endothelial growth factor (VEGF), VEGF, VEGF,
  • thyroxine triiodothyronine, calcitonin, estradiol, estrone, progesterone, testosterone, cortisol, corticosterone, aldosterone, epinephrine, norepinepherine, androstiene, calcitriol, collagen, Dexamethasone, ⁇ -mercaptoethanol, Retinoic acid, Butylated hydroxyanisole, 5-azacytidine, Amphotericin B, Ascorbic acid, Ascrorbate, isobutylxanthine, indomethacin, ⁇ -glycerolphosphate, nicotinamide, DMSO, Thiazolidinediones, and TWSI 19.
  • the candidate differentiation factor is provided to the cell population in one or more concentrations.
  • the candidate differentiation factor is provided to the cell population so that the concentration of the candidate differentiation factor in the medium surrounding the cells ranges from about 0.1 ng/ml to about 10 mg/mi.
  • the concentration of the candidate differentiation factor in the medium surrounding the cells ranges from about I ng/ml to about I mg/mi.
  • the concentration of the candidate differentiation factor in the medium surrounding the cells ranges from about 10 ng/ml to about 100 ⁇ g/ml.
  • the concentration of the candidate differentiation factor in the medium surrounding the cells ranges from about 100 ng/ml to about 10 ⁇ g/ml.
  • the concentration of the candidate differentiation factor in the medium surrounding the cells is about 5 ng/ml, about 25 ng/ml, about 50 ng/mI, about 75 ng/ml, about 100 ng/ml, about 125 ng/ml, about 150 ng/ml, about 175 ng/ml, about 200 ng/ml, about 225 ng/ml, about 250 ng/ml, about 275 ng/ml, about 300 ng/ml, about 325 ng/ml, about 350 ng/mi, about 375 ng/ml, about 400 ng/ml, about 425 ng/ml, about 450 ng/ml, about 475 ng/ml, about 500 ng/ml, about 525 ng/ml, about 550 ng/ml, about 575 ng/ml, about 600 ng/ml, about 625 ng/ml, about 650 ng/ml, about 675 ng/
  • the cell population is provided with a candidate differentiation factor which comprises any molecule other than a retinoid, FGF-10, FGF-4, BMP-4, activin A, activin B or any other foregut differentiation factor.
  • the cell population is provided with a candidate differentiation factor which comprises any molecule other than retinoic acid.
  • steps of the screening methods described herein comprise determining expression of at least one marker at a first time point and a second time point.
  • the first time point can be prior to or at approximately the same time as providing the cell population with the candidate differentiation factor.
  • the first time point is subsequent to providing the cell population with the candidate differentiation factor.
  • expression of a plurality of markers is determined at a first time point.
  • some embodiments of the screening methods described herein contemplate determining expression of at least one marker at a second time point, which is subsequent to the first time point and which is subsequent to providing the cell population with the candidate differentiation factor.
  • expression of the same marker is determined at both the first and second time points.
  • expression of a plurality of markers is determined at both the first and second time points.
  • expression of the same plurality of markers is determined at both the first and second time points.
  • marker expression is determined at a plurality of time points, each of which is subsequent to the first time point, and each of which is subsequent to providing the cell population with the candidate differentiation factor.
  • marker expression is determined by Q-PCR.
  • marker expression is determined by immunocytochemistry.
  • the marker having its expression is determined at the first and second time points is a marker that is associated with the differentiation of human dorsal and/or ventral PDX1-positive foregut endoderm cells to cells which are the precursors of cells which make up tissues and/or organs that are derived from the posterior portion of the foregut.
  • the tissues and/or organs that are derived from the posterior portion of the foregut comprise terminally differentiated cells.
  • the marker is indicative of pancreatic cells or pancreatic precursor cells.
  • the marker is a marker that is selected from Table 3 or Table 4.
  • sufficient time is allowed to pass between providing the cell population with the candidate differentiation factor and determining marker expression at the second time point.
  • Sufficient time between providing the cell population with the candidate differentiation factor and determining expression of the marker at the second time point can be as little as from about I hour to as much as about 10 days.
  • the expression of at least one marker is determined multiple times subsequent to providing the cell population with the candidate differentiation factor.
  • sufficient time is at least about 1 hour, at least about 6 hours, at least about 12 hours, at least about 18 hours, at least about 24 hours, at least about 30 hours, at least about 36 hours, at least about 42 hours, at least about 48 hours, at least about 54 hours, at least about 60 hours, at least about 66 hours, at least about 72 hours, at least about 78 hours, at least about 84 hours, at least about 90 hours, at least about 96 hours, at least about 102 hours, at least about 108 hours, at least about 114 hours, at least about 120 hours, at least about 126 hours, at least about 132 hours, at least about 138 hours, at least about 144 hours, at least about 150 hours, at least about 156 hours, at least about 162 hours, at least about 168 hours, at least about 174 hours, at least about 180 hours, at least about 186 hours, at least about 192 hours, at least about 198 hours, at least about 204 hours, at least about 210 hours, at least about 216 hours, at least about 186 hours, at
  • An increase or decrease in the expression of the at least one marker indicates that the candidate differentiation factor is capable of promoting the differentiation of the dorsal and/or ventral PDX1-positive foregut endoderm cells.
  • expression of a plurality of markers is determined, it is further determined whether the expression of the plurality of markers at the second time point has increased or decreased as compared to the expression of this plurality of markers at the first time point.
  • An increase or decrease in marker expression can be determined by measuring or otherwise evaluating the amount, level or activity of the marker in the cell population at the first and second time points.
  • the amount of increase is at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100-fold or more than at least about 100-fold. In some embodiments, the amount of increase is less than 2-fold.
  • the amount of decrease is at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100-fold or more than at least about 100-fold. In some embodiments, the amount of decrease is less than 2-fold.
  • pluripotent human cells Many of the examples below describe the use of pluripotent human cells. Methods of producing pluripotent human cells are well known in the art and have been described numerous scientific publications, including U.S. Pat. Nos. 5,453,357, 5,670,372, 5,690,926, 6,090,622, 6,200,806 and 6,251,671 as well as U.S. Patent Application Publication No. 2004/0229350, the disclosures of which are incorporated herein by reference in their entireties.
  • ES cells which are pluripotent and can divide seemingly indefinitely in culture while maintaining a normal karyotype.
  • ES cells were derived from the 5-day-old embryo inner cell mass using either immunological or mechanical methods for isolation.
  • the human embryonic stem cell line hESCyt-25 was derived from a supernumerary frozen embryo from an in vitro fertilization cycle following informed consent by the patient.
  • the hatched blastocyst was plated on mouse embryonic fibroblasts (MEF), in ES medium (DMEM, 20% FBS, non essential amino acids, beta-mercaptoethanol, ITS supplement).
  • hESCyt-25 has been serially passaged over 100 times.
  • stem cells or other pluripotent cells can also be used as starting material for the differentiation procedures described herein.
  • cells obtained from embryonic gonadal ridges which can be isolated by methods known in the art, can be used as pluripotent cellular starting material.
  • the human embryonic stem cell line, hESCyt-25 has maintained a normal morphology, karyotype, growth and self-renewal properties over 18 months in culture.
  • This cell line displays strong immunoreactivity for the OCT4, SSEA-4 and TRA-1-60 antigens, all of which, are characteristic of undifferentiated hESCs and displays alkaline phosphatase activity as well as a morphology identical to other established hESC lines.
  • the human stem cell line, hESCyt-25 also readily forms embryoid bodies (EBs) when cultured in suspension.
  • EBs embryoid bodies
  • Ectoderm production was demonstrated by Q-PCR for ZIC1 as well as immunocytochemistry (ICC) for nestin and more mature neuronal markers.
  • Immunocytochemical staining for ⁇ -III tubulin was observed in clusters of elongated cells, characteristic of early neurons.
  • VE visceral endoderm
  • Treated cells expressed high levels of ⁇ -fetoprotein (AFP) and SOX7, two markers of VE, by 54 hours of treatment.
  • AFP ⁇ -fetoprotein
  • SOX7 two markers of VE
  • the hESCyT-25 cell line was also capable of forming definitive endoderm, as validated by real-time quantitative polymerase chain reaction (Q-PCR) and immunocytochemistry for SOX17, in the absence of AFP expression.
  • Q-PCR quantitative polymerase chain reaction
  • EBs were analyzed for Brachyury gene expression at several time points. Brachyury expression increased progressively over the course of the experiment.
  • the hESCyT-25 line is pluripotent as shown by the ability to form cells representing the three germ layers.
  • the marker SOX17 is expressed throughout the definitive endoderm as it forms during gastrulation and its expression is maintained in the gut tube (although levels of expression vary along the A-P axis) until around the onset of organogenesis. SOX17 is also expressed in a subset of extra-embryonic endoderm cells. No expression of this protein has been observed in mesoderm or ectoderm. It has now been discovered that SOX17 is an appropriate marker for the definitive endoderm lineage when used in conjunction with markers to exclude extra-embryonic lineages.
  • the SOX17 antibody was utilized to specifically examine effects of various treatments and differentiation procedures aimed at the production of SOX17 positive definitive endoderm cells.
  • Other antibodies reactive to AFP, SPARC and Thrombomodulin were also employed to rule out the production of visceral and parietal endoderm (extra-embryonic endoderm).
  • SOX7 and SOX18 are the closest Sox family relatives to SOX17 as depicted in the relational dendrogram shown in FIG. 3 .
  • SOX7 and other proteins were expressed in human fibroblasts, and then, analyzed for cross reactivity with the SOX17 antibody by Western blot and ICC.
  • the following methods were utilized for the production of the SOX17, SOX7 and EGFP expression vectors, their transfection into human fibroblasts and analysis by Western blot.
  • Expression vectors employed for the production of SOX17, SOX7, and EGFP were pCMV6 (OriGene Technologies, Inc., Rockville, MD), pCMV-SPORT6 (Invitrogen, Carlsbad, CA) and pEGFP-NI (Clonetech, Palo Alto, CA), respectively.
  • telomerase immortalized MDX human fibroblasts were transiently transfected with supercoiled DNA in the presence of Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
  • Total cellular lysates were collected 36 hours post-transfection in 50 mM TRIS-HCI (pH 8), 150 mM NaCI, 0.1% SDS, 0.5% deoxycholate, containing a cocktail of protease inhibitors (Roche Diagnostics Corporation, Indianapolis, IN).
  • FIG. 5A shows that small numbers of SOX17 cells were co-labeled with AFP; however, regions were also found where there were little or no AFP+cells in the field of SOX17 + cells ( FIG. 5B ).
  • antibody co-labeling with SOX17 together with the parietal markers SPARC and/or Thrombomodulin (TM) can be used to identify the SOX17+cells that are parietal endoderm.
  • FIGS. 6 A-C Thrombomodulin and SOX17 co-labeled parietal endoderm cells were produced by random differentiation of hES cells.
  • the identity of a definitive endoderm cell can be established by the marker profile SOX17 hi /AFP lo /[TM lo or SPARC lo ].
  • the expression of the SOX17 marker is greater than the expression of the AFP marker, which is characteristic of visceral endoderm, and the TM or SPARC markers, which are characteristic of parietal endoderm. Accordingly, those cells positive for SOX17 but negative for AFP and negative for TM or SPARC are definitive endoderm.
  • SOX17 and AFP gene expression was quantitatively compared to the relative number of antibody labeled cells.
  • hESCs treated with retinoic acid (visceral endoderm inducer), or activin A (definitive endoderm inducer) resulted in a 10-fold difference in the level of SOX17 mRNA expression. This result mirrored the 10-fold difference in SOX17 antibody-labeled cell number ( FIG. 7B ).
  • activin A treatment of hESCs suppressed AFP gene expression by 6.8-fold in comparison to no treatment.
  • FIGS. 8 B-C This was visually reflected by a dramatic decrease in the number of AFP labeled cells in these cultures as shown in FIGS. 8 B-C. To quantify this further, it was demonstrated that this approximately 7-fold decrease in AFP gene expression was the result of a similar 7-fold decrease in AFP antibody-labeled cell number as measured by flow cytometry (FIGS. 9 A-B). This result is extremely significant in that it indicates that quantitative changes in gene expression as seen by Q-PCR mirror changes in cell type specification as observed by antibody staining.
  • the antibody produced against the carboxy-terminal 242 amino acids of the human SOX17 protein identified human SOX17 protein on Western blots but did not recognize SOX7, it's closest Sox family relative.
  • the SOX17 antibody recognized a subset of cells in differentiating hESC cultures that were primarily SOX17+/AFP 10 /- (greater than 95% of labeled cells) as well as a small percentage ( ⁇ 5%) of cells that co-label for SOX17 and AFP (visceral endoderm).
  • Treatment of hESC cultures with activins resulted in a marked elevation of SOX17 gene expression as well as SOX17 labeled cells and dramatically suppressed the expression of AFP mRNA and the number of cells labeled with AFP antibody.
  • Q-PCR real-time quantitative RT-PCR
  • Q-PCR provides a method of analysis that is at least complementary and potentially much superior to immunocytochemical techniques for screening the success of differentiation treatments. Additionally, Q-PCR provides a mechanism by which to evaluate the success of a differentiation protocol in a quantitative format at semi-high throughput scales of analysis.
  • Primers were designed to lie over exon-exon boundaries or span introns of at least 800 bp when possible, as this has been empirically determined to eliminate amplification from contaminating genomic DNA. When marker genes were employed that do not contain introns or they possess pseudogenes, DNase I treatment of RNA samples was performed.
  • HGs housekeeping genes
  • SOX 17 is expressed in definitive endoderm and to a smaller extent in visceral and parietal endoderm.
  • SOX7 and AFP are expressed in visceral endoderm at this early developmental time point.
  • SPARC and TM are expressed in parietal endoderm and Brachyury is expressed in early mesoderm.
  • Definitive endoderm cells were predicted to express high levels of SOX17 mRNA and low levels of AFP and SOX7 (visceral endoderm), SPARC (parietal endoderm) and Brachyury (mesoderm).
  • ZIC1 was used here to further rule out induction of early ectoderm.
  • GATA4 and HNF3b were expressed in both definitive and extra-embryonic endoderm, and thus, correlate with SOX17 expression in definitive endoderm (Table 1).
  • FIGS. 11 -14 A representative experiment is shown in FIGS. 11 -14 which demonstrates how the marker genes described in Table I correlate with each other among the various samples, thus highlighting specific patterns of differentiation to definitive endoderm and extra-embryonic endoderm as well as to mesodermal and neural cell types.
  • ES cell cultures randomly differentiate if cultured under conditions that do not actively maintain their undifferentiated state. This heterogeneous differentiation results in production of extra-embryonic endoderm cells comprised of both parietal and visceral endoderm (AFP, SPARC and SOX7 expression) as well as early ectodermal and mesodermal derivatives as marked by ZIC1 and Nestin (ectoderm) and Brachyury (mesoderm) expression. Definitive endoderm cell appearance has not been examined or specified for lack of specific antibody markers in ES cell cultures. As such, and by default, early definitive endoderm production in ES cell cultures has not been well studied.
  • the cells at the edges of the colony take on alternative morphologies that are distinct from those cells residing within the interior of the colony. Many of these outer edge cells can be distinguished by their less uniform, larger cell body morphology and by the expression of higher levels of OCT4. It has been described that as ES cells begin to differentiate they alter the levels of OCT4 expression up or down relative to undifferentiated ES cells. Alteration of OCT4 levels above or below the undifferentiated threshold may signify the initial stages of differentiation away from the pluripotent state.
  • TGF ⁇ family growth factors such as Nodal/activin/BMP
  • TGF ⁇ family growth factors such as Nodal/activin/BMP
  • activin A, activin B, BMP or combinations of these growth factors were added to cultures of undifferentiated human stem cell line hESCyt-25 to begin the differentiation process.
  • activin A As shown in FIG. 19 , addition of activin A at 100 ng/ml resulted in a 19-fold induction of SOX17 gene expression vs. undifferentiated hESCs by day 4 of differentiation. Adding activin B, a second member of the activin family, together with activin A, resulted in a 37-fold induction over undifferentiated hESCs by day 4 of combined activin treatment. Finally, adding a third member of the TGF ⁇ family from the Nodal/Activin and BMP subgroups, BMP4, together with activin A and activin B, increased the fold induction to 57 times that of undifferentiated hESCs ( FIG. 19 ).
  • Nodal and related molecules activin A, B and BMP facilitate the expression of SOX17 and definitive endoderm formation in vivo or in vitro. Furthermore, addition of BMP results in an improved SOX17 induction possibly through the further induction of Cripto, the Nodal co-receptor.
  • FIGS. 10 A-F To determine the effect of TGF ⁇ factor treatment at the individual cell level, a time course of TGF ⁇ factor addition was examined using SOX17 antibody labeling. As previously shown in FIGS. 10 A-F, there was a dramatic increase in the relative number of SOX17 labeled cells over time. The relative quantification ( FIG. 20 ) shows more than a 20-fold increase in SOX17-labeled cells. This result indicates that both the numbers of cells as well SOX17 gene expression level are increasing with time of TGF ⁇ factor exposure. As shown in FIG. 21 , after four days of exposure to Nodal, activin A, activin B and BMP4, the level of SOX17 induction reached 168-fold over undifferentiated hESCs. FIG. 22 shows that the relative number ofSOX17-positive cells was also dose responsive. activin A doses of 100 ng/ml or more were capable of potently inducing SOX 17 gene expression and cell number.
  • the Wnt family of molecules may play a role in specification and/or maintenance of definitive endoderm.
  • the use of Wnt molecules was also beneficial for the differentiation of hESCs to definitive endoderm as indicated by the increased SOX17 gene expression in samples that were treated with activins plus Wnt3a over that of activins alone ( FIG. 23 ).
  • FIGS. 25 A-D show cells labeled with SOX17/PCNA/DAPI that are in mitosis as evidenced by the PCNA/DAPI-labeled mitotic plate pattern and the phase contrast mitotic profile.
  • Chemokine Receptor 4 (CXCR4) Expression Correlates with markers for Definitive Endoderm and not Markers for Mesoderm. Ectoderm or Visceral Endoderm
  • hESCs can be induced to differentiate to the definitive endoderm germ layer by the application of cytokines of the TGF ⁇ family and more specifically of the activin/nodal subfamily.
  • FBS fetal bovine serum
  • hESCs were differentiated by growing in RPMI medium (Invitrogen, Carlsbad, CA; cat# 61870-036) supplemented with 0.5%, 2.0% or 10% FBS and either with or without 100 ng/ml activin A for 6 days.
  • RPMI medium Invitrogen, Carlsbad, CA; cat# 61870-036
  • FBS 0.5%, 2.0% or 10% FBS
  • a gradient of FBS ranging from 0.5% to 2.0% over the first three days of differentiation was also used in conjunction with 100 ng/ml of activin A.
  • replicate samples were collected from each culture condition and analyzed for relative gene expression by real-time quantitative PCR. The remaining cells were fixed for immunofluorescent detection of SOX17 protein. 104461
  • the expression levels of CXCR4 varied dramatically across the 7 culture conditions used ( FIG. 26 ).
  • CXCR4 expression was high in activin A treated cultures (A100) and low in those which did not receive exogenous activin A (NF).
  • CXCR4 expression was highest when FBS concentration was lowest. There was a remarkable decrease in CXCR4 level in the 10% FBS condition such that the relative expression was more in line with the conditions that did not receive activin A (NF).
  • Ectoderm and mesoderm lineages can be distinguished from. definitive endoderm by their expression of various markers. Early mesoderm expresses the genes Brachyury and MOXI while nascent neuro-ectoderm expresses SOX1 and ZIC1.
  • FIGS. 28 A-D demonstrate that the cultures which did not receive exogenous activin A were preferentially enriched for mesoderm and ectoderm gene expression and that among the activin A treated cultures, the 10% FBS condition also had increased levels of mesoderm and ectoderm marker expression. These patterns of expression were inverse to that of CXCR4 and indicated that CXCR4 was not highly expressed in mesoderm or ectoderm derived from hESCs at this developmental time period.
  • SOX17+ The relative number of SOX17 immunoreactive (SOX17+) cells present in each of the differentiation conditions mentioned above was also determined.
  • SOX17+ When hESCs were differentiated in the presence of high dose activin A and low FBS concentration (0.5% - 2.0%) SOX17+cells were ubiquitously distributed throughout the culture.
  • FBS FBS was included at 10% (v/v)
  • the SOX17+cells appeared at much lower frequency and always appeared in isolated clusters rather than evenly distributed throughout the culture ( FIGS. 29A and C as well as B and E). A further decrease in SOX17+cells was seen when no exogenous activin A was used.
  • the dose of activin A also effects the efficiency at which definitive endoderm can be derived from hESCs. This example demonstrates that increasing the dose of activin A increases the proportion of CXCR4+cells in the culture.
  • hESCs were differentiated in RPMI media supplemented with 0.5%-2% FBS (increased from 0.5% to 1.0% to 2.0% over the first 3 days of differentiation) and either 0, 10, or 100 ng/ml of activin A. After 7 days of differentiation the cells were dissociated in PBS without Ca 2 +/Mg 2 +containing 2% FBS and 2 mM (EDTA) for 5 minutes at room temperature. The cells were filtered through 35 ⁇ m nylon filters, counted and pelleted. Pellets were resuspended in a small volume of 50% human serum/50% normal donkey serum and incubated for 2 minutes on ice to block non-specific antibody binding sites.
  • mouse anti-CXCR4 antibody (Abcam, cat# ab10403-100) was added per 50 ⁇ l (containing approximately 105 cells) and labeling proceeded for 45 minutes on ice.
  • Cells were washed by adding 5 ml of PBS containing 2% human serum (buffer) and pelleted. A second wash with 5 ml of buffer was completed then cells were resuspended in 50 ⁇ l buffer per 105 cells.
  • Secondary antibody (FITC conjugated donkey anti-mouse; Jackson ImmunoResearch, cat# 715-096-151) was added at 5 ⁇ Lg/ml final concentration and allowed to label for 30 minutes followed by two washes in buffer as above.
  • the number of CXCR4+cells as determined by flow cytometry were observed to increase dramatically as the dose of activin A was increased in the differentiation culture media (FIGS. 30 A-C).
  • the CXCR4+cells were those falling within the R4 gate and this gate was set using a secondary antibody-only control for which 0.2% of events were located in the R4 gate.
  • the dramatically increased numbers of CXCR4+cells correlates with a robust increase in definitive endoderm gene expression as activin A dose is increased (FIGS. 31 A-D).
  • Example 8 The CXCR4+and CXCR4- cells identified in Example 8 above were collected and analyzed for relative gene expression and the gene expression of the parent populations was determined simultaneously.
  • CXCR4+cells contain not only the majority of the CXCR4 gene expression, but they also contained gene expression for other markers of definitive endoderm.
  • the CXCR4+cells were further enriched over the parent A100 population for SOX17, GSC, HNF3B, and MIXLI.
  • the CXCR4- fraction contained very little gene expression for these definitive endoderm markers.
  • the CXCR4+and CXCR4- populations displayed the inverse pattern of gene expression for markers of mesoderm, ectoderm and extra-embryonic endoderm.
  • hESCs were differentiated to produce definitive endoderm.
  • the serum concentration of the medium was controlled as follows: 0.2% FBS on dayl, 1.0% FBS on day 2 and 2.0% FBS on days 3-6.
  • Differentiated cultures were sorted by FACS using three cell surface epitopes, E-Cadherin, CXCR4, and Thrombomodulin. Sorted cell populations were then analyzed by Q-PCR to determine relative expression levels of markers for definitive and extraembryonic-endoderm as well as other cell types.
  • CXCR4 sorted cells taken from optimally differentiated cultures resulted in the isolation of definitive endoderm cells that were >98% pure.
  • Table 2 shows the results of a marker analysis for a definitive endoderm culture that was differentiated from hESCs using the methods described herein.
  • TABLE 2 Composition of Definitive Endoderm Cultures Percent Percent Percent Percent Percent of Definitive Extraembryonic hES Marker(s) culture Endoderm endoderm cells SOX17 70-80 100 Thrombomodulin ⁇ 2 0 75 AFP ⁇ 1 0 25 CXCR4 70-80 100 0 ECAD 10 0 100 other (ECAD neg.) 10-20 000 000 000 Total 100 100 100 100 100
  • Table 2 indicates that CXCR4 and SOX17 positive cells (endoderm) comprised from 70%-80% of the cells in the cell culture. Of these SOX17-expressing cells, less than 2% expressed TM (parietal endoderm) and less than 1% expressed AFP (visceral endoderm). After subtracting the proportion of TM-positive and AFP-positive cells (combined parietal and visceral endoderm; 3% total) from the proportion of SOX17/CXCR4 positive cells, it can be seen that about 67% to about 77% of the cell culture was definitive endoderm. Approximately 10% of the cells were positive for E-Cadherin (ECAD), which is a marker for hESCs, and about 10-20% of the cells were of other cell types.
  • ECAD E-Cadherin
  • Definitive endoderm cells produced by methods described herein have been maintained and expanded in culture in the presence of activin for greater than 50 days without appreciable differentiation.
  • SOX17, CXCR4, MIXLI, GATA4, HNF3p expression is maintained over the culture period.
  • TM, SPARC, OCT4, AFP, SOX7, ZIC1 and BRACH were not detected in these cultures. It is likely that such cells can be maintained and expanded in culture for substantially longer than 50 days without appreciable differentiation.
  • hESCs Human embryonic stem cells
  • DMEM/F12 media supplemented with 20% KnockOut Serum Replacement, 4 ng/ml recombinant human basic fibroblast growth factor (bFGF), 0.1 mM 2-mercaptoethanol, L-glutamine, non-essential amino acids and penicillin/streptomycin.
  • hESCs were differentiated to definitive endoderm by culturing for 5 days in RPMI media supplemented with 100 ng/ml of recombinant human activin A, fetal bovine serum (FBS), and penicillin/streptomycin.
  • the concentration of FBS was varied each day as follows: 0.1% (first day), 0.2% (second day), 2% (days 3-5).
  • FACS fluorescence activated cell sorting
  • RNA was submitted in duplicate to Expression Analysis (Durham, NC) for generation of the expression profile data using the Affymetrix platform and U 133 Plus 2.0 high-density oligonucleotide arrays. Data presented is a group comparison that identifies genes differentially expressed between the two populations, hESCs and definitive endoderm. Genes that exhibited a robust upward change in expression level over that found in hESCs were selected as new candidate markers that are highly characteristic of definitive endoderm. Select genes were assayed by Q-PCR, as described above, to verify the gene expression changes found on the gene chip and also to investigate the expression pattern of these genes during a time course of hESC differentiation.
  • FIGS. 34 A-M show the gene expression results for certain markers. Results are displayed for cell cultures analyzed 1, 3 and 5 days after the addition of 100 ng/ml activin A, CXCR4-expressing definitive endoderm cells purified at the end of the five day differentiation procedure (CXDE), and in purified hESCs.
  • CXDE five day differentiation procedure
  • FIGS. 34C and G-M demonstrates that the six marker genes, FGF17, VWF, CALCR, FOXQI, CMKORI and CRIP1, exhibit an expression pattern that is almost identical to each other and which is also identical to the pattern of expression of CXCR4 and the ratio of SOX17/SOX7.
  • SOX17 is expressed in both the definitive endoderm as well as in the SOX7-expressing extra-embryonic endoderm. Since SOX7 is not expressed in the definitive endoderm, the ratio of SOX17/SOX7 provides a reliable estimate of definitive endoderm contribution to the SOX17 expression witnessed in the population as a whole.
  • the similarity of panels G-L and M to panel C indicates that FGF17, VWF, CALCR, FOXQI, CMKORI and CRIPI are likely markers of definitive endoderm and that they are not significantly expressed in extra-embryonic endoderm cells.
  • Human embryonic stem cells were cultured with or without activins for four days. On day four, 1 ⁇ M RA and 50 ng/ml FGF-10 were added to the cell culture. Forty-eight hours after the RA/FGF-10 addition, the expression of the PDX1 marker gene and other marker genes not specific to foregut endoderm were quantitated by Q-PCR.
  • RA definitive endoderm cells
  • PDX1 gene expression was induced to levels approximately 500-fold higher than observed in definitive endoderm after 48 hours exposure to 1 ⁇ M RA and 50 ng/ml FGF-10.
  • these results show that substantial PDX1 induction occurred only in cell cultures which had been previously differentiated to definitive endoderm (SOX17) as indicated by the 160-fold higher PDX1 expression found in the. activin treated cell cultures relative to those cultures that received no activin prior to RA application.
  • FGF-10 Provides Additional Increase in PDX1 Expression Over RA Alone
  • hESCs were cultured with or without activins for four days. On day four, the cells were treated with one of the following: 1 ⁇ M RA alone; 1 ⁇ M RA in combination with either FGF-4 or FGF-10; or 1 ⁇ M RA in combination with both FGF-4 and FGF-10.
  • the expression of PDX1, SOX7 and NFM were quantitated by Q-PCR ninety six hours after RA or RAIFGF.
  • RA/FGF-4 or RA/FGF-10 combinations did not increase the expression of marker genes not associated with foregut endoderm when compared to cells not exposed to RAIFGF combinations (see FIG. 37B -C).
  • Human embryonic stem cells were cultured with or without activins for four days. On day four, FGF-10 at 50 ng/ml was added to the culture in combination with RA at 0.04 ⁇ M, 0.2 ⁇ M or 1.0 ⁇ M. The expression of the PDX1 marker gene as well as other markers not specific for foregut endoderm were quantitated by Q-PCR.
  • retinoic acid at various doses, in combination with FGF-10 at 50 ng/ml, induced differential gene expression patterns that correlate with specific anterior-posterior positional patterns.
  • the middle dose of RA (0.2 ⁇ M) induced midgut endoderm markers (CDXI, HOXC6) see FIG. 38C and 41E
  • the lowest dose of RA 0.04 ⁇ M preferentially induced a marker of hindgut endoderm (HOXA13) (see FIG. 38D ).
  • the RA dose had essentially no effect on the relative expression of either neural (SOX1) or neuronal (NFM) markers (see FIG. 38F -G).
  • SOX1 neural
  • NVM neuronal
  • PDX1 expression in definitive endoderm can be influenced by the use of a number of factors and cell growth/differentiation conditions.
  • B27 supplement enhances the expression of PDX1 in definitive endoderm cells.
  • Human embryonic stem cells were induced to differentiate to definitive endoderm by treatment of undifferentiated hES cells grown on mouse embryonic fibroblast feeders with high dose activin A (100-200 ng/ml in 0.5-2% FBS/DMEM/F12) for 4 days.
  • the no activin A control received 0.5-2% FBS/DMEMIF12 with no added activin A.
  • cultures received either no activin A in 2% FBS (none), and in 2% serum replacement (SR), or 50 ng/ml activin A together with 2 ⁇ M RA and 50 ng/ml FGF-10 in 2% FBS/DMEM/F12 (none, +FBS, +B27) and similarly in 2% Serum replacement (SR).
  • B27 supplement (Gibco/BRL) was added as a 1/50 dilution directly into 2%FBS/DMEM/F12 (+B27).
  • Duplicate cell samples where taken for each point, and total RNA was isolated and subjected to Q-PCR as previously described.
  • FIG. 39A -E shows that serum-free supplement B27 provided an additional benefit for induction of PDX1 gene expression without inducing an increase in the expression of markers genes not specific for foregut endoderm as compared to such marker gene expression in cells grown without serum.
  • This Example shows that the use of activin B enhances the differentiation of PDX1-negative cells to PDX1-positive cells in in vitro cell culture.
  • Human embryonic stem cells were induced to differentiate to definitive. endoderm by treatment of undifferentiated hESCs grown on mouse embryonic fibroblast feeders with high dose activin A (50 ng/ml) in low serum/RPMI for 6 days.
  • the FBS dose was 0% on day one, 0.2% on day two and 2% on days 3-6.
  • the negative control for definitive endoderm production (NF) received 2% FBS/RPMI with no added activin A.
  • retinoic acid at 2 ⁇ M in 2% FBS/RPMI on day 6.
  • the cultures treated with activin A on days one through five were provided with different dosing combinations of activin A and activin B or remained in activin A alone at 50ng/mI.
  • the no activin A control culture (NF) was provided neither activin A nor activin B.
  • This RA/activin treatment was carried out for 3 days at which time PDX1 gene expression was measured by Q-PCR from duplicate cell samples.
  • FIG. 40A shows that the addition of activin B at doses ranging from 10-50 ng/ml (a10, a25 and a5O) in the presence of 25 ng/ml (A25) or 50 ng/ml (A50) of activin A increased the PDX1 expression at least 2-fold over the culture that received only activin A at 50 ng/ml.
  • the increase in PDX1 as a result of activin B addition was without increase in HNF6 expression (see FIG. 40B ), which is a marker for liver as well as pancreas at this time in development. This result suggests that the proportion of cells differentiating to pancreas had been increased relative to liver.
  • the expression of PDX1 in definitive endoderm cells is influenced by the amount of serum present in the cell culture throughout the differentiation process.
  • the following experiment shows that the level of serum in a culture during the differentiation of hESCs to PDX1-negative definitive endoderm has an effect on the expression of PDX1 during further differentiation of these cells to PDX1-positive endoderm.
  • Human embryonic stem cells were induced to differentiate to definitive endoderm by treatment of undifferentiated hESCs grown on mouse embryonic fibroblast feeders with high dose activin A (100 ng/ml) in low serum/RPMI for 5 days.
  • the FBS dose was 0.1% on day one, 0.5% on day two and either 0.5%, 2% or 10% on days 3-5.
  • the no activin A control (NF) received the same daily FBS/RPMI dosing, but with no added activin A.
  • PDX1 expression was induced beginning at day 6 by the addition of RA.
  • cultures received retinoic acid at 2 ⁇ M in 0.5% FBS/RPMI, 1 M on day 8 and 0.2 ⁇ M on day 9-11.
  • the activin A was lowered to 50 ng/ml during retinoic acid treatment and was left absent from the no activin A control (NF).
  • FIG. 41A shows that the FBS dosing during the 3 day period of definitive endoderm induction (days 3, 4 and 5) had a lasting ability to change the induction of PDX1 gene expression during the retinoic acid treatment. This was without significant alteration in the expression pattern of ZIC I ( FIG. 41 B ) or SOX7 ( FIG. 41 C ) gene expression.
  • Human embryonic stem cells were induced to differentiate to definitive endoderm by treatment of undifferentiated hESCs grown on mouse embryonic fibroblast feeders with high dose activin A (100 ng/ml) in low serum RPMI for 5 days.
  • the FBS dose was 0.2% on day one, 0.5% on day two and 2% on days 3-5.
  • the definitive endoderm cultures generated by 5 days of activin A treatment were then induced to differentiate to PDX1 expressing endoderm by the addition of RA in 2% FBS/RPMI containing activin A at 25 ng/ml for four days.
  • the RA was 2 ⁇ M for the first two days of addition, 1 ⁇ M on the third day and 0.5 ⁇ M on the fourth day.
  • This base medium for PDX1 induction was provided fresh (2A25R) or after conditioning for 24 hours by one of four different cell populations.
  • CM Conditioned media
  • MEFCM mouse embryonic fibroblasts
  • CM3 activin A
  • BMP4 bone morphogenic protein 4
  • Activin A or BMP4 factors were provided at 100 ng/ml under the same FBS dosing regimen described above (0.2%, 0.5%, 2%).
  • the 3% FBS without added growth factor (NF) yields a heterogeneous population composed in large part of extraembryonic endoderm, ectoderm and mesoderm cells.
  • the activin A treated culture (A100) yields a large proportion of definitive endoderm and the BMP4 treated culture (B100) yields primarily trophectoderm and some extraembryonic endoderm.
  • FIG. 42A shows that PDX1 was induced equivalently in fresh and conditioned media over the first two days of RA treatment. However, by the third day PDX1 expression had started to decrease in fresh media and MEF conditioned media treatments. The differentiated hESCs produced conditioned media that resulted in maintenance or further increases in the PDX1 gene expression at levels 3 to 4-fold greater than fresh media. The effect of maintaining high PDX1 expression in hESC-conditioned media was further amplified on day four of RA treatment achieving levels 6 to 7-fold higher than in fresh media.
  • FIG. 42B shows that the conditioned media treatments resulted in much lower levels of CDXI gene expression, a gene not expressed in the region of PDX1 expressing endoderm.
  • FIG. 43 shows that PDX1 gene expression exhibited a positive dose response to the amount of conditioned media applied to the definitive endoderm cells.
  • Total volume of media added to each plate was 5 ml and the indicated volume (see FIG. 43 ) of conditioned media was diluted into fresh media (A25R). It is of note that just I ml of conditioned media added into 4 ml of fresh media was still able to induce and maintain higher PDX1 expression levels than 5 ml of fresh media alone.
  • Antibodies that bind to PDX1 are useful tools for monitoring the induction of PDX1 expression in a cell population. This Example shows that rabbit polyclonal and IgY antibodies to PDX1 can be used to detect the presence of this protein.
  • IgY anti-PDX1 (IgY cc-PDX1) antibody binding to PDX1 in cell lysates was validated by Western blot analysis.
  • IgY X-PDX1 antibody to 50 ⁇ g of total cell lysate from MDX12 human fibroblasts or MDX12 cells transfected 24 hrs previously with a PDX1 expression vector was compared.
  • the cell lysates separated by SDS-PAGE, transferred to a membrane by electroblotting, and then probed with the IgY ⁇ -PDX1 primary antiserum followed by alkaline phosphatase conjugated rabbit anti-IgY (Rb ⁇ -IgY) secondary antibodies.
  • A 500x dilution of primary, l0,OOOx dilution of secondary
  • B 2,000x, 10,000x
  • C 500x, 40,000x
  • D 2,000x, 40,000
  • E 8,000x, 40,000x
  • Binding was detected in cells transfected with the PDX1 expression vector (PDX1-positive) at all of the tested antibody combinations. Binding was only observed in untransfected (PDX1-negative) fibroblasts when using the highest concentrations of both primary and secondary antibody together (combination A). Such non-specific binding was characterized by the detection of an additional band at a molecular weight slightly higher than PDX1 in both the transfected and untransfected fibroblasts.
  • This Example shows that antibodies having specificity for PDX1 can be used to identify human PDX1-positive cells by immunocytochemistry.
  • paraffin embedded sections of human pancreas were stained for insulin with guinea pig anti-insulin (Gp a-Ins) primary antibody at a 1/200 dilution followed by dog anti-guinea pig (D a-Gp) secondary antibody conjugated to Cy2 at a 1/100 dilution.
  • Gp a-Ins guinea pig anti-insulin
  • D a-Gp dog anti-guinea pig
  • a rabbit anti-PDX1 (Rb a-PDX1) antibody was used to immunoprecipitate PDX1 from both RA differentiated and undifferentiated definitive endoderm cells. Immunoprecipitated RA was detected by Western blot analysis using IgY a-PDX1 antibody.
  • hESCs were treated for 5 days with activin A at 100 ng/ml in low serum (definitive endoderm) followed by treatment with activin A at 50 ng/ml and 2 ⁇ M all-trans RA for two days, 1 ⁇ M for one day and 0.2 ⁇ M for one day (PDX1-positive foregut endoderm).
  • activin A at 100 ng/ml in low serum (definitive endoderm)
  • activin A at 50 ng/ml and 2 ⁇ M all-trans RA for two days, 1 ⁇ M for one day and 0.2 ⁇ M for one day
  • PDX1-positive foregut endoderm As a positive control cell lysates were also prepared from MSI-V cells (ATCC # CRL-2460) transfected with a.PDX1 expression vector.
  • PDX1 was immunoprecipitated by adding Rb a-PDX1 and rabbit-specific secondary antibodies to each lysate.
  • the precipitate was harvested by centrifugation. Immunoprecipitates were dissolved in SDS-containing buffer then loaded onto a polyacrylamide gel. After separation, the proteins were transferred to a membrane by electroblotting, and then probed with the IgY A-PDX1 primary antibody followed by labeled Rb a-lgY secondary antibodies.
  • Immunoprecipitates collected from the MSI-V positive control cells as well as those from day 8 (lane d8, three days after the start of RA treatment) and day 9 (lane d9, four days after the start of RA) cells were positive for PDX1 protein ( FIG. 44 ).
  • Precipitates obtained from undifferentiated definitive endoderm cells that is, day 5 cells treated with activin A—designated (A) in FIG. 44
  • undifferentiated hESCs that is, untreated day 5 cells—designated as (NF) in FIG. 44
  • PDX1 marker for cell isolation, we genetically tagged PDX1-positive foregut endoderm cells with an expressible reporter gene.
  • This Example describes the construction of a vector comprising a reporter cassette which comprises a reporter gene under the control of the PDX1 regulatory region.
  • This Example also describes the preparation of a cell, such as a human embryonic stem cell, transfected with this vector as well as a cell having this reporter cassette integrated into its genome.
  • PDX1-expressing definitive endoderm cell lines genetically tagged with a reporter gene were constructed by placing a GFP reporter gene under the control of the regulatory region (promoter) of the PDX1 gene.
  • a plasmid construct in which EGFP expression is driven by the human PDX1 gene promoter was generated by replacing the CMV promoter of vector pEGFP-NI (Clontech) with the human PDX1 control region (Genbank Accession No. AF192496, the disclosure of which is incorporated herein by reference in its entirety), which comprises a nucleotide sequence ranging from about 4.4 kilobase pairs (kb) upstream to about 85 base pairs (bp) downstream of the PDX1 transcription start site.
  • This region contains the characterized regulatory elements of the PDX1 gene, and it is sufficient to confer the normal PDX1 expression pattern in transgenic mice.
  • expression of EFGP is driven by the PDX1 promoter.
  • this vector can be transfected into hESCs.
  • the PDX1 promoter/EGFP cassette was excised from the above vector, and then subcloned into a selection vector containing the neomycin phosphotransferase gene under control of the phosphoglycerate kinase-l promoter.
  • the selection cassette was flanked by flp recombinase recognition sites to allow removal of the cassette.
  • This selection vector was linearized, and then introduced into hESCs using standard lipofection methods. Following 10-14 days of selection in G41 8, undifferentiated transgenic hESC clones were isolated and expanded.
  • FACS fluorescence-activated cell sorting
  • PDX1 promoter/EGFP transgenic hESCs were differentiated for 5 days in activin A-containing media followed by two days in media comprising activin A and RA.
  • the differentiated cells were then harvested by trypsin digestion and sorted on a Becton Dickinson FACS Diva directly into RNA lysis buffer or PBS.
  • a sample of single live cells was taken without gating for EGFP (Live) and single live cells were gated into EGFP positive (GFP) and GFP negative (Neg) populations.
  • the EGFP positive fraction was separated into two equally sized populations according to fluorescence intensity (Hi and Lo).
  • immunocytochemistry analysis cells were sorted into PBS, fixed for 10 minutes in 4% paraformaldehyde, and adhered to glass slides using a Cytospin centrifuge.
  • Primary antibodies to Cytokeratinl9 (KRTI9) were from Chemicon; to Hepatocyte nuclear factor 3 beta (HNF ⁇ ) from Santa Cruz; to Glucose Transporter 2 (GLUT2) from R&D systems. Appropriate secondary antibodies conjugated to FITC (green) or Rhodamine (Red) were used to detect binding of the primary antibodies.
  • FIG. 45 A typical FACS sort of differentiated cells is shown in FIG. 45 .
  • the percent isolated PDX1-positive cells in this example was approximately 7%, which varied depending on the differentiation efficiency from about 1% to about 20%.
  • Sorted cells were further subjected to Q-PCR analysis. Differentiated cells showed a correlation of EGFP fluorescence with endogenous PDX1 gene expression. Compared to non-fluorescing cells, the EGFP positive cells showed a greater than 20-fold increase in PDX1 expression levels ( FIG. 46 ). The separation of high and low EGFP intensity cells indicated that EGFP expression level correlated with PDX1 expression level ( FIG. 47 ). In addition to PDX1 marker analysis, sorted cells were subjected to Q-PCR analysis of several genes that are expressed in pancreatic endoderm.
  • This Example describes the production of PDX1-positive, dorsally-biased, foregut endoderm as well as the production of PDX1-positive, ventrally-biased, foregut endoderm.
  • Definitive endoderm was produced from undifferentiated hESCs using a three or five day protocol in which activin A was provided to the culture medium at a concentration of 100 ng/ml each day.
  • the medium composition for the first five days was as follows: Dayl - RPMI +0% fetal bovine serum (FBS), Day 2 - RPMI +0.2% FBS, Day 3 - RPMI +2.0% FBS, Day 4 - RPMI +2.0% FBS and Day 5 - RPMI +2.0% FBS.
  • definitive endoderm was produced for 3 days in activin A at 100 ng/ml and then exposed to BMP4 at 3 ng/ml and FGFIO at 50 ng/ml.
  • BMP4/FGF10 addition was carried out in RPMI +2% FBS for the first 2 days and then subsequently in Connaught Medical Research Labs (CMRL) medium (Invitrogen, Carlsbad, CA) (see, Parker R.C., et al. 1957. N.Y. Academy of Sciences 5:303, the disclosure of which is incorporated herein by reference in its entirety) containing B27 supplement (I part B27 to 200 parts medium by volume - (1:200)) (Invitrogen, Carlsbad, CA).
  • CMRL Connaught Medical Research Labs
  • HB9 (dorsal endoderm marker) expression was not maintained and ventral liver markers, such as albumin and HHEX, were strongly induced along with PDX1 (FIGS. 50 A-D).
  • ventral liver markers such as albumin and HHEX
  • This Example describes the production of PDX1-positive, ventrally-biased, foregut endoderm from cultures comprising varying amounts of definitive endoderm cells. Cultures with no definitive endoderm show very little production of PDX1-positive, ventrally biased, foregut endoderm. As the initial amount of definitive endoderm cells increase, so does the production of ventrally-biased, foregut endoderm.
  • definitive endoderm After the first four days of differentiation, the relative levels of definitive endoderm produced were indicated by cerberus (CER) and SOX17 expression levels, whereby definitive endoderm was essentially absent under condition (a), minimal under condition (b), present under condition (c) and highly present under condition (d).
  • FIGS. 51C and 51D there was no induction of PDX1 or albumin gene expression after treatment with BMP4/FGF1O (ventral endoderm condition) ( FIGS. 51C and 51D). This was similarly true for the no growth factor condition (condition (b)), in which very minimal levels of definitive endoderm were formed as indicated by the low levels of CER and SOX17 ( FIGS. 51A and 51B). Although PDX1 and albumin gene expression was very low under the no growth factor condition ( FIGS. 51C and 51D), the amount of gene expression was significantly greater than that produced from condition (a).
  • the hESCs treated with intermediate (15 ng/ml) and high (100 ng/ml) doses of activin A yielded robust definitive endoderm differentiation, indicated by high SOX17 gene expression levels ( FIG. 51B ).
  • the high dose activin treatment produced definitive endoderm primarily of anterior character as indicated by very high CER expression levels.
  • Both the condition (c) and condition (d) treatments exhibited robust ventral endoderm differentiation as indicated by high level PDX1 and albumin gene expression ( FIGS. 51C and 51D).
  • the levels of PDX1 and albumin expression were greatest in the most anterior endoderm because anterior endoderm remains competent to differentiate to more posterior endoderm fates while posterior endoderm cells have lost competence to acquire more anterior fates.
  • BMP4 is not Necessary for PDX1-positive Ventral Foregut Endoderm
  • This Example describes the production of PDX1-positive, ventrally-biased, foregut endoderm in the absence of BMP4.
  • Definitive endoderm was produced by exposing undifferentiated hESCs to activin at 100 ng/mL in RPMI base medium supplemented with 0%, 0.2%, and 2% FBS on days I through 3, respectively. After 3 days of activin A treatment, the cultures were switched to a base medium composed of RPMI containing 2% FBS and maintained under one of the following conditions: (a) BMP4 at 3 ng/ml with FGFIO at 50 ng/ml and KAAD-cyclopamine at 0.5 uM; (b) FGFIO at 50 ng/ml and KAAD-cyclopamine at 0.5 1M; or (c-e) no exogenous factors.
  • CMRL plus B27 supplement (1:200) After two days, the base medium was changed to CMRL plus B27 supplement (1:200) and cells were maintained according to conditions (a-c) above. Alternatively, cells were maintained with no exogenous factors in RPMI with B27 supplement (1:200) (condition (d)) or RPMI with 2% FBS (condition (e)). The same factor treatment conditions were maintained for 8 more days of differentiation.
  • BMP4 was not needed to produce either PDX1-positive ventral foregut or liver endoderm cells as indicated by the robust induction of PDX1 and albumin expression in the absence of BMP4 ( FIGS. 52A and 52B). BMP4 addition appeared to be less favorable for the production of PDX1-positive ventral foregut endoderm but the addition of BMP4 to FGFIO and KAAD-cyclopamine treatment does not decrease ventral foregut liver endoderm gene expression ( FIGS. 52A and 52B).
  • CMRL with B27 supplement had some ability to induce PDX1 expression in the absence of added factors (condition (c)) while RPMI with B27 (condition (d)) and RPMI with 2% FBS (condition (e)) did not exhibit any induction of PDX1 expression ( FIG. 52A ). There did not appear to be a significant effect of base media on the induction of liver gene expression. In summary, FGF10 and KAAD-cyclopamine are sufficient to produce PDX1-positive ventral foregut endoderm.
  • This Example describes markers useful for, among other things, the identification, detection, enrichment, isolation, purification, targeting and/or validation of PDX1-positive dorsal and ventral foregut endoderm.
  • Example 24 Cell cultures differentiated as described in Example 24 were subjected to gene chip analysis to globally monitor the gene expression dynamics occurring during differentiation of hESC to definitive endoderm and further on to more mature dorsal and ventral endoderm phenotypes. Duplicate samples were isolated at the times indicated in Example 24. Gene expression profiles were determined using Affymetrix U133 plus 2.0 high density oligonucleotide arrays by Expression Analysis (Durham, NC) according to their internal standard operating procedures. We have evaluated the patterns of gene expression across these 7 conditions/time points through manual inspection as well as through hierarchical clustering analyses. We have looked for patterns of gene expression that match the temporal pattern of PDX1 expression (dorsal and ventral) to find novel genes that are expressed in both ventral and dorsal differentiation paradigms.
  • Affymetrix U133 plus 2.0 high density oligonucleotide arrays by Expression Analysis (Durham, NC) according to their internal standard operating procedures. We have evaluated the patterns of gene expression across these 7 conditions/time points through manual inspection
  • genes that have a significant similarity in expression pattern to PDX1 may be co-expressed in PDX1-expressing foregut endoderm cells
  • the genes listed in Table 3 are expressed in both the dorsal and ventral PDX1 differentiation.
  • the genes in Table 4 are dorsally biased and are preferentially expressed in the dorsal PDX1 pattern.
  • Table 3 lists 39 markers that are expressed in both dorsal and ventral PDX1-positive foregut endoderm. Column I provides the commonly known gene symbol for each marker. Columns 2 through 4 provide the Unigene, LocusLink, and OMIM accession numbers, respectively. Column 5 described the Genebank accession number for a nucleic acid sequence which includes the marker described in column 1. Finally, column 6 provides a description of the functional activity of the polypeptide marker that is encoded by the listed genetic marker.
  • accession numbers listed in Table 3 can be used by those of ordinary skill in the art to retrieve specific information about each sequence described in the table, including both the primary nucleic acid and polypeptide sequence of each of these marker.
  • TABLE 3 Markers expressed in both dorsal and ventral PDX1-positive foregut endoderm Gene Symbol Unigene LocusLink OMIM SeqDerivedFrom Gene Descriptor ANXA4 Hs.422986 307 106491 NM_001153 annexin A4 ASCL1 Hs.524672 429 100790 BC001638 achaete-scute complex-like 1 ( Drosophila ) BNC1 Hs.459153 646 601930 NM_001717 basonuclin 1 C10orf30 Hs.498740 222389 AW195407 Chromosome 10 open reading frame 30 C2orf23 Hs.368884 65055 609139 BE535746 chromosome 2 open reading frame 23 C
  • FIGS. 53 A-E further illustrate the commonality of expression profile betveen PDX1 and markers selected from Table 3.
  • FIGS. 53 A-E provide examples of genes that displayed nearly identical gene expression patterns to that of PDX1 across the 7 conditions/time monitored in this experiment. Pattern recognition to this degree of similarity most likely reflects co-expression of these genes in the same cells that express PDX1, thus making these markers excellent novel candidate markers for PDX1-positive foregut endoderm from both dorsal and ventral endoderm origins.
  • Table 4 lists 50 markers that are specifically and/or preferentially expressed in dorsal PDX1-positive foregut endoderm.
  • Column I provides the commonly known gene symbol for each marker.
  • Columns 2 through 4 provide the Unigene, LocusLink, and OMIM accession numbers, respectively.
  • Column 5 described the Genebank accession number for a nucleic acid sequence which includes the marker described in column 1.
  • column 6 provides a description of the functional activity of the polypeptide marker that is encoded by the listed genetic marker.
  • accession numbers listed in Table 4 can be used by those of ordinary skill in the art to retrieve specific information about each sequence described in the table, including both the primary nucleic acid and polypeptide sequence of each of these marker.
  • TABLE 4 Markers expressed in dorsally-biased PDX1-positive foregut endoderm Gene Symbol Unigene LocusLink OMIM SeqDerivedFrom Gene Descriptor ADORA2A Hs.197029 135 102776 NM_000675 adenosine A2a receptor AMSH-LP Hs.16229 57559 AI638611 associated molecule with the SH3 domain of STAM (AMSH) like protein BAIAP2L1 Hs.489237 55971 AA628400 BAI1-associated protein 2-like 1 CD47 Hs.446414 961 601028 BG230614 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) CHN2 Hs.203663 1124 602857
  • FIG. 54A -D provide examples of genes that display patterns of gene expression that indicate specific (HOXAI and PDEI IA) or preferential (FAM49A and WNT5A) expression in the dorsal endoderm condition (RA treatment). These markers are novel candidate genes for identification of PDX1-positive, dorsally-biased, foregut endoderm.
  • This Example describes the production of PDX1-negative foregut endoderm.
  • Human embryonic stem cells were differentiated for 7 days via a 2-step protocol to achieve PDX1 cells.
  • the first step comprised 5 days differentiation in activin A (100 ng/ml) to robustly produce DE (D'Amour, K., et al., Nature Biotechnology 23, 1534-1541, (2005)).
  • Step 2 comprised 2 days differentiation in fresh RPMI with 2% FBS containing FGFIO (50 ng/ml) and KAAD-cyclopamine (0.5 ⁇ M).
  • FGFIO FGFIO
  • KAAD-cyclopamine 0.1-2 ⁇ M, sonic hedgehog inhibitor
  • phrase consisting essentially of is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements.
  • phrase consisting essentially of indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.
  • the complete citation is in the body of the text.
  • the citation in the body of the text is by author and year, the complete citation being as follows:
  • Casanova plays an early and essential role in endoderm formation in zebrafish. Dev Biol 215, 343-357.
  • HIV-1 entry cofactor functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877.
  • Fetomodulin marker surface protein of fetal development which is modulatable by cyclic AMP. Dev Biol 122, 483-491.
  • Kanai-Azuma M., Kanai, Y., Gad, J. M., Tajima, Y., Taya, C., Kurohmaru, M., Sanai, Y., Yonekawa, H., Yazaki, K., Tam, P. P., and Hayashi, Y. (2002). Depletion of definitive gut endoderm in Soxl 7-null mutant mice. Development 129, 2367-2379.
  • Chemokines signal lamps for trafficking of T and B cells for development and effector function. J Leukoc Biol 65, 6-15.
  • chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 10, 463-471.
  • Tremblay K. D., Hoodless, P. A., Bikoff, E. K., and Robertson, E. J. (2000). Formation of the definitive endoderm in mouse is a Smad2-dependent process. Development 127, 3079-3090.
  • mouse endoderm is patterned by soluble factors from adjacent germ layers. Development 127, 1563-1572.
  • Nodal is a novel TGF-beta-like gene expressed in the mouse node during gastrulation. Nature 361, 543-547.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
US11/588,693 2005-10-27 2006-10-27 PDX1-expressing dorsal and ventral foregut endoderm Abandoned US20070122905A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US11/588,693 US20070122905A1 (en) 2005-10-27 2006-10-27 PDX1-expressing dorsal and ventral foregut endoderm
US12/729,084 US20100233755A1 (en) 2005-10-27 2010-03-22 Pdx1-expressing dorsal and ventral foregut endoderm
US13/962,978 US9499795B2 (en) 2005-10-27 2013-08-09 PDX1-expressing dorsal and ventral foregut endoderm
US15/290,850 US20170022474A1 (en) 2005-10-27 2016-10-11 Pdx1-expressing dorsal and ventral foregut endoderm
US16/200,493 US11427805B2 (en) 2005-10-27 2018-11-26 Methods of producing human foregut endoderm cells expressing PDX1 from human definitive endoderm
US17/814,791 US20230040286A1 (en) 2005-10-27 2022-07-25 Methods of producing human foregut endoderm cells expressing pdx1 from human definitive endoderm

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73091705P 2005-10-27 2005-10-27
US11/588,693 US20070122905A1 (en) 2005-10-27 2006-10-27 PDX1-expressing dorsal and ventral foregut endoderm

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/729,084 Continuation US20100233755A1 (en) 2005-10-27 2010-03-22 Pdx1-expressing dorsal and ventral foregut endoderm

Publications (1)

Publication Number Publication Date
US20070122905A1 true US20070122905A1 (en) 2007-05-31

Family

ID=37769419

Family Applications (6)

Application Number Title Priority Date Filing Date
US11/588,693 Abandoned US20070122905A1 (en) 2005-10-27 2006-10-27 PDX1-expressing dorsal and ventral foregut endoderm
US12/729,084 Abandoned US20100233755A1 (en) 2005-10-27 2010-03-22 Pdx1-expressing dorsal and ventral foregut endoderm
US13/962,978 Active US9499795B2 (en) 2005-10-27 2013-08-09 PDX1-expressing dorsal and ventral foregut endoderm
US15/290,850 Abandoned US20170022474A1 (en) 2005-10-27 2016-10-11 Pdx1-expressing dorsal and ventral foregut endoderm
US16/200,493 Active US11427805B2 (en) 2005-10-27 2018-11-26 Methods of producing human foregut endoderm cells expressing PDX1 from human definitive endoderm
US17/814,791 Abandoned US20230040286A1 (en) 2005-10-27 2022-07-25 Methods of producing human foregut endoderm cells expressing pdx1 from human definitive endoderm

Family Applications After (5)

Application Number Title Priority Date Filing Date
US12/729,084 Abandoned US20100233755A1 (en) 2005-10-27 2010-03-22 Pdx1-expressing dorsal and ventral foregut endoderm
US13/962,978 Active US9499795B2 (en) 2005-10-27 2013-08-09 PDX1-expressing dorsal and ventral foregut endoderm
US15/290,850 Abandoned US20170022474A1 (en) 2005-10-27 2016-10-11 Pdx1-expressing dorsal and ventral foregut endoderm
US16/200,493 Active US11427805B2 (en) 2005-10-27 2018-11-26 Methods of producing human foregut endoderm cells expressing PDX1 from human definitive endoderm
US17/814,791 Abandoned US20230040286A1 (en) 2005-10-27 2022-07-25 Methods of producing human foregut endoderm cells expressing pdx1 from human definitive endoderm

Country Status (10)

Country Link
US (6) US20070122905A1 (ja)
EP (3) EP2674485B1 (ja)
JP (5) JP5404047B2 (ja)
CN (1) CN101351547A (ja)
AU (1) AU2006305879B2 (ja)
CA (2) CA2627645C (ja)
DK (2) DK1957636T3 (ja)
ES (2) ES2743202T3 (ja)
PL (1) PL1957636T3 (ja)
WO (1) WO2007051038A2 (ja)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070259421A1 (en) * 2006-03-02 2007-11-08 D Amour Kevin A Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US20070281355A1 (en) * 2004-08-13 2007-12-06 Stephen Dalton Compositions And Methods For Self-Renewal And Differentiation In Human Embryonic Stem Cells
US20090010900A1 (en) * 2004-07-07 2009-01-08 The University Of North Carlolina At Chapel Hill Embryonic Stem Cell Derivatives, and Methods of Making and Using the Same
US20090042287A1 (en) * 2004-04-27 2009-02-12 D Amour Kevin Allen Pdx1 expressing endoderm
US7534608B2 (en) 2006-07-26 2009-05-19 Cythera, Inc. Methods of producing pancreatic hormones
US20090186407A1 (en) * 2001-08-06 2009-07-23 Bresagen, Inc. Alternative Compositions and Methods for the Culture of Stem Cells
US20090263896A1 (en) * 2008-04-21 2009-10-22 Olivia Kelly Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
US20090298178A1 (en) * 2008-06-03 2009-12-03 D Amour Kevin Allen Growth factors for production of definitive endoderm
US20100112691A1 (en) * 2008-11-04 2010-05-06 Chad Green Stem Cell Aggregate Suspension Compositions and Methods of Differentiation Thereof
WO2010053472A1 (en) 2008-11-04 2010-05-14 Novocell, Inc. Stem cell aggregate suspension compositions and methods for differentiation thereof
US20100124564A1 (en) * 2008-11-14 2010-05-20 Laura Martinson Encapsulation of pancreatic cells derived from human pluripotent stem cells
US20100233755A1 (en) * 2005-10-27 2010-09-16 D Amour Kevin Allen Pdx1-expressing dorsal and ventral foregut endoderm
US20100260728A1 (en) * 2006-03-02 2010-10-14 Laura Martinson Methods of producing pancreatic hormones
US20100272695A1 (en) * 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
US20110014702A1 (en) * 2009-07-20 2011-01-20 Jean Xu Differentiation of Human Embryonic Stem Cells
US20110014703A1 (en) * 2009-07-20 2011-01-20 Jean Xu Differentiation of Human Embryonic Stem Cells
US8415158B2 (en) 2006-02-23 2013-04-09 Viacyte, Inc. Compositions and methods useful for culturing differentiable cells
EP2730649A1 (en) 2012-11-08 2014-05-14 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US20150252327A1 (en) * 2007-11-27 2015-09-10 Lifescan, Inc. Differentiation of human embryonic stem cells
US9433557B2 (en) 2011-02-21 2016-09-06 Viacyte, Inc. Loading system for an encapsulation device
CN107189979A (zh) * 2010-03-01 2017-09-22 詹森生物科技公司 纯化衍生自多能干细胞的细胞的方法
US20170304369A1 (en) * 2014-10-08 2017-10-26 Agency For Science, Technology And Research Methods of differentiating stem cells into liver cell lineages
US9951314B2 (en) 2010-08-31 2018-04-24 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9969972B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
US9969973B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Methods and compositions for cell attachment and cultivation on planar substrates
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US10066203B2 (en) 2008-02-21 2018-09-04 Janssen Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
US10066210B2 (en) 2012-06-08 2018-09-04 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US10076544B2 (en) 2009-07-20 2018-09-18 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10138463B2 (en) 2008-11-04 2018-11-27 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
US10138465B2 (en) 2012-12-31 2018-11-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators
US10233421B2 (en) 2008-06-30 2019-03-19 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US10316293B2 (en) 2007-07-01 2019-06-11 Janssen Biotech, Inc. Methods for producing single pluripotent stem cells and differentiation thereof
US10344264B2 (en) 2012-12-31 2019-07-09 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10358628B2 (en) 2011-12-22 2019-07-23 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US10377989B2 (en) 2012-12-31 2019-08-13 Janssen Biotech, Inc. Methods for suspension cultures of human pluripotent stem cells
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
US10420803B2 (en) 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
US10456424B2 (en) 2007-07-31 2019-10-29 Janssen Biotech, Inc. Pancreatic endocrine cells and methods thereof
US10704025B2 (en) 2009-12-23 2020-07-07 Janssen Biotech, Inc. Use of noggin, an ALK5 inhibitor and a protein kinase c activator to produce endocrine cells
US10724052B2 (en) 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
US11051900B2 (en) 2014-04-16 2021-07-06 Viacyte, Inc. Tools and instruments for use with implantable encapsulation devices
US11104918B2 (en) 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells
US11116797B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
US11566230B2 (en) 2020-12-31 2023-01-31 Crispr Therapeutics Ag Universal donor cells

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
CN103898045B (zh) 2003-12-23 2019-02-01 维亚希特公司 定形内胚层
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
EP1888123B1 (en) 2005-06-08 2013-01-09 Janssen Biotech, Inc. A cellular therapy for ocular degeneration
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
JP5738591B2 (ja) * 2007-07-18 2015-06-24 ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． ヒト胚幹細胞の分化
WO2009027654A1 (en) * 2007-08-24 2009-03-05 University Court Of The University Of Edinburgh Regionalised endoderm cells and uses thereof
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US9012218B2 (en) 2008-10-31 2015-04-21 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
RU2522001C2 (ru) 2008-10-31 2014-07-10 Сентокор Орто Байотек Инк. Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток
JP2012527880A (ja) * 2009-05-29 2012-11-12 ノヴォ ノルディスク アー／エス ｈＰＳ細胞由来の胚体内胚葉からの特定の内胚葉の派生
KR101923537B1 (ko) 2009-12-23 2018-11-29 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
BR112012028855A2 (pt) 2010-05-12 2015-09-22 Janssen Biotech Inc diferenciação das células-tronco embrionárias humanas
AU2011296383B2 (en) 2010-08-31 2016-03-10 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
SG10201506852VA (en) 2010-08-31 2015-10-29 Janssen Biotech Inc Differentiation of human embryonic stem cells
AU2013230020B2 (en) 2012-03-07 2018-08-09 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
CN104428410B (zh) 2012-05-25 2016-08-31 学校法人埼玉医科大学 胰激素产生细胞的制造方法及胰激素产生细胞、以及分化诱导促进剂
AU2014248167B2 (en) * 2013-04-03 2019-10-10 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
JP6352908B2 (ja) 2013-05-24 2018-07-04 学校法人 埼玉医科大学 新規ペプチド及びその用途
KR102523912B1 (ko) 2013-06-11 2023-04-21 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
EP2896688A1 (en) * 2014-01-20 2015-07-22 Centre National de la Recherche Scientifique (CNRS) A method of producing beta pancreatic cells from progenitor cells through the use of hydrogen peroxide
JP6687544B2 (ja) 2014-05-28 2020-04-22 チルドレンズ ホスピタル メディカル センター 前駆細胞を指向性分化によって胃組織に変換するための方法及びシステム
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
EP4374863A2 (en) 2014-12-18 2024-05-29 President and Fellows of Harvard College Methods for generating stem cell-derived beta cells and uses thereof
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
RU2017125728A (ru) * 2014-12-19 2019-01-22 Янссен Байотек, Инк. Культивирование плюрипотентных стволовых клеток в суспензии
WO2017192997A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
JP7068305B2 (ja) 2016-12-05 2022-05-16 チルドレンズ ホスピタル メディカル センター 結腸オルガノイドならびにその作製方法および使用方法
WO2018139600A1 (ja) * 2017-01-27 2018-08-02 株式会社カネカ 内胚葉系細胞集団、及び多能性細胞から三胚葉のいずれかの細胞集団を製造する方法
WO2018232180A1 (en) 2017-06-14 2018-12-20 Semma Therapeutics, Inc. Devices and methods for delivering therapeutics
MX2020004939A (es) 2017-11-15 2020-11-11 Semma Therapeutics Inc Fabricacion de composiciones de celulas islote y metodos de uso de las mismas.
AU2019320072A1 (en) 2018-08-10 2021-02-25 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
EP3972990A4 (en) * 2019-05-22 2023-10-11 The Cleveland Clinic Foundation GENERATION OF ENDODEREM CELLS OF THE DORSAL INTESTINAL TUBE AND THE ANTERIOR AREA
EP3976237A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates Inc. Cell encapsulation devices with controlled oxygen diffusion distances
EP3975925A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates, Inc. A biocompatible membrane composite
US20220234006A1 (en) 2019-05-31 2022-07-28 W. L. Gore & Associates, Inc. A biocompatible membrane composite
US20220233298A1 (en) 2019-05-31 2022-07-28 W. L. Gore & Associates, Inc. A biocompatible membrane composite
US11850303B2 (en) 2020-10-27 2023-12-26 Uqora, Inc. Gel and a suppository and methods to provide the gel and suppository

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453357A (en) * 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) * 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
US5817637A (en) * 1993-01-26 1998-10-06 The Trustees Of The University Of Pennsylvania Genetic immunization
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6015671A (en) * 1995-06-07 2000-01-18 Indiana University Foundation Myocardial grafts and cellular compositions
US6090622A (en) * 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6165993A (en) * 1992-03-23 2000-12-26 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US6251671B1 (en) * 1996-02-28 2001-06-26 Vanderbilt University Compositions and methods of making embryonic stem cells
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US20020072117A1 (en) * 2000-01-11 2002-06-13 Chunhui Xu Human feeder cells that support proliferation of undifferentiated pluripotent stem cells
US6458589B1 (en) * 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US20020187548A1 (en) * 1994-11-21 2002-12-12 National Jewish Medical And Research Center Method for identification of cell growth or differentiation factors
US20030138948A1 (en) * 2001-12-07 2003-07-24 Fisk Gregory J. Islet cells from human embryonic stem cells
US20030138949A1 (en) * 2001-12-12 2003-07-24 Anil Bhushan Methods for the regeneration of pancreatic islets and expansion of pancreatic endocrine cells
US20030175956A1 (en) * 1997-10-23 2003-09-18 Bodnar Andrea G. Feeder-free culture method for embryonic stem cell
US20030190748A1 (en) * 2000-03-09 2003-10-09 Thomson James A. Serum free cultivation of primate embryonic stem cells
US20030224411A1 (en) * 2003-03-13 2003-12-04 Stanton Lawrence W. Genes that are up- or down-regulated during differentiation of human embryonic stem cells
US20040127406A1 (en) * 2002-05-28 2004-07-01 Presnell Sharon C. Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells
US20040229350A1 (en) * 2003-05-12 2004-11-18 Nikolai Strelchenko Morula derived embryonic stem cells
US6872389B1 (en) * 1999-07-08 2005-03-29 Rhode Island Hospital Liver stem cell
US6921811B2 (en) * 1998-09-22 2005-07-26 Biosurface Engineering Technologies, Inc. Bioactive coating composition and methods
US20060003313A1 (en) * 2003-12-23 2006-01-05 D Amour Kevin A Methods for identifying factors for differentiating definitive endoderm
US20060003446A1 (en) * 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
US20060040385A1 (en) * 2002-12-05 2006-02-23 Technion Research & Development Foundation Ltd. Cultured human pancreatic islets, and uses thereof
US20060128017A1 (en) * 2002-12-24 2006-06-15 Philippe Geffard Process for the production of an active molecule vector used to diffuse active substances and vector thus obtained
US20060148081A1 (en) * 2003-12-23 2006-07-06 Olivia Kelly Expansion of definitive endoderm cells
US20060276420A1 (en) * 2002-05-17 2006-12-07 Keller Gordon M Mesoderm and definitive endoderm cell populations
US7256042B2 (en) * 2000-04-27 2007-08-14 Geron Corporation Process for making hepatocytes from pluripotent stem cells
US20070281355A1 (en) * 2004-08-13 2007-12-06 Stephen Dalton Compositions And Methods For Self-Renewal And Differentiation In Human Embryonic Stem Cells

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2161804A (en) 1935-11-09 1939-06-13 Baldwin Southwark Corp Hydraulic press
US4873702A (en) 1988-10-20 1989-10-10 Chiu Ran Fun Method and apparatus for DC restoration in digital receivers
US7153684B1 (en) * 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5748681A (en) 1995-10-27 1998-05-05 Lucent Technologies Inc Offset correction for a homodyne radio
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5964261A (en) * 1996-05-29 1999-10-12 Baxter International Inc. Implantation assembly
JP2001508302A (ja) 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換
US5798644A (en) 1997-02-20 1998-08-25 At&T Corp Method and apparatus for locating buried conveyances using locating & confirmation signals with an array of sensors
US5793230A (en) 1997-02-26 1998-08-11 Sandia Corporation Sensor readout detector circuit
US6331406B1 (en) * 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
ES2279580T3 (es) 1997-09-15 2007-08-16 Genetic Immunity, Llc Composiciones para administrar genes a celulas de la piel que presentan antigenos.
US20030008919A1 (en) * 1999-06-03 2003-01-09 Jean-Baptiste Roullet Use of retinoids to treat high blood pressure and other cardiovascular disease
DE19852800C1 (de) 1998-11-16 2000-04-13 Univ Albert Ludwigs Freiburg Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist
AU780794B2 (en) 1999-02-10 2005-04-14 Es Cell International Pte Ltd Pancreatic progenitor cells, methods and uses related thereto
JP2004504834A (ja) 2000-08-01 2004-02-19 イスム　リサーチ　ディベロップメント　カンパニー 胚性細胞の定方向分化
AU2002226075A1 (en) 2000-10-23 2002-05-06 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
WO2002059278A2 (en) 2001-01-24 2002-08-01 The Government Of The United States Of America, As Represented By The Secretary Of Department Of Health & Human Services Differentiation of stem cells to pancreatic endocrine cells
US20050079159A1 (en) * 2001-06-13 2005-04-14 Massachusetts Instiute Of Technology In vivo bioreactors
EP1298201A1 (en) 2001-09-27 2003-04-02 Cardion AG Process for the production of cells exhibiting an islet-beta-cell-like state
JP2005506074A (ja) * 2001-10-18 2005-03-03 イクシオン・バイオテクノロジー・インコーポレーテッド 肝臓の幹細胞および前駆細胞の膵臓機能細胞への転換
JP2005510232A (ja) 2001-11-26 2005-04-21 アドバンスド セル テクノロジー、インク． 再プログラムされたヒト体細胞核ならびに自系および同系なヒト幹細胞の製造および使用方法
US7157278B2 (en) * 2001-12-04 2007-01-02 Organogenesis, Inc. Cultured cells from pancreatic islets
CN1668324A (zh) 2002-05-28 2005-09-14 诺沃塞尔公司 用于胰岛素产生细胞的方法、组合物及生长与分化因子
US20060128018A1 (en) * 2003-02-07 2006-06-15 Zwaka Thomas P Directed genetic modifications of human stem cells
WO2005045001A2 (en) 2003-02-14 2005-05-19 The Board Of Trustees Of The Leland Stanford Junior University Insulin-producing cells derived from stem cells
AU2004241380A1 (en) 2003-05-20 2004-12-02 Riken Preparation of endodermal stem cells
WO2005017131A2 (en) 2003-08-14 2005-02-24 THE GOUVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT F HEALTH AND HUMAN SERVICES Methods for the differentiation of human stem cells
US20050170502A1 (en) 2003-09-30 2005-08-04 Regents Of The University Of California Methods for maintaining hepatocytes in culture and for differentiating embryonic stem cells along a hepatocyte lineage
CN103898045B (zh) * 2003-12-23 2019-02-01 维亚希特公司 定形内胚层
WO2007059007A2 (en) * 2005-11-14 2007-05-24 Cythera, Inc. Markers of definitive endoderm
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US7985585B2 (en) * 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
WO2005086860A2 (en) * 2004-03-09 2005-09-22 Gang Xu Methods for generating insulin-producing cells
WO2005097980A2 (en) 2004-03-26 2005-10-20 Geron Corporation New protocols for making hepatocytes from embryonic stem cells
KR20070029681A (ko) * 2004-04-01 2007-03-14 위스콘신 얼럼나이 리서어치 화운데이션 줄기 세포의 내배엽 및 이자 혈통으로의 분화
CN103103158B (zh) * 2004-04-27 2016-08-03 韦尔赛特公司 细胞培养基
MX2007000317A (es) 2004-07-09 2007-03-26 Cythera Inc Celulas mesoendodermicas y del disco germinativo.
WO2006016999A1 (en) * 2004-07-09 2006-02-16 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
WO2006034873A1 (en) 2004-09-29 2006-04-06 Cellartis Ab METHODS FOR THE GENERATION OF HEPATOCYTE-LIKE CELLS FROM HUMAN BLASTOCYST-DERIVED STEM (hBs)
WO2006083782A2 (en) 2005-01-31 2006-08-10 Es Cell International Pte Ltd. Directed differentiation of embryonic stem cells and uses thereof
CN100425694C (zh) 2005-04-15 2008-10-15 北京大学 诱导胚胎干细胞向胰腺细胞分化的方法
WO2007002210A2 (en) 2005-06-20 2007-01-04 Bresagen, Inc. Embryonic stem cell culture compositions and methods of use thereof
US7732202B2 (en) 2005-10-21 2010-06-08 International Stem Cell Corporation Oxygen tension for the parthenogenic activation of human oocytes for the production of human embryonic stem cells
CN101351547A (zh) * 2005-10-27 2009-01-21 赛瑟拉公司 表达pdx1的背侧和腹侧前肠内胚层
GB0602063D0 (en) 2006-02-02 2006-03-15 Univ Manchester Cell Culture
US8129182B2 (en) 2006-03-02 2012-03-06 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US7695965B2 (en) * 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
AU2007277364B2 (en) * 2006-07-26 2010-08-12 Viacyte, Inc. Methods of producing pancreatic hormones
US20080241250A1 (en) * 2006-11-08 2008-10-02 Emans Pieter J In vivo bioreactors and methods of making and using same
US7695963B2 (en) * 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US11586805B2 (en) 2021-07-26 2023-02-21 Atlassian Pty Ltd. Machine-learning-based natural language processing techniques for low-latency document summarization

Patent Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165993A (en) * 1992-03-23 2000-12-26 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5670372A (en) * 1992-10-08 1997-09-23 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) * 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
US5453357A (en) * 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5817637A (en) * 1993-01-26 1998-10-06 The Trustees Of The University Of Pennsylvania Genetic immunization
US5830876A (en) * 1993-01-26 1998-11-03 The Trustees Of The University Of Pennsylvania Genetic immunization
US20020187548A1 (en) * 1994-11-21 2002-12-12 National Jewish Medical And Research Center Method for identification of cell growth or differentiation factors
US6200806B1 (en) * 1995-01-20 2001-03-13 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6015671A (en) * 1995-06-07 2000-01-18 Indiana University Foundation Myocardial grafts and cellular compositions
US6251671B1 (en) * 1996-02-28 2001-06-26 Vanderbilt University Compositions and methods of making embryonic stem cells
US6090622A (en) * 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US20030175956A1 (en) * 1997-10-23 2003-09-18 Bodnar Andrea G. Feeder-free culture method for embryonic stem cell
US6921811B2 (en) * 1998-09-22 2005-07-26 Biosurface Engineering Technologies, Inc. Bioactive coating composition and methods
US20060019387A1 (en) * 1999-07-08 2006-01-26 Faris Ronald A Liver stem cell
US6872389B1 (en) * 1999-07-08 2005-03-29 Rhode Island Hospital Liver stem cell
US20020072117A1 (en) * 2000-01-11 2002-06-13 Chunhui Xu Human feeder cells that support proliferation of undifferentiated pluripotent stem cells
US20030190748A1 (en) * 2000-03-09 2003-10-09 Thomson James A. Serum free cultivation of primate embryonic stem cells
US6506574B1 (en) * 2000-04-27 2003-01-14 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US7256042B2 (en) * 2000-04-27 2007-08-14 Geron Corporation Process for making hepatocytes from pluripotent stem cells
US6458589B1 (en) * 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US7033831B2 (en) * 2001-12-07 2006-04-25 Geron Corporation Islet cells from human embryonic stem cells
US20060040387A1 (en) * 2001-12-07 2006-02-23 Fisk Gregory J Islet cells from human embryonic stem cells
US20030138948A1 (en) * 2001-12-07 2003-07-24 Fisk Gregory J. Islet cells from human embryonic stem cells
US20030138949A1 (en) * 2001-12-12 2003-07-24 Anil Bhushan Methods for the regeneration of pancreatic islets and expansion of pancreatic endocrine cells
US20060003446A1 (en) * 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
US20060276420A1 (en) * 2002-05-17 2006-12-07 Keller Gordon M Mesoderm and definitive endoderm cell populations
US20040127406A1 (en) * 2002-05-28 2004-07-01 Presnell Sharon C. Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells
US20060040385A1 (en) * 2002-12-05 2006-02-23 Technion Research & Development Foundation Ltd. Cultured human pancreatic islets, and uses thereof
US20060128017A1 (en) * 2002-12-24 2006-06-15 Philippe Geffard Process for the production of an active molecule vector used to diffuse active substances and vector thus obtained
US20030224411A1 (en) * 2003-03-13 2003-12-04 Stanton Lawrence W. Genes that are up- or down-regulated during differentiation of human embryonic stem cells
US20040229350A1 (en) * 2003-05-12 2004-11-18 Nikolai Strelchenko Morula derived embryonic stem cells
US20060003313A1 (en) * 2003-12-23 2006-01-05 D Amour Kevin A Methods for identifying factors for differentiating definitive endoderm
US20060148081A1 (en) * 2003-12-23 2006-07-06 Olivia Kelly Expansion of definitive endoderm cells
US20070281355A1 (en) * 2004-08-13 2007-12-06 Stephen Dalton Compositions And Methods For Self-Renewal And Differentiation In Human Embryonic Stem Cells

Cited By (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186407A1 (en) * 2001-08-06 2009-07-23 Bresagen, Inc. Alternative Compositions and Methods for the Culture of Stem Cells
US20090042287A1 (en) * 2004-04-27 2009-02-12 D Amour Kevin Allen Pdx1 expressing endoderm
US8633024B2 (en) 2004-04-27 2014-01-21 Viacyte, Inc. PDX1 expressing endoderm
US20090010900A1 (en) * 2004-07-07 2009-01-08 The University Of North Carlolina At Chapel Hill Embryonic Stem Cell Derivatives, and Methods of Making and Using the Same
US20070281355A1 (en) * 2004-08-13 2007-12-06 Stephen Dalton Compositions And Methods For Self-Renewal And Differentiation In Human Embryonic Stem Cells
US8187878B2 (en) 2004-08-13 2012-05-29 University Of Georgia Research Foundation, Inc. Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors
US20100233755A1 (en) * 2005-10-27 2010-09-16 D Amour Kevin Allen Pdx1-expressing dorsal and ventral foregut endoderm
US9499795B2 (en) 2005-10-27 2016-11-22 Viacyte, Inc. PDX1-expressing dorsal and ventral foregut endoderm
US11427805B2 (en) 2005-10-27 2022-08-30 Viacyte, Inc. Methods of producing human foregut endoderm cells expressing PDX1 from human definitive endoderm
US8658352B2 (en) 2006-02-23 2014-02-25 Viacyte, Inc. Compositions and methods useful for culturing differentiable cells
US8415158B2 (en) 2006-02-23 2013-04-09 Viacyte, Inc. Compositions and methods useful for culturing differentiable cells
US11896622B2 (en) 2006-03-02 2024-02-13 Viacyte, Inc. Methods of producing pancreatic hormones
US10370645B2 (en) 2006-03-02 2019-08-06 Emory University Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US20100260728A1 (en) * 2006-03-02 2010-10-14 Laura Martinson Methods of producing pancreatic hormones
US20070259421A1 (en) * 2006-03-02 2007-11-08 D Amour Kevin A Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
US7993920B2 (en) 2006-03-02 2011-08-09 Viacyte, Inc. Methods of producing pancreatic hormones
US9980986B2 (en) 2006-03-02 2018-05-29 Viacyte, Inc. Methods of producing pancreatic hormones
US8129182B2 (en) 2006-03-02 2012-03-06 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US10517901B2 (en) 2006-03-02 2019-12-31 Viacyte, Inc. Methods of lowering blood glucose levels in a mammal
US8603811B2 (en) 2006-03-02 2013-12-10 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US9585917B2 (en) 2006-03-02 2017-03-07 Viacyte, Inc. Methods of producing pancreatic hormones
US7534608B2 (en) 2006-07-26 2009-05-19 Cythera, Inc. Methods of producing pancreatic hormones
US10316293B2 (en) 2007-07-01 2019-06-11 Janssen Biotech, Inc. Methods for producing single pluripotent stem cells and differentiation thereof
US10456424B2 (en) 2007-07-31 2019-10-29 Janssen Biotech, Inc. Pancreatic endocrine cells and methods thereof
CN107574142A (zh) * 2007-11-27 2018-01-12 生命扫描有限公司 人胚胎干细胞的分化
US20150252327A1 (en) * 2007-11-27 2015-09-10 Lifescan, Inc. Differentiation of human embryonic stem cells
US9969982B2 (en) * 2007-11-27 2018-05-15 Lifescan, Inc. Differentiation of human embryonic stem cells
US11505783B2 (en) 2007-11-27 2022-11-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US11001802B2 (en) 2008-02-21 2021-05-11 Nunc A/S Surface of a vessel with polystyrene, nitrogen, oxygen and a static sessile contact angle for attachment and cultivation of cells
US10066203B2 (en) 2008-02-21 2018-09-04 Janssen Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
US9045736B2 (en) 2008-04-21 2015-06-02 Viacyte, Inc. Methods for enriching for pancreatic endocrine cells
US9506034B2 (en) 2008-04-21 2016-11-29 Viacyte, Inc. Method of enriching for pancreatic endoderm cells
US20090263896A1 (en) * 2008-04-21 2009-10-22 Olivia Kelly Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
US10266808B2 (en) 2008-04-21 2019-04-23 Viacyte, Inc. Method of enriching for pancreatic endocrine cells that express chromogranin A
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
US20090298178A1 (en) * 2008-06-03 2009-12-03 D Amour Kevin Allen Growth factors for production of definitive endoderm
US10233421B2 (en) 2008-06-30 2019-03-19 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US8445273B2 (en) 2008-11-04 2013-05-21 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
US20100112691A1 (en) * 2008-11-04 2010-05-06 Chad Green Stem Cell Aggregate Suspension Compositions and Methods of Differentiation Thereof
EP3550012A1 (en) 2008-11-04 2019-10-09 ViaCyte, Inc. Stem cell aggregate suspension compositions and methods for differentiation thereof
US10138463B2 (en) 2008-11-04 2018-11-27 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
WO2010053472A1 (en) 2008-11-04 2010-05-14 Novocell, Inc. Stem cell aggregate suspension compositions and methods for differentiation thereof
US11015170B2 (en) 2008-11-04 2021-05-25 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
US9913930B2 (en) 2008-11-14 2018-03-13 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US10272179B2 (en) 2008-11-14 2019-04-30 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US8425928B2 (en) 2008-11-14 2013-04-23 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US20100124564A1 (en) * 2008-11-14 2010-05-20 Laura Martinson Encapsulation of pancreatic cells derived from human pluripotent stem cells
US9132226B2 (en) 2008-11-14 2015-09-15 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US8278106B2 (en) 2008-11-14 2012-10-02 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US11660377B2 (en) 2008-11-14 2023-05-30 Viacyte, Inc. Cryopreserved in vitro cell culture of human pancreatic progenitor cells
US9764062B2 (en) 2008-11-14 2017-09-19 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US9969972B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
US9969973B2 (en) 2008-11-20 2018-05-15 Janssen Biotech, Inc. Methods and compositions for cell attachment and cultivation on planar substrates
US9988604B2 (en) 2009-04-22 2018-06-05 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US9982235B2 (en) 2009-04-22 2018-05-29 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US11905530B2 (en) 2009-04-22 2024-02-20 Viacyte, Inc. Cell encapsulation device comprising a pancreatic progenitor cell population
US20100272695A1 (en) * 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
US20110014703A1 (en) * 2009-07-20 2011-01-20 Jean Xu Differentiation of Human Embryonic Stem Cells
US8785185B2 (en) * 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10076544B2 (en) 2009-07-20 2018-09-18 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10471104B2 (en) 2009-07-20 2019-11-12 Janssen Biotech, Inc. Lowering blood glucose
US20110014702A1 (en) * 2009-07-20 2011-01-20 Jean Xu Differentiation of Human Embryonic Stem Cells
US8785184B2 (en) * 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US10704025B2 (en) 2009-12-23 2020-07-07 Janssen Biotech, Inc. Use of noggin, an ALK5 inhibitor and a protein kinase c activator to produce endocrine cells
US10329534B2 (en) 2010-03-01 2019-06-25 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
CN107189979A (zh) * 2010-03-01 2017-09-22 詹森生物科技公司 纯化衍生自多能干细胞的细胞的方法
US9969981B2 (en) 2010-03-01 2018-05-15 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
US9951314B2 (en) 2010-08-31 2018-04-24 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9433557B2 (en) 2011-02-21 2016-09-06 Viacyte, Inc. Loading system for an encapsulation device
US11377640B2 (en) 2011-12-22 2022-07-05 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
US10358628B2 (en) 2011-12-22 2019-07-23 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
US10066210B2 (en) 2012-06-08 2018-09-04 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US10208288B2 (en) 2012-06-08 2019-02-19 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
EP4053264A1 (en) 2012-11-08 2022-09-07 ViaCyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
EP2730649A1 (en) 2012-11-08 2014-05-14 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US10377989B2 (en) 2012-12-31 2019-08-13 Janssen Biotech, Inc. Methods for suspension cultures of human pluripotent stem cells
US10138465B2 (en) 2012-12-31 2018-11-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators
US10344264B2 (en) 2012-12-31 2019-07-09 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10947511B2 (en) 2012-12-31 2021-03-16 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using thyroid hormone and/or alk5, an inhibitor of tgf-beta type 1 receptor
US11446335B2 (en) 2013-03-14 2022-09-20 Viacyte, Inc. Cryopreserved endocrine cells that express chromogranin A
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US10376545B2 (en) 2013-03-14 2019-08-13 Viacyte, Inc. Methods for producing hormone secreting cells in a subject
US9650610B2 (en) 2013-03-14 2017-05-16 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US11925488B2 (en) 2014-04-16 2024-03-12 Viacyte, Inc. Tools and instruments for use with implantable encapsulation devices
US11051900B2 (en) 2014-04-16 2021-07-06 Viacyte, Inc. Tools and instruments for use with implantable encapsulation devices
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US10870832B2 (en) 2014-05-16 2020-12-22 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US20170304369A1 (en) * 2014-10-08 2017-10-26 Agency For Science, Technology And Research Methods of differentiating stem cells into liver cell lineages
US10420803B2 (en) 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
US11904001B2 (en) 2017-07-12 2024-02-20 Viacyte, Inc. Universal donor cells and related methods
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
US10724052B2 (en) 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
US11008587B2 (en) 2018-09-07 2021-05-18 Crispr Therapeutics Ag Universal donor cells
US10865424B2 (en) 2018-09-07 2020-12-15 Crispr Therapeutics Ag Universal donor cells
US11180776B1 (en) 2018-09-07 2021-11-23 Crispr Therapeutics Ag Universal donor cells
US11008586B2 (en) 2018-09-07 2021-05-18 Crispr Therapeutics Ag Universal donor cells
US11118196B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
US11433103B2 (en) 2019-09-05 2022-09-06 Crispr Therapeutics Ag Universal donor cells
US11434505B2 (en) 2019-09-05 2022-09-06 Crispr Therapeutics Ag Universal donor cells
US11118195B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
US11116798B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
US11116797B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
US11104918B2 (en) 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells
US11566230B2 (en) 2020-12-31 2023-01-31 Crispr Therapeutics Ag Universal donor cells
US11578309B2 (en) 2020-12-31 2023-02-14 Crispr Therapeutics Ag Universal donor cells

Also Published As

Publication number Publication date
US20230040286A1 (en) 2023-02-09
WO2007051038A3 (en) 2007-06-14
US9499795B2 (en) 2016-11-22
JP6077046B2 (ja) 2017-02-08
JP5404047B2 (ja) 2014-01-29
CA2869687C (en) 2024-01-23
US11427805B2 (en) 2022-08-30
JP6366115B2 (ja) 2018-08-01
US20190144822A1 (en) 2019-05-16
JP2018148912A (ja) 2018-09-27
EP1957636A2 (en) 2008-08-20
WO2007051038A2 (en) 2007-05-03
CA2869687A1 (en) 2007-05-03
JP2009513143A (ja) 2009-04-02
AU2006305879B2 (en) 2012-05-10
DK1957636T3 (en) 2018-10-01
EP2674485B1 (en) 2019-06-12
US20130316357A1 (en) 2013-11-28
US20170022474A1 (en) 2017-01-26
EP1957636B1 (en) 2018-07-04
CN101351547A (zh) 2009-01-21
JP6595041B2 (ja) 2019-10-23
US20100233755A1 (en) 2010-09-16
EP3584311A1 (en) 2019-12-25
ES2687233T3 (es) 2018-10-24
JP2015133987A (ja) 2015-07-27
EP2674485A1 (en) 2013-12-18
DK2674485T3 (da) 2019-08-26
WO2007051038A9 (en) 2017-11-09
PL1957636T3 (pl) 2018-12-31
JP5968270B2 (ja) 2016-08-10
JP2013188234A (ja) 2013-09-26
CA2627645A1 (en) 2007-05-03
CA2627645C (en) 2015-07-07
JP2017070295A (ja) 2017-04-13
AU2006305879A1 (en) 2007-05-03
ES2743202T3 (es) 2020-02-18

Similar Documents

Publication Publication Date Title
US20230040286A1 (en) Methods of producing human foregut endoderm cells expressing pdx1 from human definitive endoderm
US7541185B2 (en) Methods for identifying factors for differentiating definitive endoderm
EP1786896B1 (en) Methods for identifying factors for differentiating definitive endoderm
US8633024B2 (en) PDX1 expressing endoderm
US8647873B2 (en) PDX1 expressing endoderm
EP1740612A2 (en) Pdx1 expressing endoderm
EP2377922A2 (en) PDX1 expressing endoderm
AU2015221494B2 (en) Pdx1- expressing dorsal and ventral foregut endoderm
AU2016235001B2 (en) Methods for identifying factors for differentiating definitive endoderm
AU2012202481B2 (en) PDX1-expressing dorsal and ventral foregut endoderm
AU2011203583B2 (en) Methods for identifying factors for differentiating definitive endoderm

Legal Events

Date Code Title Description
AS Assignment

Owner name: CYTHERA, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:D'AMOUR, KEVIN;AGULNICK, ALAN D.;ELIAZER, SUSAN;AND OTHERS;REEL/FRAME:018889/0404

Effective date: 20070130

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION